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ABSTRACT 
 
 
Stroke is the fifth leading cause of death in the United States and a major cause 
of long-term disability in industrialized countries. The core region of an ischemic stroke 
dies within minutes due to activation of necrotic pathways. Outside of this core region is 
the penumbral zone, where some perfusion is maintained via collateral arteries. Delayed 
cell death occurs in this area due to the triggering of apoptotic mechanisms, which 
expands the ischemic injury over time. The cellular and molecular events that produce 
the expansion of the ischemic core continue to be poorly understood. The increases in 
the amyloid precursor protein and pathogenic secretases lead to the increase in amyloid-
β (Aβ) production. The relatively small amount of research in this area has hampered 
development of stroke therapy designed to prevent neuronal and glial cell degeneration 
in the penumbra. Currently, there is a significant lack of therapeutic options for acute 
ischemic stroke, and no drug has been approved for treating patients at delayed time 
points (≥ 4.5 hr post-stroke).  
Afobazole, an anxiolytic currently used clinically in Russia, has been shown to 
reduce neuronal and glial cell injury in vitro following ischemia, both of which have been 
shown to play important roles following an ischemic stroke. Treatment with afobazole 
decreased microglial activation in response to ATP and Aβ, as indicated by reduced 
membrane ruffling and cell migration. Prolonged exposure of microglia to ischemia or Aβ 
conditions resulted in glial cell death that was associated with increased expression of 
x 
 
the pro-apoptotic protein, Bax, the death protease, caspase-3 and a reduced expression 
in Bcl-2. Co-application of afobazole decreased the number of cells expressing both Bax 
and caspase-3, while increasing the cells expressing Bcl-2 resulting in a concomitant 
enhancement in cell survival. While afobazole inhibited activation of microglia cells by 
Aβ25-35, it preserved normal functional responses in these cells following exposure to the 
amyloid peptide. Intracellular calcium increases induced by ATP were depressed in 
microglia after 24 hr exposure to Aβ25-35. However, co-incubation with afobazole returned 
these responses to near control levels. Therefore, stimulation of σ-1 and σ-2 receptors 
by afobazole prevents Aβ25-35 activation of microglia and inhibits Aβ25-35-associated 
cytotoxicity. 
Examining the molecular mechanisms involved in the increased neuronal survival 
demonstrates that ischemia or Aβ results in an increased expression of the pro-apoptotic 
protein Bax and the death protease caspase-3, while at the same time decreasing 
expression of the anti-apoptotic protein, Bcl-2. However, unlike observations made with 
microglia, afobazole was unable to modulate this ischemia-induced expression, but was 
able to modulate Aβ-induced expression of apoptotic proteins while still rescuing 
neurons from death. Additional experiments were carried out to understand this disparity 
between the failures of afobazole to prevent the up-regulation of pro-apoptotic genes 
while retaining the ability to mitigate neuronal death. Although the neurons were still alive 
they were in a senescent state and were unresponsive to depolarization by high K+. 
However, these findings are still positive due to the ability of afobazole to delay neuron 
death, thus minimalizing the toxic environment of the penumbra.  
xi 
 
These comorbidities of ischemia and Aβ toxicity may lead to potentiated 
responses and increase the risk for various vascular dementias. It was of particular 
interest to study how the convergence of ischemia, acidosis and Aβ influence cellular 
activity and survival within core and penumbral regions. Application of Aβ increased the 
[Ca2+]i overload produced by concurrent ischemia + acidosis application in isolated 
cortical neurons. We found that the acid-sensing ion channels 1a (ASIC1a) are involved 
in the potentiation of [Ca2+]i overload induced by Aβ. Furthermore, afobazole (100 µM) 
abolished Aβ potentiation of ischemia + acidosis evoked [Ca2+]i overload, which may 
represent a therapeutic strategy for mitigating injury produced by Aβ and stroke.  
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CHAPTER 1 
 
 
Introduction 
 
 
Significance 
 
Ischemic stroke often overlaps with diseases involving Aβ, such as Alzheimer’s 
disease (AD) and cerebral amyloid angiopathy. These comorbidities can lead to 
potentiated responses that ultimately result in vascular dementia (Wilcock et al., 2009, 
Nelson et al., 2013, Sudduth et al., 2014). The mechanisms contributing to this 
potentiation remain poorly understood. One key player in the pathobiology both of stroke 
and Aβ toxicity is the dysregulation of [Ca2+]i homeostasis (Cuevas et al., 2011a, Cuevas 
et al., 2011b, Behensky et al., 2013a, b). Previous studies have suggested that a link 
may exist between cerebral ischemia and AD (Koistinaho and Koistinaho, 2005, Pluta et 
al., 2013) due to the increased Aβ expression following an ischemic stroke (Selkoe, 
2001, Shiota et al., 2013). The Aβ fragment, Aβ25-35, which has been found in AD brains, 
has been proposed as a contributor to the pathogenesis of AD (Kaminsky et al., 2010). 
This Aβ fragment has been shown to induce injury via various mechanisms including 
production of reactive oxygen species (ROS) (Schubert et al., 1995), dysregulation in 
intracellular Ca2+ (Joseph and Han, 1992), enhanced NMDA channel activity (Molnar et 
al., 2004), and increased activation of caspase-3 (Marin et al., 2000). In addition, Aβ has 
been shown to initiate a sequence of events in microglia, including a pro-inflammatory 
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cascade and enhanced hemichannel formation, which ultimately results in neuronal and 
glial cell death (Orellana et al., 2011). Aβ toxicity is therefore of particular interest in 
lacunar stroke, where following a micro infarct, Aβ production increases thereby 
disrupting both the microvascular and the intracellular calcium levels in the neighboring 
neurons. This resulting Aβ toxicity may promote future infarcts with potentiated injury. 
Studies have shown that in mice with increased amyloid precursor protein expression, 
there is an increased risk of ischemic stroke, but as of yet there are no studies that can 
elucidate the molecular mechanisms by which this injury occurs (Zhang et al., 1997). 
 
Background 
 
Stroke is the second leading cause of death globally and continues to be a major 
cause of serious long-term disability (Go et al., 2013). In 2013 the reported annual cost 
associated of this disease in the United States was approximately $35 billion. This 
economic strain has driven the search for potential treatments to alleviate the debilitating 
effects of this disease. Stroke is the sudden loss or interruption of blood circulation to the 
brain. There are two types of stroke. Hemorrhagic stroke, where a blood vessel ruptures 
and bleeds into the brain.  Although hemorrhagic only accounts for a small percentage of 
all strokes the survival rate for these patients is low with 60% dying within the first year 
following the insult. An ischemic stroke in the most common type of stroke accounting for 
about 87% and occurs when blood flow to the brain is interrupted. The clot can occur 
locally by a thrombus or from an embolus forming elsewhere in the body and migrating 
into the brain. For the present study, when referring to a stroke we are denoting an 
ischemic stroke. The central region affected by the ischemic insult, or the core, is an 
3 
 
 
area with little to no blood perfusion and dies within minutes of stroke onset via necrosis. 
Outside of this core region is the penumbral zone, where some perfusion is maintained 
by collateral arteries. In this area, delayed cell death occurs due to the triggering of 
apoptotic mechanisms, and over the course of hours to days the size of the lesion 
expands. The cellular and molecular events that produce the expansion of the ischemic 
core continue to be poorly understood, which has hampered development of stroke 
therapies designed to prevent neuronal and glial cell degeneration in the penumbra. In 
addition to large vessel ischemic strokes there are also small vessel ischemic strokes. 
Known as lacunar infarcts, these strokes account for approximately 25% of all ischemic 
insults (Samuelsson et al., 1996). They result from the blockage of small penetrating 
arteries to the subcortical regions of the brain (Kang et al., 2012). While the injury from 
these strokes were once thought to be negligible, lacunar infarcts can and do result in 
death and long-term disability. This type infarct is a leading cause of cognitive 
impairment and vascular dementia (Charidimou and Werring, 2012). While the risk 
factors resulting in lacunar verse large artery infarcts differ, the resulting cellular cascade 
promoting cerebral cell death most likely have overlapping mechanisms. 
Treatments have been explored to provide neuroprotection in an effort to mitigate 
neuronal injury following ischemic stroke. One main area of research had been to inhibit 
N-methyl-D-aspartate (NMDA) and (±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid (AMPA) receptors. While some in vitro studies were promising, the in vivo results 
were less assuring. One such drug was Selfotel, a synthetic NMDA antagonist, which 
showed significant improvements in an animal model of transient focal ischemia 
(Finnegan et al., 1993). However, Selfotel needed to be administered 1hr prior to the 
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ischemic insult for best results, and showed no benefit if treatment was started >60 min 
post stroke (Smith et al., 2008). Furthermore, clinical trials were terminated early due to 
adverse effects (Kurokawa et al., 2011a). One potential reason for the failures of 
neuroprotective drugs that target a single ion channel is the fact that ischemic stroke is a 
complex syndrome acting on a multitude of ion channels and receptors. Furthermore, 
recent studies have shown that microglia, part of the immune/inflammatory response, 
migrate to the site of insult, become over-activated and contribute to the stroke injury 
(Eichhoff et al., 2011). 
 The only treatment currently approved by the FDA for ischemic stroke is 
recombinant tissue plasminogen activator (tPA), a thrombolytic agent used to restore 
blood-flow interrupted by a blood clot (Weintraub, 2006). However, tPA therapy is time 
sensitive, and the drug must be administered < 4.5 hours post-infarct. In addition, aging 
patients presenting various comorbidities lead to an increase in tPA’s risk to benefit ratio, 
resulting in less than 4% of patients being able to use it (Armstead et al., 2010). The goal 
of future therapies would be to treat these patients at 24 to 48 hrs follow the insult. 
However, for this to be accomplished the mechanisms of stroke must be further 
elucidated.  
 
Pathobiology of Ischemic Stroke 
 
To better understand neurodegeneration following an ischemic stroke, it is 
important to study the mechanisms underlying stroke. Figure 1.1 shows a simplified 
overview of the biochemical events that are involved in ischemic stroke. Following an 
ischemic insult, the core rapidly depletes its energy stores due to decreased blood flow.  
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Figure 1.1 
 
Pathoneurobiology of Ischemic Stroke. Intracellular calcium plays an important role in the 
events during ischemia. Ischemia leads to acidosis in the core and penumbra regions, 
which contributes to further calcium dysregulation. Calcium toxicity results in the 
activation these secondary events that result in apoptosis and subsequent expansion of 
the core. 
 
The susceptibility of neurons to ischemia is in part due to their high consumption of 
oxygen and glucose. Penumbra cell death is delayed in part due to blood flow from 
collateral arteries supplying minimal oxygen and glucose. This reduced supply, however, 
is not enough to maintain normal cellular respiration and neurons are forced to switch 
from oxidative metabolism to anaerobic glycolysis. This provides neurons with some 
energy in the hopes that blood flow will be restored. However, lactate builds up within the 
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cells reducing the surrounding pH (Munoz Maniega et al., 2008). This drop in tissue pH, 
along with synaptic proton release triggered in neurons by ischemia, activates the acid 
sensing ion channel 1a (ASIC1a) (Xiong et al., 2004, Mari et al., 2010). ASIC1a is 
permeable to both Na+ and Ca2+ (Xiong et al., 2004) and following activation contributes 
to the intracellular Na+ loading and [Ca2+]i dysregulation seen following an ischemic 
stroke. This convergence of ischemia and acidosis has been shown to potentiate [Ca2+]i 
dyshomeostasis (Mari et al., 2010).   
Despite neuronal attempts to generate ATP, the reduction in cerebral blood flow 
causes a massive energy shortage. Energy depletion triggers cell depolarization due to 
the failure of Na+/K+ ATPase (Besancon et al., 2008) and results in cations, Na+ and 
Ca2+, rushing into the cell. The increasing presence of calcium triggers the release of 
glutamate from the extracellular stores, which then over-activate NMDA and AMPA 
receptors (Mark et al., 2001, Lipton, 2004, Muir, 2006), thus resulting in wide spread 
intracellular ionic imbalances. In addition, because the Na+/K+ ATPase cannot function 
there is a buildup of intracellular sodium ([Na+]i) and extracellular potassium ([K+]o). The 
increase in [K+]o triggers neighboring neurons to depolarize. Whereas, sodium loading 
leads to edema and results in the reversal of the Na+/Ca2+ and Na+/Ca2+ K+-dependent 
exchangers, which contribute to [Ca2+]i dysfunction (Kiedrowski, 2007). This calcium 
overload triggers reactive oxygen species (ROS) and nitrite oxide (NO) production, which 
in turn breakdown proteins, lipids and nucleic acids (Mattson, 2000, Camello-Almaraz et 
al., 2006). Additionally, the buildup of [Ca2+]i triggers the activation of secondary events 
including the release of cytochrome c from the mitochondria initiating the expression of 
pro-apoptotic genes and the release of pro-inflammatory mediators (Figure 1.1). This in 
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turn triggers the activation of microglia and reactive astrocytes, which are then capable 
of exacerbating neuronal injury and expanding the ischemic core (Takano et al., 2009). 
Moreover, despite studies which have shown that following an ischemic stroke there is 
an increase the expression of amyloid precursor protein (APP) and both β and γ 
secretase, which lead to increased Aβ production, there have been little to no studies 
addressing the neuronal and glial injury induced by Aβ following ischemia (Popa-Wagner 
et al., 1998, Guglielmotto et al., 2009, Pluta et al., 2013).  
 
Amyloid-β 
 
Amyloid-β (Aβ) is a peptide found in many diseases and is best known with 
contributing to Alzheimer’s disease. Aβ is formed following cleavage of the amyloid 
precursor protein (APP) by secretases. It was once believed that cleavage of APP would 
enter one of two pathways which would either result in a physiological (secretases α and 
γ) or pathological (secretases β and γ) peptide (Zhang et al., 2011). However, we now 
know this to be incorrect and that both pathways produce physiologic and pathologic 
peptides. The functions of Aβ have been largely debated to have no physiological 
endogenous function, only pathological. However, in recent years low picomolar (pM) 
concentrations of Aβ has been shown to promote platelet aggregation and be essential 
to synaptic plasticity, memory formation and fear conditioning (Shen et al., 2008, 
Lawrence et al., 2014). It is only when concentrations of Aβ elevate ≥ 200 pM that it 
becomes toxic (Puzzo and Arancio, 2013). It was previously thought that amyloid 
precursor protein was acting as a signaling molecule rather than Aβ to promote synaptic 
plasticity (Octave et al., 2013). However, studies by (Puzzo and Arancio, 2013) revealed 
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that siRNA against APP could impaired synaptic plasticity, which was rescued with 
concurrent Aβ1-42 application. While there have been studies for (Nagele et al., 2002) 
and against (Small et al., 2007) Aβ binding to α-7 nicotinic acetylcholine receptors 
(α7nAChRs), it was only recently that studies from (Lawrence et al., 2014) showed that 
Aβ (pM) worked as an agonist on presynaptic α7nAChRs to enhance long-term 
potentiation (LTP). The controversy as to whether Aβ functions as agonist or antagonist 
is dependent on which fragment is binding. Aβ1-40 has been shown to inhibit 
glutamatergic transmitter release via the antagonism of α7nAChRs (Nery et al., 2013, Ju 
et al., 2014, Salamone et al., 2014), whereas, the fragments 1-42 and 25-35 both bind to 
α7nAChRs and enhance their synaptic transmission (Talantova et al., 2013, Lee et al., 
2014).  
Amyloid-β accumulation is more commonly associated with diseases such as 
Alzheimer’s (AD) and cerebral amyloid angiopathy. However, an ischemic insult has 
been shown to increase APP mRNA by >200% (Pluta et al., 2009). It been suggested 
that this increase in APP might be protective following an insult (Koike et al., 2012). 
However, the additional up-regulation of the β and γ secretases lead to increased 
cleavage of APP and the deposition of Aβ in the penumbral zone (Guglielmotto et al., 
2009, Pluta et al., 2013). These depositions were found to be significantly higher on day 
4 following the ischemic episode with peak tissue levels at day 7 (Stephenson et al., 
1992, Jablonski et al., 2011). Aβ levels remained significantly high when checked during 
a one year follow up, which has been postulated as a potential risk factor for developing 
AD (Jablonski et al., 2011). In addition to an increase Aβ, there is also an increase in the 
hyperphosphorylation of tau following a stroke, which is known to contribute to AD (Wen 
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et al., 2004). There is some evidence that a stroke or other cerebrovascular disease 
liken the chances of developing AD. It was found during the autopsies of AD patients that 
approximately 40% had some form of cerebrovascular incident prior to developing AD. 
With studies showing the increase in Aβ, many view Aβ as a potential target in the 
prevention of AD. However, there are virtually no studies looking at the injury Aβ incurs 
directly following a stroke. There are more than a few overlapping mechanisms between 
ischemia and Aβ induced toxicity. Aβ has been shown to disrupt ionic homeostasis 
through several pathways, which involve Aβ having a direct and indirect action on 
neuronal and glial cells. Aβ can cause the release of astrocytic and microglial glutamate 
that activates neuronal AMPA, NMDA or metabotropic glutamate receptors, as well as, 
being able to directly bind to neuronal NMDA receptors, whereby increasing the influx of 
Na+ and Ca2+ ions (Alberdi et al., 2010, Texido et al., 2011, Talantova et al., 2013). This 
influx of Na+ and Ca2+ leads to an increase in Ca2+ dyshomeostasis, triggering 
mitochondrial dysfunction and initiating apoptosis (Cha et al., 2012, Oseki et al., 2014, 
Ferreira et al., 2015). As previously mentioned, the dysregulation of [Ca2+]i leads to 
secondary responses including activation of reactive astrocytes and microglia (Figure 
1.1). 
 
Microglia 
 
Microglia are the resident macrophages of the brain, and constitute nearly 10% of 
the total cell population of this organ. The function of these cells in normal and 
pathological conditions has been an area of significant research, and considerable 
controversy surrounds the role of these cells in diseases of the CNS. It has been shown 
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that microglia transform from a resting to an activated state in response to various 
stimuli, such as neuronal injury, release of ATP, or pathogen infiltration (Melani et al., 
2005, Hanisch and Kettenmann, 2007). Upon stimulation, these cells migrate to the site 
of injury, phagocytose debris and release pro-inflammatory compounds (Hanisch and 
Kettenmann, 2007). Such a microglial response has been reported to occur as a result of 
a cerebral ischemic insult, following which microglia are attracted to the site of injury and 
proliferate (Weinstein et al., 2010). In addition, microglial cells have been shown to be 
attracted to, and are required for, the clearance of Aβ (Wilcock et al., 2004, Morgan, 
2009). Once phagocytosed, Aβ is degraded by the endothelin-converting enzymes in the 
endosomal/ lysosomal pathway (Pacheco-Quinto and Eckman, 2013).  
Since it has been shown that Aβ concentrations increase following an ischemic 
insult it has been suggested that these microglia then contribute to the 
neuroinflammatory response that results in the demise of neurons (Rogove et al., 2002, 
Streit et al., 2004, Dheen et al., 2007). It is plausible that in brains with abnormally high 
concentrations of Aβ, the inflammatory injury normally caused by microglial migration 
following ischemia increases. This dual insult of ischemia and Aβ results in the over-
activation of microglial cells and maintaining prolonged microglia activation leads to cell 
death or senescence. The loss of functional microglia to clear the accumulation Aβ may 
lead to various vasculature dementias including cerebral amyloid angiopathy and AD. As 
of yet, there have been no successful therapies in the treatment of stroke or AD. These 
failures are compounded by not addressing the multiple receptor and/or pathways to 
injury, in addition to not accounting for the interactions between multiple cell types. One 
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potential target for the treatment of stroke are the sigma receptors, which have been 
shown to interact with multiple receptors, pathways and cell types.   
 
Sigma Receptors 
 
Sigma (σ) receptors were first identified by(Martin et al., 1976) and classified as 
an opioid receptor following the binding actions observed with racemic benzomorphans. 
However, it was later discovered that only the (+) enantiomer of benzomorphans bound 
to σ receptors, which was found to be inaccessible to naloxone placing them in their 
current class of “opioid-like receptors” (Walker et al., 1990). σ receptors have been 
shown to bind to a wide variety of substances including antipsychotics, opiates and 
antidepressants to name a few. Studies by (Hellewell and Bowen, 1990) showed a 
decreased affinity for (+)-benzomorphans in PC12 cells suggesting a second σ subtype. 
Thus far there have been two σ receptor subtypes identified pharmacologically, termed 
σ-1 and σ-2. Receptors that bind (+)-benzomorphans with high affinity are classified as 
σ-1receptors. Whereas, those that have a high affinity for ibogaine are labeled σ-2 
receptors (Bowen, 2000, Vilner and Bowen, 2000). Moreover, some drugs have been 
shown to be pan-selective for both sigma receptors. This includes the pan-agonist 1,3-di-
o-tolyguanidine, the pan-antagonist metaphit and the σ-1 antagonist and σ-2 agonist 
haloperidol. 
Thus far, only the σ-1 receptor has been cloned. Consisting of 223 amino acids, 
this receptor shows no homology with any other mammalian protein (Seth et al., 1998, 
Mei and Pasternak, 2001). Predictions from the early studies of the amino acid sequence 
suggested two different but possible transmembrane configurations. The first was a 
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single transmembrane domain with an extracellular N-terminus and intracellular C-
terminus. Whereas, the second possibility retain the N- and C-termini intracellularly with 
two transmembrane spanning domains (Guitart et al., 2004), with more recent studies 
favoring the latter (Pal et al., 2007). Moreover, these studies predict that σ-1 receptors 
have two intracellular drug binding domains. In depth pharmacological studies by 
(Glennon, 2005) describe the σ-1 receptor binding site as a figure eight configuration 
with a central amine moiety flanked by two hydrophobic regions, one of which consisting 
an aromatic ring. These studies were reaffirmed with the discovery of the σ receptors 
endogenous ligand N,N-dimethyltryptamine (DMT) (Fontanilla et al., 2009). Furthermore, 
σ-1 receptors were shown to have a DMT concentration dependent action, which at low 
concentrations of DMT, σ-1 receptors would act as a chaperone between the rough 
endoplasmic reticulum (ER) and the mitochondria at the mitochondrion-associated ER 
membrane (MAM) to regulate intra-mitochondrial calcium concentrations. However, at 
high DMT concentrations, σ-1 receptors would migrate to the plasma membrane or 
subplasmalemmal ER to regulate various channels and receptors (Su et al., 2009, Tsai 
et al., 2009, Su et al., 2010). This makes σ-1 receptors highly attractive as a therapeutic 
target for numerous neurological diseases. 
Despite years of study, the identity of σ-2 receptors is still unknown. There have 
been studies in recent years suggesting the σ-2 receptors might be either a histone 
binding protein (Colabufo et al., 2006, Abate et al., 2010) or the progesterone receptor 
membrane component-1 (PGRMC-1) (Xu et al., 2011, Abate et al., 2015). However, the 
molecular identity of σ-2 receptors has not been unequivocally established. In studies 
using human SK-N-SH neuroblastoma cells there is evidence to support that σ-2 
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receptors also localize with the ER, mitochondria, lysosomes and plasma membrane 
(Vilner and Bowen, 2000, Zeng et al., 2007, Cassano et al., 2009). It has been 
suggested that σ-2 receptors may be a splice variant of the σ-1 receptor (Monassier and 
Bousquet, 2002). However, this hypothesis was refuted by the finding that σ-1 receptor 
knockout mice still retained σ-2 receptor function (Langa et al., 2003).  
The distribution of σ receptor in the mammalian body is quite ubiquitous being 
expressed in the central nervous, liver, kidney, immune and cardiac cells (Dumont and 
Lemaire, 1991, Wolfe and De Souza, 1993, Hellewell et al., 1994). Not much is known 
about the functions of σ-2 receptors. However, what is known about their function varies 
greatly depending on the cell type. In cancer cells, activation of σ-2 receptors causes the 
toxic release of calcium from ER stores leading to apoptosis (Vilner and Bowen, 2000, 
Cassano et al., 2009). Whereas, in immune cells σ-2 receptors are protective by 
mitigating the activation and migration of microglia and T lymphocytes. Additional, σ-2 
receptors have been shown to inhibit high-voltage-activated calcium channels in 
intracardiac neurons (Zhang and Cuevas, 2002, Hall et al., 2009a, Iniguez et al., 2013). 
In contrast to σ-2, σ-1 receptors have been identified as having extensive physiological 
and pathophysiological functions. They are known to promote learning, memory and 
synaptic plasticity in normal and in experimental stroke models (Ruscher et al., 2011, 
Kourrich et al., 2012). Moreover, σ-1 receptors maintain intracellular ionic homeostasis 
through regulation of 1,4,5-triphosphate (IP3) and ryanodine receptors at the 
endoplasmic reticulum, as well as calcium signaling and the influx of Na+ and Ca2+ 
through voltage-gated, ionotropic and metabotropic receptors (Hayashi et al., 2000, Su 
and Hayashi, 2003, Tchedre et al., 2008, Mueller et al., 2013).  
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There are numerous studies showing the cytoprotective ability of σ-1 receptors, 
both in neurons and glial cells. σ-1 receptors have been shown to regulate intracellular 
calcium increases following in vitro models of ischemia, acidosis and ischemia-acidosis 
(Katnik et al., 2006, Herrera et al., 2008, Mari et al., 2014). In addition, σ-1 receptor 
activation reduces oxidative and nitrosative stresses, while inhibiting apoptosis (Tchedre 
and Yorio, 2008, Meunier and Hayashi, 2010, Pal et al., 2012). Following the in vivo 
middle cerebral artery occlusion (MCAO) stroke model σ receptor activation was able to 
reduce the injury of both white and grey matter when the agonist was administered 24 
hours after the insult (Ajmo et al., 2006, Leonardo et al., 2010). Lastly, σ receptor 
activation has been shown to be neuroprotective against Aβ-induced toxicity (Marrazzo 
et al., 2005, Behensky et al., 2013a, b), which as previously mentioned is up-regulated 
following an ischemic stroke. Therefore, σ receptor agonists offer great potential for the 
treatment of ischemic stroke and related Aβ toxicity. One such pan-selective σ receptor 
agonist which has shown promise is afobazole. 
 
Afobazole 
 
Afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole), is a drug 
currently used in Russia to treat anxiety and has shown the potential to be 
neuroprotective in both in vitro and in vivo models (Galaeva et al., 2005, Zenina et al., 
2005, Seredenin et al., 2008). In vitro and in vivo studies have shown that afobazole can 
decrease neuronal death caused by oxidative stress and glutamate excitotoxicity and 
increase survival rates, while decreasing neurological deficits in rats suffering from a 
post-traumatic hematoma, respectively (Galaeva et al., 2005, Zenina et al., 2005). 
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Similarly, afobazole was shown to be neuroprotective in rats after bilateral local 
photothrombosis of vessels in the prefrontal cortex and after global transient ischemia 
(Seredenin et al., 2008, Baykova et al., 2011). Previous work in our laboratory has 
shown that afobazole can reduce ischemic injury following a stroke. These studies 
showed that afobazole affects cellular responses to ischemia via the stimulation of σ 
receptors (Cuevas et al., 2011a, Cuevas et al., 2011b). Activation of σ-1 receptors by 
afobazole blocks intracellular calcium overload produced by ischemia and acidosis and 
reduces neuronal death after in vitro ischemia (Cuevas et al., 2011a). This activation of 
σ-1 receptors results in the block of multiple ion channels that are functionally 
upregulated following ischemia and acidosis, including the acid-sensing ion channel 1a 
(ASIC1a) (Cuevas et al., 2011a). In microglia, activation of both σ-1 and σ-2 receptors by 
afobazole reduces membrane ruffling and migration of these cells in response to ATP 
(Cuevas et al., 2011b). Moreover, afobazole prevents microglial cell death following 
ischemia, even when the drug was applied after the ischemic insult (Cuevas et al., 
2011b). Lastly, in vivo studies using the middle cerebral artery occlusion (MCAO) stroke 
model showed that afobazole through σ receptor activation was able to reduce the total 
stroke injury, which resulted in and increased survival of both neuronal and glial cells 
even when administered 24-48 hrs post infarct (Katnik et al., 2014). The protection 
conveyed by afobazole translated to an increase in the animal’s behavior and cognition. 
Therefore, studies suggest that afobazole, acting on σ receptors, can decrease ischemic 
brain injury as well as improving functional outcomes. This makes afobazole an attractive 
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drug, not only for the treatment of ischemic stroke but also for the treatment of Aβ-
induced toxicity, which may contribute to secondary infarcts.    
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CHAPTER 2 
 
 
In Vitro Evaluation of Guanidine Analogues as Sigma Receptor 
Ligands for Potential Anti-Stroke Therapeutics 
 
 
Introduction 
 
Treatments that provide neuroprotection have been explored in an effort to 
mitigate neuronal injury following ischemic stroke. The main area of research has been 
inhibition of N-methyl-D-aspartate (NMDA) and (±)-α-Amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptors. While some in vitro studies were 
promising, the in vivo results were less assuring. For example, Selfotel, a synthetic 
NMDA antagonist, showed significant improvements in an animal model of transient 
focal ischemia (Finnegan et al., 1993). However, Selfotel needed to be administered 1hr 
prior to the ischemic insult for best results, and showed no benefit if treatment was 
started >60 min post stroke (Smith et al., 2008). Furthermore, clinical trials were 
terminated early due to adverse effects (Kurokawa et al., 2011a). 
One reason for the failure of neuroprotective drugs that target a single ion channel 
is the fact that ischemic stroke is a complex syndrome. For example, after an ischemic 
insult, neurons switch from oxidative metabolism to anaerobic glycolysis, leading to the  
 
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics.  
Copyright © 2013 by the American Society for Pharmacology and Experimental Therapeutics 
 
18 
 
 
buildup of lactate within the cells and a reduction in tissue pH (Munoz Maniega et al., 
2008).  
This drop in tissue pH, along with synaptic proton release triggered in neurons by 
ischemia, activates the acid sensing ion channel 1a (ASIC1a) (Xiong et al., 2004, Mari et 
al., 2010). These channels contribute directly and indirectly to [Ca2+]i dysregulation in 
neurons during ischemia (Herrera et al., 2008), and are responsible for significant NMDA 
channel-independent brain injury following an stroke (Xiong et al., 2004). In addition, 
activated microglia migrate to the site of insult and are part of the immune/inflammatory 
response that significantly contributes to stroke injury (Eichhoff et al., 2011).  
Sigma (σ) receptors have been shown to be widely expressed in mammalian 
brain tissue (Cobos et al., 2008) and perform a number of functions, including regulation 
of plasma membrane ion channels and expression of anti-apoptotic transcription factors 
(Zhang and Cuevas, 2002, 2005, Meunier and Hayashi, 2009, Kurokawa et al., 2011b). 
Activation of σ receptors was shown to regulate multiple Ca2+ influx pathways known to 
be functionally upregulated during stroke, including ASIC1a (Katnik et al., 2006, Mari et 
al., 2010). In light of these findings and other reports in the literature, there has been 
much interest in exploring σ receptors as neuroprotective mediators during an ischemic 
stroke. One of the most exciting discoveries relating to σ receptors in stroke therapeutics 
is the potential of these receptors as viable targets for stroke therapy at delayed time 
points. Our group showed that activation of σ receptors using o-DTG reduced neuronal 
injury in an animal model of ischemic stroke even when the drug was administered 24 hr 
post-stroke (Ajmo et al., 2006).  
19 
 
 
o-DTG is a pan-selective agonist of σ receptors, binding to both σ-1 and σ-2 
receptors at nanomolar concentrations, interacting with the σ-1 receptor via an amine 
moiety on the guanidine core (Glennon, 2005). From this parent molecule, novel 
compounds were designed and synthesized with the objective of developing σ ligands 
that inhibit increases in [Ca2+]i with higher potency during in vitro experiments. 
Experiments were conducted to compare the capacity of DTG analogues to affect three 
important contributors to the demise of brain cells following ischemic stroke: intracellular 
Ca2+ dysregulation produced in neurons by 1) acidosis and 2) ischemia, and 3) activation 
and migration of microglial cells. While previous studies using guanidine substitutions 
were made in an attempt to characterize the structure-affinity relationships (Reddy et al., 
1994, Schetz et al., 2007) our focus was to identify what affects steric hindrance, 
electrostatic interactions, or increased lipid permeability had on the structure-activity 
relationship in mitigating increases in [Ca2+]i. p-BrDPhG showed the greatest block in 
inhibiting increase in [Ca2+]i evoked via ischemia or acidosis and in mitigating activation 
and migration of microglial cells.  
 
Materials and Methods 
 
 
Preparation of Cortical Neurons 
All experiments were carried out on cultured cortical neurons from mixed sex 
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used 
here were identical to those previously reported for the isolation and culturing of these 
cells (Katnik et al., 2006). Cortical neurons were used between 10-21 days in culture, 
which permits synaptic contact formation and yields the most robust responses to 
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ischemia and acidosis. Animals were cared for in accordance with the regulations and 
guidelines set forth by the University of South Florida’s College of Medicine Institution on 
Animal Care and Use Committee. 
 
Calcium Imaging 
 
Intracellular Ca2+ concentration was measured in isolated cortical neurons using 
ratiometric fluorometry as previously described (Katnik et al., 2006). Cells plated on poly-
L-lysine coated coverslips were incubated at room temperature for 1 hr in B27 
supplemented Neurobasal medium (Invitrogen) containing 3 µg/ml of the 
acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO. Prior to beginning the 
experiments, the coverslips were rinsed with physiological saline solution (PSS). For 
experiments in which cells were exposed to in vitro ischemia, the control PSS (PSS-1) 
consisted of (in mM): 140 NaCl, 3 KCl, 10 HEPES, 7.8 glucose, 2.5 CaCl2, and 1.2 
MgCl2 (pH to 7.2 with NaOH). The control PSS (PSS-2) for acidosis experiments 
contained (in mM): 140 NaCl, 4.5 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0 MgCl2 
(pH to 7.4 with NaOH). 
PSS was used as the control solution in all experiments. Solutions were delivered 
onto the cells via a rapid application system identical to that described previously 
(Cuevas and Berg, 1998). In vitro ischemia was achieved using glucose-free PSS-1 
containing 4 mM sodium azide (NaN3) (Katnik et al., 2006) and acidosis was evoked via 
application of PSS-2 with a pH of 6.0 (Herrera et al., 2008). Cells were only exposed to 
three or fewer episodes of ischemia or acidosis separated by 10 min wash to prevent 
rundown of cellular responses. For both ischemia and acidosis experiments, control 
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recordings were made prior to application of σ ligands. In experiments using the σ-1 
inhibitor, BD-1063, a second control recording was made in the presence of the inhibitor 
prior to application of p-BrDPhG. All test compounds were applied in PSS for 10 min 
prior to ischemia or acidosis onset, and throughout the ischemic or acidic insult.  
 
In Vitro Competition Binding Assays 
 
Rat liver P2 membrane (~350 µg protein) was used for all σ binding assays. 
Membrane homogenates were incubated for 120 min in 50 mM Tris-HCl buffer, pH 8.0, 
with radioligand and various concentrations of test ligand in a total volume of 500 µl, at 
25⁰C, in 96-well Unifilter GF/B filter plates (Perkin Elmer 50-905-1601). σ-1 receptors 
were labeled with 5 nM [3H](+)-pentazocine, and σ-2 receptors were labeled with 3 nM 
[3H]o-DTG in the presence of 300 nM (+)-pentazocine to block σ-1 receptors. Ten 
concentrations of each test ligand (0.001-10,000 nM) were run in triplicate. Nonspecific 
binding was determined in the presence of 50 µM haloperidol, with filters pre-soaked in 
polyethyleneimine for 45 min. Following incubation and subsequent equilibrium, the 
samples were harvested, washed three times, and the bound radioactivity was counted. 
Data from the competition binding studies were analyzed using GraphPad Prism (San 
Diego, CA) and nonlinear regression to determine the concentration of test ligand that 
inhibits 50% of the specific binding of the radioligand (IC50 value). Ki values were 
calculated using the Cheng-Prusoff equation. 
 
Primary Cultures of Microglia 
 
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat 
pups (post-natal day 2-3) as previously described by our laboratory (Hall et al., 2009a, 
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Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C 
prior to experiments being carried out. Microglia were mechanically separated from the 
cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS 
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine 
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum 
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific 
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells 
were used immediately for migration and cytotoxicity assays or plated on glass 
coverslips for one day for imaging experiments.  
 
Microglial Migration 
 
The migration assays were carried out using a 48-well microchemotaxis chamber 
(Neuro Probe, Inc., Gaithersburg, MD) as described previously (Cuevas et al., 2011b). 
The bottom wells of the chamber were filled with DMEM containing the chemoattractant, 
ATP (100 µM), and 0.1% DMSO. In the upper chamber, 1x106 freshly isolated microglia 
were applied in DMEM. The test compounds, p-BrDPhG (30 µM) and o-DTG (30 µM), 
were applied both with the ATP and the microglia in the appropriate wells. These 
chambers were separated by a polycarbonate membrane containing 8 µm pores at a 
density of 1 x 103 pores/mm2. Each well has an exposed filter area of 8 mm2. Prior to 
experiments, the membrane was coated with fibronectin at 10 µg/ml in phosphate buffer 
solution (PBS) for 1 hr at room temperature. The microglia were permitted to migrate for 
2 hr in a CO2 incubator (5% CO2) at 37oC. The membrane was then removed and non-
migrating microglia adhering to the top of the membrane were scraped off. The 
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membrane was then incubated in 4% paraformaldehyde in PBS for 15 min at room 
temperature, washed 2 times in ice cold PBS, and washed once in distilled water. The 
membrane was then cut to separate the wells and placed on microscope slides, bottom 
of the membrane facing up. Once the membrane dried, Vectashield Hardset mounting 
media containing 4'-6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA) 
was applied to the membrane and a coverslip affixed to the slide. Cells were illuminated 
at 359 nm and visualized at 461 nm using a Zeiss Axioskop 2 outfitted with a 20X 
objective. DAPI positive cells were identified and counted using Image-J in four random 
fields/well and the average for the fields used as the value for the well. For each 
experiment, a minimum of three wells were used, and the results of at least three 
experiments were averaged together.  
 
Drugs and Chemicals 
 
The following drugs were used in this investigation: o-DTG and BD-1063 (Tocris 
Biosciences, Ellisville, MO); adenosine 5′-triphosphate disodium salt hydrate (Sigma-
Aldrich, St. Louis, MO); and fura-2 acetoxymethyl ester (Invitrogen). The DTG analogues 
were synthesized in our laboratory via copper-catalyzed-cross-coupling guanidinylation 
as we have previously reported (Cortes-Salva et al., 2010). The structures of the DTG 
analogues synthesized were subjected to verification via 13C-, 1H-NMR and mass 
spectrometry. Vehicles for drugs used were either dimethyl sulfoxide (DMSO) or ethanol 
(EtOH).  
 
 
24 
 
 
Data Analysis:  
Fluorescence intensities were recorded from cortical neurons in the same manner 
as previously described (Katnik et al., 2006, Herrera et al., 2008). Data were analyzed 
using Sigma Plot/Sigma Stat 11(Systat Software, Inc., San Jose, CA). Data points 
represent peak means ± standard error of the mean (S.E.M.). Paired and unpaired 
Student’s t tests were used to determine significant differences within- and between-
groups, respectively. Results were considered statistically significant if p < 0.05. One- 
and two-way analysis of variance were used for determining significant differences for 
multiple group comparisons, as appropriate, followed by post hoc analysis using either a 
Tukey or Dunn’s test. Mean relative inhibitions were calculated using the following 
equation: Mean Relative Inhibition =  
𝐶𝐶−𝑋𝑋
𝐶𝐶
�
𝐶𝐶−𝐷𝐷𝐷𝐷𝐷𝐷
𝐶𝐶
�
 
where C is the control response, X is the response in the presence of the test compound, 
and DTG represents the response in the presence of 100 µM o-DTG. The Langmuir-Hill 
equation was used to analyze concentration-response data.  
 
Results 
 
 Experiments were conducted to determine the effects of o-DTG and derivatives 
on elevations in [Ca2+]i induced in cultured cortical neurons by ischemia. Figure 2.1A 
shows representative traces of [Ca2+]i as a function of time recorded from four neurons 
during ischemia in the absence (Control) and presence of the indicated drugs (all at 100  
µM). Similar inhibitions were observed for all of the compounds shown. Identical 
experiments showed that while removal of the methyl moiety resulted in a compound  
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(DPhG) that was more potent than m-DTG and p-DTG, none of these compounds were 
statistically more potent than o-DTG in this assay (Figure. 2.1B). 
 
Figure 2.1 
 
Shifting the location of the methyl moiety produces o-DTG analogues that inhibit 
ischemic-induced increases in [Ca2+]i similar to the parent compound. A, representative 
traces of intracellular calcium as a function of time recorded from four neurons during 
chemical ischemia in the absence (Control) and presence of the indicated compounds. 
B, mean change in peak relative inhibition of [Ca2+]i (±S.E.M.) obtained in response to 
ischemia for the indicated compounds all at 100 µM. Experiments preformed are 
identical to those in (A) (n > 47). Dagger indicates significant difference between DPhG 
and m-, p-DTG (p < 0.05). 
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Recent studies have shown that activation of σ receptors inhibit acidosis-evoked 
[Ca2+]i overload (Herrera et al., 2008, Cuevas et al., 2011a). Experiments were 
conducted to determine whether migration or removal of the methyl moiety would alter 
 
Figure 2.2 
 
Removal, but not migration, of the methyl moiety increases capacity of o-DTG analogues 
to inhibit acidosis-evoked elevations in [Ca2+]i. A, representative traces of [Ca2+]i as a 
function of time recorded from four neurons during acidosis in the absence (Control) and 
presence of the indicated drug. B, bar graph of mean change in peak relative inhibition of 
acidosis-evoked [Ca2+]i (±S.E.M.) for the indicated compounds, all at 100 µM; 
experiments are identical to (A). For each condition, n > 50. Asterisk denotes significant 
difference between o-DTG and DPhG (p < 0.05); Dagger represents significance 
between DPhG and m-DTG (p < 0.05). 
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the ability of the o-DTG derivatives to inhibit acid-evoked elevations in [Ca2+]i. Figure 
2.2A shows representative traces of [Ca2+]i recorded from four neurons during acidosis in 
the absence (Control) and presence of the indicated DTG analogues. Data show that all 
of these compounds inhibit the acid-induced elevations in [Ca2+]i. While m- and p-DTG 
showed similar potency relative to o-DTG, DPhG, which lacks the methyl moiety, 
produced a block statistically greater than the parent compound (p < 0.05) (Figure 2.2B) 
Fluoro substitution of piperidine compounds has been shown to increase the 
lipophilicity of the molecules (de Candia et al., 2009) and several piperidine derivatives 
have long been used as σ receptor ligands (Nakazawa et al., 1998, Schetz et al., 2007). 
Further experiments were conducted to evaluate whether methyl-to-fluoro substitution of 
o-DTG would result in increased drug potency. Representative traces of [Ca2+]i as a 
function of time recorded from three neurons are shown in Figure 2.3A. Cells were 
exposed to ischemia in the absence (Control) and presence of fluoro substituted 
guanidine analogues in the ortho, meta, and para positions. Inhibitions of [Ca2+]i 
elevations were noted for all compounds. Identical experiments revealed that while these 
compounds produced statistically significant inhibitions of ischemia evoked increases in 
[Ca2+]i, none of the compounds were more potent than o-DTG (Figure 2.3B). 
Furthermore, only p-FDPhG produced inhibition which was greater than that observed 
for the compound with the methyl moiety at the same site (i.e. p-DTG). Figure 2.3C 
shows representative traces of [Ca2+]i recorded from three neurons evoked by acidosis in  
the absence (Control) and presence of the specified fluoro substituted analogues (all at 
100 µM). In experiments identical to those previously shown, the fluoro substituted 
guanidine analogues did not produce greater inhibitions relative to o-DTG or when 
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Figure 2.3 
Fluoro substitution does not affect o-DTG analogue inhibition of ischemia- or acidosis-
evoked increases in [Ca2+]i. A, representative traces [Ca2+]i as a function of time 
recorded from three neurons during chemical ischemia in the absence (Control) and 
presence of the indicated drug. B, mean change in peak relative inhibition of [Ca2+]i 
(±S.E.M.) evoked by ischemia for the indicated compounds at 100 µM; measurements of 
experiments are identical to those in (A) (n > 58). Daggers indicate significance between 
o- and p-FDPhG from m-FDPhG (p < 0.05.). Pound symbol represents significant 
difference from relative inhibition produced by the methyl moiety in the equivalent 
position (p < 0.05). For comparison, block by the methyl compound is indicated by the 
line and arrow. C, representative traces of [Ca2+]i as a function of time recorded from 
three neurons during acidosis in the absence (Control) and presence of the indicated 
drugs. D, bar graph of mean change in peak relative inhibition of [Ca2+]i (±S.E.M.) 
obtained in response to acidosis for the indicated compounds at 100 µM (n > 67). There 
is no significant difference between o-DTG and the analogues. 
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compared to the compounds with a methyl moiety at the same site (i.e. m-DTG and p-
DTG; Figure 2.3C). 
Halogen substitution is often used for enhancing permeability of a drug. It has 
been shown that replacing a single hydrogen residue with a chloro moiety in compounds 
with comparable size to DTG increased the hydrophobicity of a compound (Gerebtzoff et 
al., 2004). Experiments were carried out to assess how methyl-to-chloro substitution of 
DTG in the ortho, meta, and para positions altered the ability of the compounds to affect 
[Ca2+]i increases evoked by ischemia and acidosis. Figure 4A shows representative 
traces of [Ca2+]i recorded from three neurons during episodes of ischemia in the absence 
(Control) and presence of the chloro substituted compounds. Inhibition of ischemia-
evoked elevations in [Ca2+]i was observed for all compounds. However, only the chloro 
moiety substituted at either the meta or the para position increased the potency of the 
drug (Figure 2.4B). Both m- and p-ClDPhG yielded statistically significant increases in 
inhibition p < 0.05 and p < 0.001, respectively, of ischemia-induced elevations in [Ca2+]i 
relative to o-DTG. These compounds were also more potent than the compounds with a 
methyl moiety at the equivalent position (Figure 2.4B). Figure 2.4C shows representative 
traces of [Ca2+]i obtained from three neurons in response to acidosis in the absence 
(Control) and presence of the indicated drugs. The pattern of inhibition of acidosis- 
evoked elevations in [Ca2+]i produced by the chloro substituted compounds was similar 
to that observed in the ischemia experiments. While the block produced by o-ClDPhG 
did not show a significant difference when compared to o-DTG at the same 
concentration, both m-ClDPhG and p-ClDPhG produced a statistically significant (p < 
0.001) increase in the degree of block of acidosis-elicited [Ca2+]i overload that was >2-
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fold greater than that of o-DTG, and greater than that of the equivalent methyl 
substitutions (Figure 2.4D). 
 
Figure 2.4 
 
Chloro substitution at the meta and para positions increase inhibition of intracellular 
calcium elevations. A, representative traces of [Ca2+]i as a function of time recorded from 
three neurons during ischemia in the absence (Control) and presence of the drugs 
shown. B, bar graph of mean change in peak relative inhibition of [Ca2+]i (±S.E.M.) 
induced by ischemia for the drugs indicated at 100 µM (n > 55). C, representative traces 
of [Ca2+]i from three neurons recorded as a function of time induced by acidosis in the 
absence (Control) and presence of the drugs shown. D, bar graph of mean change in 
peak relative inhibition of [Ca2+]i (± S.E.M.) evoked via acidosis for the drugs indicated at 
100 µM (n > 59). For both (B) and (D), asterisks indicate significant differences between 
o-DTG and m- and p-ClDPhG groups (p < 0.001), daggers indicate statistical difference 
from o-ClDPhG (p < 0.001), and pound symbols  represent significant differences from 
relative inhibition produced by the methyl moiety in the equivalent position (p < 0.001 for 
all). Lines and arrows in (B) and (D) mark the block by the methyl compound at each 
site, and are shown for comparison.  
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Experiments were also carried out to determine if the substitution of a bromo 
moiety could likewise affect the potency of the compounds. Figure 2.5A shows 
representative traces of [Ca2+]i recorded from three neurons responding to ischemia in 
the absence (Control) and presence of o-, m-, or p-BrDPhG, with all compounds 
producing some degree of block. The attenuation of ischemia-evoked elevations in 
[Ca2+]i resulting when the ortho substituted compound (o-BrDPhG) was applied was 
similar to that seen with o-DTG. However, both m-BrDPhG and p-BrDPhG blocked the 
[Ca2+]i overload to a greater degree with the inhibition produced by each compound 
being statistically greater than o-DTG, p < 0.001. The bromo substituted compounds also 
inhibited acidosis-evoked [Ca2+]i increase. Representative traces of [Ca2+]i recorded from 
three neurons and demonstrating such inhibition by all of these compounds are shown in 
Figure 2.5C. As with the ischemia assay, the m-BrDPhG and p-BrDPhG compounds 
were significantly more potent than o-DTG at inhibiting acidosis-induced [Ca2+]i increases 
p < 0.001, but o-BrDPhG was comparable in effectiveness to o-DTG (Figure 2.5D). In 
both the ischemia and acidosis experiments, the m- and p-BrDPhG were more potent 
than the equivalent methyl substitutions (Figure 2.5B and 5D). 
The guanidine analogue that exhibited the most pronounced inhibition of [Ca2+]i 
overload in both assays was p-BrDPhG. Thus, further experiments were carried out to 
precisely measure the concentration response relationship for p-BrDPhG inhibition of 
[Ca2+]i overload produced by ischemia. Representative traces of [Ca2+]i as a function of 
time recorded from two neurons in response to ischemia in the absence (Control) and 
presence of 10 µM and 100 µM o-DTG and p-BrDPhG are shown in Figure 2.6A and 6B, 
respectively. Inhibitions of the [Ca2+]i elevations by both of these compounds showed a  
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Figure 2.5 
 
Substitution of the methyl moiety with bromide at the meta and para positions enhances 
[Ca2+]i inhibition. A, representative traces of [Ca2+]i as a function of time recorded from 
three neurons induced via chemical ischemia in the absence (Control) and presence of 
the indicated bromo derivatives at 100 µM. B, mean relative inhibition of ischemia-
induced change in peak [Ca2+]i (±S.E.M.) evoked by bromo derivatives at 100 µM for 
each drug (n > 55). C, representative traces of [Ca2+]i as a function of time recorded from 
three neurons during acidosis in the absence (Control) and presence of the drugs 
shown. D, bar graph of mean relative inhibition of change in peak [Ca2+]i (±S.E.M.) 
induced via acidosis for the drugs indicated (all at 100 µM, n > 53). For both (B) and (D), 
asterisks indicate statistical differences from o-DTG (p < 0.001), daggers indicate 
significant difference from o-BrDPhG (p < 0.001), and pound symbols represents 
significant differences from the methyl moiety in that position (p < 0.001). For 
comparison, block by the methyl compounds in the equivalent site is indicated by the 
lines and arrows in (B) and (D). 
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concentration dependence. Plots of the mean relative change in [Ca2+]i as a function of 
drug concentration for both o-DTG and p-BrDPhG are shown in Figure 2.6C. The data 
were best fit by single-site Langmuir-Hill equations, and indicate a 34-fold greater 
potency for p-BrDPhG in inhibiting ischemia-evoked increases in [Ca2+]i relative to o-
DTG.  
 
Figure 2.6 
 
Inhibition of ischemia-evoked increases in [Ca2+]i by p-BrDPhG is concentration-
dependent. Representative traces of [Ca2+]i recorded as a function of time from a single 
neuron during chemical ischemia in the absence (Control) and presence of 10 and 100 
µM o-DTG (A) or in the absence (Control) and presence of 10 and 100 µM p-BrDPhG 
(B). C, concentration-response relationship for mean change in peak [Ca2+]i (±S.E.M.) 
measured during chemical ischemia in the presence of o-DTG (open circle) and p-
BrDPhG (closed circle). Drugs were normalized to their respective controls (ischemia in 
absence of drug for each cell). Lines were best fit to the data using single-site Langmuir-
Hill equations with IC50 values and Hill coefficients of 74.7 µM and 0.58 (o-DTG), and 2.2 
µM and 0.63 (p-BrDPhG), respectively. For each data point, n > 65. 
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Similar experiments were carried out to determine the concentration-response 
relationship for p-BrDPhG inhibition of elevations in [Ca2+]i caused by acidosis. Figure 
2.7A shows representative traces of [Ca2+]i recorded as a function of time from a single 
neuron during acidosis in the absence (Control) and presence of 10 and 100 µM p-
BrDPhG. Increasing the p-BrDPhG concentration resulted in further depression of 
acidosis-induced [Ca2+]i overload. Figure 2.7B shows a plot of the mean change in peak 
[Ca2+]i as a function of p-BrDPhG concentration obtained from multiple experiments. 
These results show an 8-fold greater potency of p-BrDPhG in inhibiting increases in 
[Ca2+]i induced via acidosis when compared to o-DTG. The efficacy of p-BrDPhG was 
similar to that of o-DTG in both the ischemia and the acidosis assay. 
To determine if the o-DTG derivative p-BrDPhG retains the σ receptor binding 
properties of the parent compound, a binding assay was performed using o-DTG for  
comparison. Results of the binding study are presented in Table 2.1 and show that p-
BrDPhG binds both σ-1 and σ-2 receptors. However, the affinity for both receptors was 
decreased, with the affinity for σ-2 decreasing to a greater extent. The Ki for p-BrDPhG 
was statistically less than o-DTG at both σ-1 and σ-2 receptors, and the affinity of p-
BrDPhG for σ-2 receptors was significantly lower than for σ-1 receptors (for all, p < 
0.001; Table 2.1. While the binding study suggests that p-BrDPhG can act via σ  
receptors to inhibit [Ca2+]i dysregulation, functional experiments were carried out using 
the σ-1 receptor antagonist, BD-1063, to confirm this possibility. Figures 2.8A and 8B 
show representative traces of [Ca2+]i as a function of time recorded from two neurons in 
response to acidosis in the absence (Control) and presence of 30 µM p-BrDPhG (Figure 
2.8A) or p-BrDPhG with 10 nM BD-1063 (Figure 2.8B). p-BrDPhG produced a reduction  
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Figure 2.7 
 
p-BrDPhG inhibits acidosis-evoked increases in [Ca2+]i in a concentration-dependent 
manner. A, representative traces of [Ca2+]i recorded as a function of time from a single 
neuron during acidosis in the absence (Control) and presence of p-BrDPhG at the 
indicated concentrations. B, concentration-response relationship for mean change in 
peak [Ca2+]i (±S.E.M.) recorded during acidosis in the absence and presence of p-
BrDPhG. Responses obtained in the presence of p-BrDPhG were normalized to control 
(absence of drug) for each cell (n > 72). Black line represents best fit to the data p-
BrDPhG using a Langmuir-Hill equation with an IC50 value of 13.5 µM and a Hill 
coefficient of 1.2. Presented for comparison was the best fit to the data obtained for o-
DTG inhibition of acid-evoked elevations in [Ca2+]i (gray line, IC50 = 109.3 µM; Hill 
coefficient, 0.9) (Herrera et al., 2008). 
 
in [Ca2+]i in the absence and presence of BD-1063. However, less block by p-BrDPhG 
was noted when BD-1063 was included with the guanidine analogue. In identical 
experiments, a reduction in [Ca2+]i was noted for both p-BrDPhG and p-BrDPhG + BD-
1063. However, the effects of p-BrDPhG were significantly reduced in the presence of 
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the σ-1 antagonist and this decrease was statistically significant (p < 0.001) (Figure 
2.8C). BD-1063 alone had no effect on acidosis-induced [Ca2+]i elevations (Figure 2.8C). 
 
Figure 2.8 
 
σ-1 receptor antagonist BD-1063 attenuates p-BrDPhG inhibition of acidosis-evoked 
increases in [Ca2+]i. A, representative traces of [Ca2+]i as a function of time recorded from 
a single neuron during acidosis in the absence (Control) and presence of 30 µM p-
BrDPhG. B, representative traces of [Ca2+]i as a function of time recorded from a single 
neuron during acidosis in the absence (Control) and presence of 10 nM BD-1063, or 10 
nM BD-1063 + 30 µM p-BrDPhG (p-BrDPhG + BD-1063). C, Bar graph of relative mean 
change in peak [Ca2+]i induced by acidosis (n > 50). Data were normalized to values 
obtained for each cell in the absence of σ ligands. Asterisks denote significant 
differences between p-BrDPhG and their respective DMEM (p > 0.001), and a dagger 
indicates a statistical difference between the p-BrDPhG groups of Control and BD-1063 
(p > 0.001), pound denotes significance between p-BrDPhG with BD-1063 and the 
DMEM Control (p > 0.001). There was no difference between DMEM groups. 
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Figure 2.9 
 
p-BrDPhG blocks the migration of microglia elicited by ATP. A, concentration-response 
relationship for p-BrDPhG (closed circles) and o-DTG (open circles) inhibition of ATP-
induced (100 µM) migration of microglial cells. The black line represents the best fit to 
the o-DTG data using a Langmuir-Hill equation with an IC50 value and Hill coefficient of 
23.33 µM and 0.67, respectively. The grey line represents the best fit to the p-BrDPhG 
data using a Langmuir-Hill equation with an IC50 value and Hill coefficient of 6.53 µM and 
0.75, respectively. Points represent mean (±S.E.M.) and for all points, n > 9. 
 
Recently, our laboratory showed that activation of σ receptors with pan-selective 
ligands such as o-DTG or afobazole modulates microglial activation, and inhibits 
microglial cell migration in response to chemoattractants such as ATP (Cuevas et al., 
2011b). This effect on microglial cell activation has been postulated to be a mechanism 
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by which σ receptor activation reduces ischemic stroke injury (Cuevas et al., 2011b). For 
this reason, experiments were carried out to determine if p-BrDPhG is also more potent  
than o-DTG in preventing microglial cell migration. Figure 2.9 shows a plot of the mean 
number of migrating microglial cells as a function of p-BrDPhG concentration obtained 
from multiple experiments. Data from 30 µM p-BrDPhG were best fit using the Langmuir-
Hill equation with an IC50 value of 6.53 µM and a Hill coefficient of 0.53. Data from 30 µM 
o-DTG were best fit using the Langmuir-Hill equation showed an IC50 = 23.33 µM and Hill 
coefficient of 0.67. These results represent just under a 4-fold greater potency of p-
BrDPhG in inhibiting microglial migration induced via 100 µM ATP when compared to o-
DTG. 
Table 2.1 
 
o-DTG binds to both σ receptor subtypes with greater affinity than p-BrDPhG. 
 Average Ki values ± S.E.M. determined from binding assays using membrane protein 
extracts from rat livers. σ-1 receptors were labeled with 5 nM [3H](+)-pentazocine and σ-
2 receptors were labeled with 3 nM [3H] o-DTG in the presence of 300 nM (+)-
pentazocine to block σ-1 receptors. Nonspecific binding was determined in the presence 
of 50 µM haloperidol. Asterisks indicate significant difference between p-BrDPhG and o-
DTG binding at σ-1 (p < 0.01) and σ-2 (p < 0.001) receptors. Pound symbol denotes 
significant difference between p-BrDPhG affinity for σ-1 versus σ-2 sites. 
 
 Receptor Average Ki (nM) SEM 
p-BrDPhG Sigma-1 296 46.01 
 Sigma-2 800.33 56.96 
o-DTG Sigma-1 * 91.02 9.7 
 Sigma-2 * 60 8.76 
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Discussion 
This study demonstrates three novel findings. First, methyl-to-chloro or methyl-to-
bromo substitution of DTG in the meta and para positions results in new compounds with 
greater potency relative to o-DTG for inhibiting [Ca2+]i overload induced by chemical 
ischemia or acidosis in neurons. Of the compounds tested, p-BrDPhG, is the most potent 
in these assays. Second, our data show that p-BrDPhG binds σ receptors with a reduced 
affinity relative to o-DTG, but that the inhibition of [Ca2+]i overload continues to be 
dependent on σ-1 receptor activation. The fact that p-BrDPhG has reduced σ receptor 
binding but increased potency in the functional assay suggests that increased lipid 
permeability may account for the enhanced inhibition. Finally, p-BrDPhG is also more 
potent than o-DTG in preventing microglial migration in response to ATP, indicating that 
this novel compound can effectively reduce microglial activation at lower concentrations 
relative to o-DTG.  
Our initial experiments involved shifting and removal of the methyl moiety of DTG 
to ascertain effects on in vitro functional assays used to predict therapeutic potential in 
ischemic stroke. Our findings with the DTG analogues show that rearrangement of the 
methyl moiety does not produce a compound which behaves differently from the parent 
compound in terms of modulating [Ca2+]i increases induced via ischemia and acidosis. 
Removal of the group entirely (DPhG) produces a significant 18.3 ± 0.05% increase over 
o-DTG in inhibiting elevations in [Ca2+]i during acidosis. Similarly, DPhG show a 12.2 ± 
0.04% greater inhibition than o-DTG in the ischemia assay, but this difference was not 
statistically significant. Previous studies have reported that the σ receptor binding 
affinities for o-, m-, and p-DTG are approximately 30, 50, and 530 nM, respectively; 
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whereas the affinity of DPhG for σ receptors is ~400 nM (Scherz et al., 1990, Reddy et 
al., 1994). Results from our functional studies, therefore, do not reflect the decrease in 
affinity observed for the p-DTG or DPhG. Calcium elevations evoked by ischemia and 
acidosis are in part due to activation of NMDA receptors (Katnik et al., 2006, Herrera et 
al., 2008). However, neither p-DTG nor DPhG shows increased affinity for NMDA 
receptors compared to o-DTG (Scherz et al., 1990, Reddy et al., 1994), and thus actions 
on that receptor cannot account for the discrepancy between σ receptor binding and 
functional effects. Since the earlier studies did not examine specifically σ receptor 
subtype binding affinity, the difference may be due to changes in affinity for one receptor 
subtype versus the other (i.e. σ-2 receptor affinity decreases significantly but σ-1 
receptor affinity remains unchanged). 
While migration and removal of the methyl moiety failed to alter functional 
properties of the molecule significantly, pronounced enhancement in potency were found 
with halide substitutions. Data presented here show that substituting a chloro for a 
methyl moiety in the meta and para positions of DTG produced compounds that had 
~15% higher potency relative to the parent compound (o-DTG) at 100 µM concentration 
in the ischemia-induced increases in [Ca2+]i assay. The enhancement in potency was 
even more pronounced in the acidosis-evoked [Ca2+]i dysregulation assay. In this assay, 
m- and p-ClDPhG (100 µM) produced blocks of >100% greater than o-DTG. In contrast, 
substitution of a chloro moiety in the ortho position did not alter the functional effects of 
the parent compound in either the ischemia or acidosis assay. Similar observations were 
made using compounds with bromo substitutions (BrDPhG) of DTG in the meta and para 
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positions with an ~22% increase of inhibition during ischemia and an ~160% increase 
during acidosis applications over o-DTG, respectively. The most potent compound tested 
was p-BrDPhG, which had an IC50 indicating 8-fold and 34-fold greater potency over that 
of o-DTG in the acidosis [Ca2+]i and ischemia [Ca2+]i assays, respectively.  
Functional assays indicated that p-BrDPhG was significantly more potent than o-
DTG, but a radioligand binding assay showed decreased affinity for both σ receptor 
subtypes. Our experiments showed that o-DTG binds σ-1 and σ-2 receptors with an 
affinity in the range of 60-90 nM, which is similar to what was previously reported in the 
literature (Torrence-Campbell and Bowen, 1996). In contrast, p-BrDPhG was found to 
bind σ-1 and σ-2 receptors with 296 ± 46 nM and 800 ± 57 nM affinities, respectively, 
with the σ-2 receptor affinity being significantly lower. These values are similar to a 
previous report which indicates that p-BrDPhG binds guinea pig brain membrane 
extracts with an affinity of 540 ± 25 nM (Scherz et al., 1990). That study also 
demonstrated that p-BrDPhG has lower binding affinity for the NMDA receptor than the 
parent compound (o-DTG), and therefore, the increased functional potency cannot be 
explained by increased action at the NMDA receptor. 
Confirmation that p-BrDPhG mitigates [Ca2+]i dysregulation via activation of σ-1 
receptors was achieved via the use of the σ-1 receptor antagonist BD-1063. Using the 
acidosis [Ca2+]i functional assay, BD-1063 was shown to inhibit the effects of p-BrDPhG 
by >50% at a concentration of 10 nM, which is consistent with p-BrDPhG acting via σ-1 
receptors (Matsumoto et al., 1995, Herrera et al., 2008). To date, only activation of the σ-
1 receptor has been shown to affect ischemia- and acidosis-evoked [Ca2+]i dysregulation 
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(Katnik et al., 2006, Herrera et al., 2008), and thus effects by the σ-2 receptor were not 
tested in these assays. 
The current study shows that p-BrDPhG also inhibits microglial activation and this 
DTG analogue is 4-fold more potent than the parent compound and a second pan-
selective σ agonist, afobazole (Hall et al., 2009a, Cuevas et al., 2011b). Unlike ischemia- 
and acidosis-evoked [Ca2+]i dysregulation, which appears to be exclusively affected by σ-
1 receptor activation, both σ-1 and σ-2 receptors can modulate microglial migration 
(Cuevas et al., 2011b). This observation may explain why p-BrDPhG, which has even 
lower affinity for σ-2 than σ-1, is only 4-fold more potent than o-DTG in the microglial 
migration assay but 8- to 34-fold more potent than the parent compound in the [Ca2+]i 
dysregulation experiments. The observation that p-BrDPhG is more potent than o-DTG 
in inhibiting microglial activation may have important therapeutic implications. Previous 
studies have demonstrated that activation of microglia following an ischemic insult 
results in the release of pro-inflammatory cytokines by these cells, which promotes 
neuronal death (Lee et al., 2001).  
One mechanism which may explain the discrepancy between decreased binding 
affinity but increased functional potency of p-BrDPhG may be increased membrane 
permeability of the compound. It has been shown that chloro and bromo substitution in 
the para position on phenylalanine increases hydrophobicity and blood-brain barrier 
permeability of a drug (Gentry et al., 1999). Likewise, halogenation of small molecules 
has been demonstrated to increase membrane permeation (Gerebtzoff et al., 2004). It 
has been shown that increasing membrane permeability of a σ ligand by deprotonation 
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increases potency of the compound, which was interpreted to suggest that the binding 
site for ligands such as BD-1063 are intracellular (Vilner and Bowen, 2000). Immuno-
labeling studies have confirmed this hypothesis, showing that σ-1 receptors localize to 
the endoplasmic reticulum (Dussossoy et al., 1999, Seminerio et al., 2012). Moreover, 
the proposed binding site for drugs such as o-DTG are, in part, located in the 
transmembrane domain of the receptor (Pal et al., 2007). Thus, by increasing membrane 
permeability, chloro and bromo substitution more than compensate for the decreased 
binding affinity. 
Our data, however, also suggest that factors other than membrane permeability 
are likely involved in the effects of the halogenation and methylation. Electronegativity 
and conformation of the molecule are also important. For example, fluoro substitution of 
a distal phenyl group of a piperidine greatly increased the lipophilicity of the compound 
(de Candia et al., 2009). Despite the likely increased lipid permeability, our findings show 
that fluoro substitution does not result in increased inhibition of [Ca2+]i dysregulation 
evoked via ischemia or acidosis relative to o-DTG. One possibility is that while the fluoro 
substitution may increase the drugs lipophilicity, the added increase in electronegativity 
caused by addition of a fluoro moiety may have disrupted binding of the compound to the 
σ receptors. While fluorine has an electronegativity of 4.0, that of chlorine and bromine 
are ~ 3.0. Moreover, our data suggest that location of chloro and bromo substitutions on 
the phenyl ring for enhanced potency were limited to either the meta or para positions. A 
previous report on structure-activity relationship of DTG analogues suggested that the 
ortho position was the most tolerant to structural modifications, including addition of 
electronegative moiety (Scherz et al., 1990). However, that report did not distinguish 
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between σ-1 and σ-2 receptor binding, and thus the effects of those modifications on the 
respective receptors remains to be determined.  
In conclusion, these findings show that the chloro and bromo substituted 
analogues of DTG have potential applications as anti-stroke therapeutics, showing a 
greater potency for inhibiting intracellular calcium dysregulation over o-DTG. In addition, 
p-BrDPhG blocks microglial migration with greater potency than o-DTG, indicating that 
this DTG analogue will both provide neuroprotection and mitigate the neuroinflammatory 
response known to contribute to stroke injury. It is of significant interest to determine if 
the noted enhancement in potency of p-BrDPhG in vitro translates to superior in vivo 
outcomes.  
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CHAPTER 3 
 
 
Afobazole Activation of Sigma-1 Receptors Modulates  
Neuronal Responses to Amyloid-β25-35 
 
 
Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the 
most common form of senile dementia in the United States (Gaugler et al., 2013). While 
the full pathophysiological underpinnings of AD remain elusive, one of the hallmarks of 
AD is an increase in amyloid-β (Aβ) plaque formation in the brain (Selkoe, 2001). The Aβ 
fragment, Aβ25-35, which has been found in AD brains, has been proposed as a major 
contributor to the pathogenesis of AD (Kaminsky et al., 2010). This Aβ fragment has 
been shown to induce injury via various mechanisms including production of reactive 
oxygen species (ROS) (Schubert et al., 1995), dysregulation in intracellular Ca2+ (Joseph 
and Han, 1992), enhanced NMDA channel activity (Molnar et al., 2004), and increased 
activation of caspase-3 (Marin et al., 2000).  
Previous studies have shown that a possible link might exist between sigma 
receptors and the etiology of AD. A loss of sigma binding sites has been observed in AD, 
and specific σ-1 receptor polymorphisms have been associated with altered risk for this  
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disease (Jansen et al., 1993, Uchida et al., 2005, Mishina et al., 2008, Feher et al., 
2012).  
Sigma-1 selective agonists have also been shown to reduce memory loss 
produced by Aβ25-35 injections in mice (Maurice et al., 1998). Recently, tetrahydro-N, N-
dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) was shown to 
reduce tau hyperphosphorylation and Aβ1-42 generation in a mouse model of Alzheimer’s 
disease via the activation of both σ-1 and muscarinic receptors (Lahmy et al., 2013). 
However, it is unclear if other sigma receptor ligands, particularly ligands that do not 
affect muscarinic receptors, have similar neuroprotective properties. The molecular 
mechanism(s) by which σ-1 receptors decrease neuronal injury upon Aβ exposure have 
not been identified, and the effects of σ-2 receptor activation on neuronal responses to 
Aβ need to be elucidated. 
Sigma (σ) receptors, once thought to be a class of opioid receptors, are known to 
have widespread regulatory actions during neuropathophysiological states (Tsai et al., 
2009). The σ-1 receptor has been shown to be an inter-organelle chaperone localized to 
the mitochondrion-associated ER membrane (MAM) (Su et al., 2010). The σ-1 receptor-
MAM relationship plays important roles in cell signaling, mitochondrial function and 
maintaining intracellular Ca2+ ([Ca2+]i) homeostasis (Su et al., 2010). Furthermore, upon 
stimulation with high agonist concentrations, σ-1 receptors migrate to sub-plasmalemmal 
ER or the plasma membrane and interact with various ion channels (Su et al., 2010). In 
response to ischemia or acidosis, activation of σ-1 receptors prevents [Ca2+]i overload 
and concomitant cell death, likely via actions at multiple targets, including acid-sensing 
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ion channels and NMDA receptors (Katnik et al., 2006, Herrera et al., 2008). In addition 
to regulation of [Ca2+]i homeostasis, other sigma receptor-mediated effects may 
contribute to neuroprotection, including decreased production of ROS and reactive 
nitrogen species (RNS), activation of the anti-apoptotic protein Bcl-2, and inhibition of the 
pro-apoptotic protein Bax (Tchedre and Yorio, 2008, Meunier and Hayashi, 2009, 
Kourrich et al., 2012, Pal et al., 2012). It remains to be established if some or all of these 
effects are linked to σ receptor-mediated neuroprotection following neuronal ischemia, 
and if they contribute to neuroprotection following Aβ exposure. 
Our laboratory recently showed that afobazole (5-ethoxy-2-[2-(morpholino)-
ethylthio]benzimidazole), a drug currently used in Russia to treat anxiety and panic 
disorders, is both a σ-1 and σ-2 receptor agonist, and provides neuroprotection in an in 
vitro ischemia model (Cuevas et al., 2011a, Cuevas et al., 2011b). Unlike ANAVEX2-73, 
afobazole does not interact with muscarinic receptors (Seredenin and Voronin, 2009). 
Activation of σ-1 receptors by afobazole results in a decrease in ischemia-induced Ca2+ 
overload, which is due in part to inhibition of NMDA channel activation (Katnik et al., 
2006, Cuevas et al., 2011a). Previous studies have suggested other mechanisms for the 
neuroprotective properties of afobazole, including decreased caspase-3 activation and 
reduced oxidative stress (Zenina et al., 2005, Antipova et al., 2010). Thus, afobazole is 
an excellent ligand for examining the relationship between sigma receptors and Aβ-
induced neurotoxicity, and is a potential candidate for the treatment of Alzheimer’s 
disease. 
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Experiments were carried out to determine how afobazole affects neuronal 
responses to the Aβ fragment, Aβ25-35. Afobazole mitigated Aβ25-35-evoked increases in 
[Ca2+]i in neurons and these effects were blocked by inhibition of σ-1, but not σ-2 
receptors. Afobazole was also found to lessen NO production in response to Aβ25-35 
application, and reduced neuronal death. The decrease in cell death produced by 
afobazole was associated with reduced neuronal expression of the pro-apoptotic protein 
Bax and the death protease caspase-3 and enhanced expression of the anti-apoptotic 
gene product, Bcl-2.  
 
Materials and Methods 
 
 
Preparation of Rat Cortical Neurons 
All experiments were carried out on cultured cortical neurons from mixed sex 
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used 
here were identical to those previously reported for the isolation and culturing of these 
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated 
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium 
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for 
experiments after 10-21 days in culture, which permits synaptic contact formation and 
yields robust responses to other pathophysiological conditions such as in vitro ischemia 
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in 
accordance with the regulations and guidelines set forth by the University of South 
Florida’s College of Medicine Institution on Animal Care and Use Committee. 
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Calcium Imaging 
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using 
ratiometric fluorometry as previously described (Katnik et al., 2006). For most 
experiments, cultured neurons were incubated in 25 µM Aβ25-35 for 1-24 hr prior to [Ca2+]i 
being measured. Neurons were loaded with fura-2 by adding 3 µg/ml of the 
acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO to the media and 
incubating the cells at room temperature for 1 hr. Prior to beginning the experiments, the 
coverslips were rinsed with physiological saline solution (PSS) consisting of (in mM): 140 
NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0 MgCl2 (pH to 7.4 with NaOH). 
For each cell, [Ca2+]i was measured once a second for a 20 second period and the 
values averaged to determine baseline [Ca2+]i. The Aβ-induced increases in [Ca2+]i 
(∆[Ca2+]i) in experiments using σ receptor antagonists were calculated by subtracting 
average [Ca2+]i measured in control cells for each condition tested (i.e. absence or 
presence of σ receptor ligand) from those recorded for the individual cells when Aβ was 
added under the same conditions.  In one series of experiments, the acute effects of 
Aβ25-35 on neuronal [Ca2+]i were determined by first loading neurons with fura-2 and then 
administering Aβ25-35 via a rapid application system while measuring [Ca2+]i.   
 
ROS and NO Imaging 
 
Intracellular ROS and NO concentrations were measured in isolated cortical 
neurons using fluorometric digital microscopy (CoolSnap HQ2; Photometrics, Surrey, 
BC, Canada). Cells were plated as described above and incubated for 24 hr at 37  C in 
Neurobasal Complete containing 25 µM Aβ25-35 (± afobazole). Cultured cells were then 
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incubated at 37°C for 30 min in 10 µM DHE with 0.25% DMSO to measure ROS and for 
1 hr in 5 µM DAF-FM with 0.1 % DMSO to measure NO, both in Neurobasal Complete 
and with 25 µM Aβ25-35 (± afobazole). The fluorophores were then removed by rinsing 
coverslips with physiological saline solution (PSS). DHE and DAF-FM loaded neurons 
were excited with light at 518 nm and 495 nm, respectively.  ROS and NO 
concentrations were then measured as fluorescent emission intensities at 605 nm and 
515 nm wavelengths, respectively. Image analysis was performed using Nikon Elements 
software (Nikon, Melville, NY, USA). No afobazole autofluorescence was observed at the 
wavelengths tested.       
 
Cytotoxicity Assay 
 
Neurons plated on poly-L-lysine coverslips were incubated at 37°C for 72 hr in 
Neurobasal Complete with 25 µM Aβ25-35 in the absence (Control) and presence of 100 
µM afobazole or 100 µM DTG. The coverslips were rinsed with PBS followed by 30 min 
incubation at room temperature in PBS with 4 µL of a 2 mM ethidium homodimer-1 
(EthD-1) dissolved in 1:4 DMSO:H2O solution. The coverslips were washed with PBS 
and deionized water, dried, and mounted on a microscope slide with Vectashield Hardset 
mounting media (Vector Labs, Burlingame, CA). EthD-1 loaded cells were illuminated 
with light at 530 nm and visualized at 645 nm using a Zeiss Axioskop 2 equipped with a 
20X objective. EthD-1-positive cells were identified and counted using Image-J in four 
random fields per slide, and the average for the fields used as the value for the slide. For 
each experiment, a minimum of three slides were used, and the results of at least three 
experiments were averaged together for each condition tested.   
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Immunocytochemistry 
Neurons plated on poly-L-lysine coverslips were incubated at 37°C for 24 hr in 
Neurobasal Complete with 25 µM Aβ25-35 in the absence and presence of 100 µM 
afobazole. The coverslips were rinsed with phosphate-buffered saline (PBS) followed by 
an ethanol step-wise fixation. The cells were permeabilized with 0.1% Triton X in PBS for 
15 min, then rehydrated with PBS and washed with 0.5% bovine serum albumin (BSA) in 
PBS. Blocking was achieved with 45 min incubation in 2% BSA, followed by multiple 
washes with 0.5% BSA. Primary antibodies were diluted in PBS with 0.5% BSA and 
applied onto cells at 4°C for 24 hr. Primary antibody dilutions were as follows: Bax 1:20, 
Caspase-3 1:25 and Bcl-2 1:100. The cells were then washed multiply times with 0.5% 
BSA in PBS and then incubated in secondary antibodies for 60 min at room temperature. 
Secondary antibodies were Alexa Fluor 488 conjugated anti-mouse or anti-rabbit, as 
appropriate, both diluted at a ratio of 1:300 in PBS with 0.5% BSA. Following incubation 
in secondary antibodies, cells were washed with 0.5% BSA in PBS and then with PBS 
alone. Coverslips were rinsed with deionized water, inverted and sealed onto a slide with 
VectaShield containing DAPI.  DAPI and the Alexa Fluor 488 conjugated secondary 
antibodies were illuminated at 359 and 485 nm and visualized at 461 and 530 nm, 
respectively, using a Zeiss Axioskop 2 outfitted with a 40X objective. Images of DAPI 
and Alexa Fluor 488 positive cells were counted and merged to demonstrate co-
localization using Image-J software. Four random fields per slide were used to determine 
an average value for the slide. For each experiment, a minimum of three slides were 
used, and the results of at least three experiments were averaged together.   
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Compounds, Reagents and Antibodies 
The following compounds and reagents were used in this investigation: Aβ25-35  
(American Peptides, Sunnyvale, CA); DTG and BD-1047 (Tocris Biosciences, Ellisville, 
MO); rimcazole (Sigma-Aldrich, St. Louis, MO); fura-2 acetoxymethyl ester, DHE, DAF-
FM, Live/Dead Viability/Cytotoxicity Kit (Life Technologies). The following antibodies 
were used: Alexa Fluor 488 anti-mouse (A-11001) and anti-rabbit (A-11008) (Life 
Technologies); anti-Bax (ab5714), anti-activated caspase-3 (ab32351) and anti-Bcl-2 
(ab32370) (abcam, Cambridge, MA). Afobazole was generously provided by IBC 
Generium (Moscow, Russian Federation). Vehicle for drugs and reagents used were 
either water (H2O), ethanol (EtOH) or dimethyl sulfoxide (DMSO), and appropriate 
vehicle controls were carried out for each study.  
 
Data Analysis 
 
Data were analyzed using SigmaPlot 11 software (Systat Software, Inc., San 
Jose, CA). Data points represent peak means ± standard error of the mean (S.E.M.). 
One- and two-way analysis of variance were used for determining significant differences 
for multiple group comparisons, as appropriate, followed by post hoc analysis using the 
Holm-Sidak test. Results were considered statistically significant if p < 0.05. 
 
Results 
 
Experiments were first carried out to determine the effects of Aβ25-35 on [Ca2+]i in 
isolated cortical neurons from embryonic (E18) rats. Figure 3.1A shows representative 
traces of [Ca2+]i measured in cortical neurons exposed to acute applications of 25 µM 
Aβ25-35 (≤ 15 min). During this time period, the Aβ fragment did not significantly affect 
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[Ca2+]i in the neurons. To examine if extended incubation in Aβ25-35 alters [Ca2+]i, neurons 
were incubated from 1 hr  to 24 hr in media contain 25 µM Aβ25-35. Figure 3.1B shows a 
bar graph of mean [Ca2+]i recorded from different groups of neurons incubated in Aβ25-35 
for the indicated time points. The Aβ fragment produced a statistically significant 
increase in [Ca2+]i at all time points tested, with peak increases occurring 12 hr after 
Aβ25-35 application. 
 
Figure 3.1 
 
Aβ25-35 promotes time-dependent elevations in neuronal intracellular calcium. A, 
representative traces of intracellular calcium as a function of time recorded from five 
neurons during acute application of 25 µM Aβ25-35. Line above traces indicates duration 
of Aβ application. B, Bar graph of mean (±SEM) [Ca2+]i measured in neurons exposed to 
media (Control) or media containing 25 µM Aβ25-35 for the indicated times. Control value 
is compiled from measurements made at all time points. Asterisk denotes significant 
difference from Control (p < 0.05); for all time points, n > 1500 neurons.  
 
Given that activation of σ receptors can inhibit increases in intracellular Ca2+ 
under various pathological conditions, we hypothesized that activation of σ receptors 
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with the pan-selective σ receptor agonists, afobazole or DTG, could affect the elevations 
in [Ca2+]i triggered by incubation of cortical neurons in Aβ25-35. Cortical neurons were 
incubated in 25 µM Aβ25-35 for 24 hr in the absence and presence of 100 µM afobazole or 
100 µM DTG (Figure 3.2A). Following the 24 hr incubation with Aβ25-35, there was a 
statistically significant increase in [Ca2+]i consistent with results shown in Figure 3.1B. 
Incubation of neurons in media containing afobazole alone did not significantly affect 
neuronal [Ca2+]i. However, incubation in afobazole blocked the Aβ25-35-evoked increases 
in [Ca2+]i by 58 ± 12% (Figure 3.2A). In contrast, application of DTG (100 µM), failed to 
inhibit the Aβ25-35-evoked increase in [Ca2+]i, and instead, potentiated the response by 67 
± 21%.  
The discrepancy between the results obtained for afobazole and DTG leave doubt 
as to the role of σ receptors in the regulation of Aβ25-35-induced increases in [Ca2+]i by 
afobazole. Therefore, to test if σ receptors are involved in these effects, selective 
inhibitors of σ-1 (BD-1047) and σ-2 (rimcazole) receptors were used (Matsumoto et al., 
1995, Gilmore et al., 2004). Cortical neurons were incubated in 25 µM Aβ25-35 for 12 hr in 
the absence and presence of 100 µM afobazole with and without BD-1047 or rimcazole 
(Figure 3.2B). Application of afobazole reduced elevations in [Ca2+]i produced by Aβ25-35  
by 77 ± 3%, which was statistically significant. While 10 µM BD-1047 alone lessened the 
effects of Aβ25-35 on [Ca2+]i, the σ-1 receptor antagonist prevented any further reduction 
by afobazole such that the block produced by the combination of afobazole + BD-1047 
was almost identical to that produced by BD-1047 alone and 34 ± 4% less than that 
produced by afobazole alone. Unlike BD-1047, rimcazole (300 nM) alone did not  
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Figure 3.2 
 
Afobazole inhibits increases in [Ca2+]i evoked by Aβ25-35. A, Bar graph of mean (±SEM) 
[Ca2+]i measured in neurons incubated for 24 hr in media in the absence (Control) or 
presence of 25 µM Aβ25-35 (Aβ) with or without 100 µM Afobazole (Afob) or 100 µM DTG 
(DTG). Asterisks denote significant difference between Control and Aβ within the Media, 
Afob and DTG groups (p < 0.001 for Media and DTG groups, p < 0.05 for Afob group). 
Pound symbols denote significant difference from the Media group within the Aβ group (p 
< 0.001 for both). Dagger indicates significant difference between Afob and DTG groups 
within Aβ (p < 0.01). For all groups, n ≥ 125 neurons. B, Bar graph of mean (±SEM) Aβ-
induced increase in [Ca2+]i (∆[Ca2+]i) measured in neurons incubated for 12 hr in 25 µM 
Aβ25-35 alone (Aβ) or in 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob). Aβ or Aβ + Afob 
were applied in media alone (Media), in media with 10 µM BD-1047 (BD), or in media 
with 300 nM rimcazole (Rim 0.3) or 10 µM rimcazole (Rim 10). Asterisks denote 
significant difference between Aβ and Aβ + Afob within Media and rimcazole groups, 
respectively (for all p < 0.001). Pound symbols denote significant difference between BD-
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1047 (BD) and all other groups within Aβ and between BD-1047 and the Media and 300 
nM rimcazole (Rim 0.3) within Aβ + Afob, respectively (p < 0.01 for all). Dagger indicates 
significant difference between Rim 10 and Control groups within Aβ (p < 0.001). C, Bar 
graph of relative mean (±SEM) elevations in [Ca2+]i evoked by Aβ25-35 in the presence of 
afobazole and in the absence (Control) or presence of 10 µM BD 1047 (BD), 300 nM 
rimcazole (Rim 0.3) and 10 µM rimcazole (Rim 10). Data were normalized to mean 
∆[Ca2+]i evoked by Aβ in the appropriate control (i.e. media or the corresponding σ 
receptor antagonist). Asterisks, pound symbols and dagger denote significant difference 
from Control, BD and Rim 0.3, respectively (for all p < 0.05). For all groups in B and C, n 
≥ 168 neurons. 
 
significantly inhibit Aβ25-35-evoked increases in [Ca2+]i. When afobazole was co-applied 
with the low concentration of rimcazole (300 nM), which primarily affects σ-2 receptors, 
afobazole reduced Aβ25-35-evoked [Ca2+]i elevations by 83 ± 5% (Figure 3.2B). This 
decrease was similar to that seen with afobazole alone.  Like BD-1047, a higher 
concentration of rimcazole (10 µM), predicted to interact with σ-1 receptors (Husbands et 
al., 1999), reduced Aβ25-35-induced increases in [Ca2+]i, (Figure 3.2B). However, Aβ25-35-
evoked increases in [Ca2+]i observed  in the cells incubated in 10 µM rimcazole + 
afobazole were not significantly different from those produced by the Aβ fragment in the 
presence of afobazole (p = 0.179).  In order to account for these direct effects of the 
antagonists on Aβ25-35 evoked elevations in [Ca2+]i, we normalized the increases in [Ca2+]i 
observed when afobazole was added along with the σ receptor antagonist to those 
observed when Aβ was added with the antagonist alone. The mean normalized 
responses observed for the different conditions are shown in Figure 3.2C. The effects of 
afobazole were blocked by both BD 1047 and the higher concentration of rimcazole (10 
µM, Rim 10), but not by the lower concentrations of rimcazole (300 nM, Rim 0.3) (Figure 
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3.2C).  Therefore, inhibition of σ-1, but not σ-2 receptors lessened the effects of 
afobazole. 
 
Figure 3.3 
 
Afobazole does not inhibit Aβ25-35 evoked ROS production but does inhibit nitric oxide 
production in neurons. A, Bar graph of mean (±SEM) DHE fluorescence intensity (ROS 
levels) measured in neurons incubated for 24 hr in the absence (Control) or presence of 
25 µM Aβ25-35 (Aβ) without (Media) or with 100 µM Afobazole (Afob). Asterisks denote 
significant difference between Control and Aβ within Media and Afob groups (p < 0.05 for 
both). Pound symbols denote significant difference between Media and Afob groups 
within Control (p < 0.001) and Aβ (p < 0.05) groups. B, Bar graph of mean (±SEM) DAF-
FM fluorescence intensity (NO levels) measured in neurons incubated for 24 hr in media 
alone (Control) or media containing 25 µM Aβ25-35 (Aβ), 100 µM Afobazole (Afob) or 25 
µM Aβ25-35 and 100 µM Afobazole (Aβ + Afob). Asterisks denote significant difference 
between Control and Aβ within Media and Afob (p < 0.001 for both). Pound symbol 
denotes significant difference between Media and Afob groups within Aβ (p < 0.001). For 
all groups, (n > 108 neurons). 
 
Cortical neuron [Ca2+]i overload has been shown to enhance production of 
reactive oxygen species (ROS) and nitric oxide, with the latter molecule being converted 
to reactive nitrogen species (RNS) in the presence of ROS. Activation of σ receptors has 
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been associated with changes in both ROS and nitric oxide levels. Thus, we evaluated if 
afobazole preservation of [Ca2+]i homeostasis consequently affects ROS and/or nitric 
oxide levels following exposure to Aβ25-35. Figure 3.3A shows a bar graph of the average 
DHE fluorescence intensities measured in neurons in response to 24 hr incubation in 
Aβ25-35 in the absence and presence of 100 µM afobazole. Greater DHE fluorescence 
was observed in neurons exposed to Aβ25-35 relative to media alone, indicating an Aβ-
induced increase in ROS production (Figure 3.3A).  Incubation of the neurons in 
afobazole alone also produced a small but significant increase in neuronal ROS, and a 
further increase in ROS was noted when Aβ25-35 was co-applied with afobazole (Figure 
3.3A). NO levels were also measured in neurons exposed to Aβ25-35 for 24 hr. Incubation 
of neurons in Aβ25-35 significantly enhanced neuronal NO levels. In contrast to the results 
obtained for ROS, afobazole alone had no effects on basal neuronal NO content. 
However, the σ agonist significantly decreased Aβ25-35-evoked elevations in NO by 53 ± 
5% (Figure 3.3B). 
Afobazole suppression of Aβ25-35-evoked [Ca2+]i dysregulation and NO production 
suggests that this compound may be neuroprotective in this injury model. Thus, 
experiments were conducted to ascertain if afobazole can reduce Aβ25-35 cytotoxicity and 
enhance cell survival following exposure of cortical neurons to this Aβ fragment. For 
comparison, a second σ receptor agonist, DTG, which has been shown to augment 
survival in other neuronal injury models but does not block Aβ25-35-elicited [Ca2+]i 
increases was included. Neurons were incubated for 72 hr in 25 µM Aβ25-35 in the 
absence and presence of 100 µM afobazole or 100 µM DTG and cell survival determined  
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Figure 3.4 
 
Afobazole, but not DTG, reduces neuronal death produced by application of Aβ25-35. A, 
Photomicrographs showing EthD-1 labeling (red), a marker of cell death, observed 
following 72 hr incubation of neurons in media alone (i), or media containing 25 µM Aβ25-
35 (ii), 100 µM afobazole (iii), 100 µM DTG (v), 25 µM Aβ + 100 µM afobazole (iv), or 25 
µM Aβ + 100 µM DTG (vi). Fields of view shown are representative regions within larger 
images used to calculate number of neurons labeled with EthD-1. B, Bar graph of 
relative neuronal death observed for the same conditions as in (A). Data were 
normalized to the average number of EthD-1-positive cells observed with media alone 
(i.e. no Aβ or σ ligand). Asterisks denote significant difference between Control and Aβ 
within Media and DTG groups, respectively (p < 0.001 for both). Pound symbol indicate 
significant difference between Afob and the other groups within Aβ (p < 0.001) and 
dagger indicates significant difference between DTG and the other groups within Control 
(p < 0.05). For all groups, n ≥ 12. Scale bar in (i) is 20 µm. 
 
60 
 
 
using EthD-1 to identify apoptotic cells. Figure 3.4A shows representative 
photomicrographs of neurons labeled with EthD-1. While EthD-1 staining was noted in all 
groups, a higher number of cells were observed when Aβ25-35 was applied alone or in the 
presence of DTG (Figure 3.4A ii & vi), but not when co-applied with afobazole (Figure 
3.4A iv). In identical experiments, incubation in Aβ25-35 resulted in a 130 ± 6% increase in 
the percentage of cells exhibiting positive labeling with EthD-1, relative to control (media 
alone, Figure 3.4B). When afobazole (100 µM) was applied alone, there was no change 
in the percentage of dead cells noted. However, application of afobazole along with the 
Aβ25-35 resulted in an 88 ± 4% reduction in the percentage of EthD-1 positive cells 
relative to the Aβ fragment alone group, which was statistically significant (Figure 3.4B). 
In contrast, DTG alone increased the percentage of EthD-1 positive cells compared to 
control (Figure 3.4B). Moreover, DTG failed to reduce the percentage of cells exhibiting 
EthD-1 staining when co-incubated with Aβ25-35 such that the number of apoptotic cells 
seen with Aβ25-35 alone and Aβ25-35 + DTG were similar (Figure 3.4B).   
Experiments were next focused on identifying underlying molecular mechanisms 
contributing to the enhanced survival of cortical neurons following afobazole application. 
Previous studies have shown that σ-1 receptor activation by the selective agonist, (+)-
SKF10047, can protect RGC-5 cells from glutamate-induced apoptosis by reducing 
expression of the pro-apoptotic gene product Bax (Tchedre and Yorio, 2008). To 
determine if a similar pathway is involved in afobazole-mediated neuroprotection during 
Aβ25-35 exposure, the cellular expression of this protein was determined. Representative 
photomicrographs of cells co-labeled with DAPI and an anti-Bax antibody are shown in 
Figure 3.5A. While Bax is detected in control neurons (Figure 3.5A i), there is a marked  
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Figure 3.5 
 
Afobazole prevents upregulation of the pro-apoptotic gene product, Bax, caused by 
application of Aβ25-35 in neurons. A, Photomicrographs of merged images of cultured 
neurons exposed for 24 hr to media alone (Control) (i), or media containing 25 µM Aβ25-
35 (Aβ) (ii), 100 µM afobazole (Afob) (iii) or 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob) 
(iv). Neurons were double labeled with DAPI (blue) and anti-Bax antibody (green). Fields 
of view shown are representative regions within larger images used to calculate Bax 
expression. B, Bar graph of mean percent of Bax-positive neurons observed in multiple 
experiments in which cells were exposed to the same conditions described in (A). Data 
are expressed as mean percent (±SEM) of the total number of neurons staining positive 
for DAPI. Asterisks denote significant difference between Control and Aβ within Media 
and Afob groups, respectively (p < 0.001). Pound symbols indicate significant difference 
between Afob and Media groups within Control (p < 0.05) and Aβ (p < 0.001). Scale bar 
in (i) is 10 µm and n = 9 for all groups in (B). 
 
increase following incubation in Aβ25-35 (Figure 3.5A ii). Bax is also expressed in low 
levels in neurons exposed to afobazole alone (Figure 3.5A iii), and there is only a modest 
increase when neurons are incubated in both 100 µM afobazole and the Aβ fragment 
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(Figure 3.5A iv). Analysis of images collected from multiple experiments shows that Bax 
is detected in less than half of the control cells, but following exposure to Aβ25-35 there is 
a 100 ± 5% increase in the number of cells testing positive for this pro-apoptotic gene 
(Figure 5B). Application of afobazole reduces Bax expression below that observed in 
control cells by 13 ± 5%, and the increase in expression occurring after Aβ25-35 
incubation is reduced to 58 ± 5% (Figure 3.5B). The net result is a 39 ± 5% reduction in 
the total number of cells expressing Bax in response to Aβ25-35 when afobazole was 
applied.  
Given that σ receptors have also been linked to decreased caspase-3 expression 
(Tchedre and Yorio, 2008), immunocytochemistry was also employed to examine how 
afobazole affects the levels of the active form of this death protease after neuronal 
exposure to Aβ25-35. Representative photomicrographs of cells labeled with DAPI and 
anti-activated caspase-3 antibody show an increase in the number of  caspase-3 positive 
neurons 24 hr after incubation in Aβ25-35 relative to control (Figure 3.6A i & ii). Neuronal 
expression of the active form of caspase-3 was not affected by incubation of the cells in 
100 µM afobazole alone, but co-application of afobazole with Aβ25-35 significantly lowered 
activated caspase-3 expression when compared to cells treated only with Aβ25-35 (Figure 
3.6A iii & iv). Figure 3.6B shows a bar graph of mean (±SEM) percentages of active 
caspase-3 positive neurons detected from multiple experiments using the same 
conditions as in Figure 3.6A. There is a statistically significant upregulation of activated 
caspase-3 expression following Aβ25-35 application, which results in a 104 ± 7% increase 
in the percentage of neurons testing positive for the death protease. However, treatment 
with afobazole reduces the increased cellular expression of activated caspase-3  
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Figure 3.6 
 
Afobazole reduces expression of activated caspase-3 in response to application of Aβ25-
35 in neurons. A, Photomicrographs of merged images of cultured neurons exposed for 
24 hr to media alone (Control) (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 100 µM 
afobazole (Afob) (iii) or 25 µM Aβ25-35 + 100 µM afobazole (Aβ + Afob) (iv). Neurons were 
double labeled with DAPI (blue) and anti-active caspase-3 antibody (green). Fields of 
view of each photomicrograph are representative regions within larger image used to 
calculate caspase-3 expression. B, Bar graph of mean percent (±SEM) of neurons 
testing positive for the active form of caspase-3 in experiments in which the cells were 
exposed to the same conditions as (A). Asterisk denotes significant difference between 
Control and Aβ within Media (p < 0.001). Pound symbol indicates significant difference 
between Media and Afob within Aβ (p < 0.001). Scale bar in (i) is 10 µm and n = 9 for all 
groups in (B). 
 
produced by Aβ25-35 by 89 ± 7% (Figure 3.6B). Neuronal expression of active caspase-3 
observed in cells treated with afobazole alone and afobazole with Aβ25-35 were not 
statistically different (p = 0.20). 
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Activation of σ receptors has been shown to provide neuroprotection against 
toxicity produced by the HIV-1 protein gp120 via upregulation of the anti-apoptotic gene 
Bcl-2 (Zhang et al., 2012). Therefore, we examined the possible involvement of Bcl-2 in 
the protection provided by afobazole against Aβ25-35-induced cytotoxicity. A significant 
number of neurons were found to express Bcl-2 in our culture model under all conditions 
tested at both 24 and 48 hrs (Figure 3.7A i-vii). Quantification of the results indicates that 
69 ± 6% of control neurons expressed Bcl-2, and that incubation in 25 µM Aβ25-35 for 24 
hr increased this number to 90 ± 2% (Figure 3.7B). The addition of afobazole alone also 
produced a 24 ± 2% increase in the percentage of Bcl-2 expressing cells, which was 
statistically significant when compared to the control (Figure 3.7B). However, after a 24 
hr incubation, no further increase in Bcl-2 was noted when afobazole was applied with 
Aβ25-35 compared to incubation in Aβ25-35 alone. In contrast, increasing the incubation 
time of the cells in Aβ25-35 to 48 hr resulted in reduction in the number of cells showing 
positive labeling for Bcl-2 expression, with Bcl-2 being observed in 71 ± 1% of cells 
incubated in media alone and 46 ± 2% of the cells incubated in media containing the Aβ 
fragment (Figure 3.7B). Extending the application time of afobazole to 48 hr continued to 
produce a similar increase in Bcl-2 expression as seen with the 24 hour incubation, with 
85 ± 1% of the afobazole treated neurons showing Bcl-2 expression. However, the 
addition of afobazole to Aβ25-35 prevented the Aβ-induced suppression of Bcl-2 seen at 
48 hr, withBcl-2 being observed in 81 ± 1% of the neurons exposed to Aβ25-35 in the 
presence of this drug (Figure 3.7B). In fact, in cultures exposed to afobazole + Aβ there 
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was a 14 ± 2% increase in the number of neurons testing positive for Bcl-2 expression 
compared to control (no Aβ or afobazole). 
 
Figure 3.7 
 
Afobazole prevents Bcl-2 down-regulation following 48 hr exposure of neurons to Aβ25-35. 
A, Photomicrographs of merged images of cultured neurons exposed for 24 or 48 hr to 
100 µM afobazole (Afob, i and iv), 25 µM Aβ25-35 (Aβ, ii and v), or 100 µM afobazole + 25 
µM Aβ25-35 (Afob + Aβ, iii and vi). For comparison, a photomicrograph of merged images 
of neurons exposed to media alone for 48 hr is shown (Control, vii). Neurons were 
double labeled with DAPI (blue) and anti-Bcl-2 antibody (green). Fields of view of each 
photomicrograph are representative regions within larger images used to calculate Bcl-2 
expression. B, Bar graph of mean percent (±SEM) of Bcl-2-positive neurons exposed to 
the conditions described in (A). Asterisks indicate significant difference between Control 
and Aβ within the 24 hr and 48 hr groups, respectively.  Pound symbols indicate 
significant difference between Control and Afob within the 24 hr and 48 hr groups, 
respectively, and between Aβ and Aβ + Afob within the 48 hr group. For 24 hr group n = 
9 for all, for 48 hr group n = 12 for all, p ≤ 0.001 for all.  Scale bar in (vii) is 10 µm. 
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Discussion 
The major finding reported in this study is that afobazole, acting via σ-1 receptors, 
provides neuroprotection against Aβ25-35-induced toxicity in cortical neurons. Activation of 
σ-1 receptors by afobazole appears to impinge on multiple molecular mechanisms 
associated with the demise of neurons. First, afobazole, acting via σ-1 receptors, 
decreases neuronal [Ca2+]i dyshomeostasis resulting from prolonged exposure (1 to 24 
hr) of the cells to Aβ25-35. Second, afobazole mitigates Aβ25-35-evoked elevations in nitric 
oxide production in cortical neurons that coincides with increases in ROS production, 
thus nitrosative stress is likely lessened. Finally, afobazole blunts the pro-apoptotic 
signaling induced by Aβ25-35 by inhibiting the upregulation of the pro-apoptotic gene 
product Bax and the death protease, caspase-3, while preventing long-term 
downregulation of the anti-apoptotic protein, Bcl-2.   
 In our culture system, Aβ25-35 was found to produce increases in [Ca2+]i after 
cells were incubated in the Aβ fragment for ≥ 1 hr, with short applications ≤ 15 min failing 
to alter [Ca2+]i. Maximal increases in [Ca2+]i were observed after 12 hr incubation of the 
neurons in Aβ25-35 and [Ca2+]i remained significantly elevated even after 24 hr incubation 
in the Aβ fragment. The observed 2-fold increase in [Ca2+]i caused by Aβ25-35 is similar to 
that previously reported for rat cortical neurons incubated for 24 hr in Aβ25-35 (Ferreiro et 
al., 2004). Incubation of neurons in 100 µM afobazole reduced Aβ25-35-evoked increases 
in [Ca2+]i by ~60%. This decrease in [Ca2+]i is similar to that observed when afobazole 
was used to inhibit [Ca2+]i increases produced in cortical neurons by acidosis (IC50 = 164 
µM) (Cuevas et al., 2011a). Reducing Aβ25-35 perturbation of [Ca2+]i is likely to promote 
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neuronal survival, since [Ca2+]i destabilization has been linked to cell death in AD 
(Mattson and Chan, 2003b). Moreover, the Aβ25-35-induced changes in [Ca2+]i  precede 
pro-apoptotic signals in the model used here (e.g. decrease in Bcl-2 levels occurring 48 
hrs after Aβ25-35 application).  
The inhibition of Aβ25-35-elicited increases in [Ca2+]i by afobazole is due to 
activation of σ-1, but not σ-2 receptors. Incubation in the σ-1 receptor antagonist, BD-
1047 (Matsumoto et al., 2004), reduced the effects of afobazole by ~40%. The 
concentration and degree of block reported here is consistent with previous studies 
showing BD-1047 inhibition of σ-1 receptor-mediated effects in cortical neurons and 
retinal ganglion cells (Katnik et al., 2006, Cuevas et al., 2011a, Mueller et al., 2013). The 
lack of involvement of σ-2 receptors is confirmed by results obtained using the σ-2 
receptor antagonist, rimcazole (Gilmore et al., 2004). Rimcazole binds to σ-2 receptors 
with nanomolar affinity, but to σ-1 receptor with low micro molar affinity (Ferris et al., 
1986, Husbands et al., 1999, Rybczynska et al., 2008). Given that 300 nM rimcazole 
failed to inhibit the actions of afobazole on Aβ25-35-evoked increases in [Ca2+]i, but that 
the higher concentration of the drug reduced these effects, it is unlikely that afobazole 
activates σ-2 receptors to suppress Aβ25-35-evoked increases in [Ca2+]i. Surprisingly, a 
second pan-selective σ receptor agonist, DTG, failed to mimic the effects of afobazole on 
Aβ25-35-evoked [Ca2+]i perturbation. DTG and afobazole both block acidosis- and 
ischemia-induced Ca2+ overload in neurons to a similar extent (Cuevas et al., 2011a). It 
was shown that ischemia-induced [Ca2+]i increases were due primarily to Ca2+ influxes 
through voltage-gated Ca2+ channels and NMDA receptors which were regulated by σ-1 
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receptor activation (Katnik et al., 2006). However, the difference between afobazole and 
DTG effects on Aβ modulation of [Ca2+]i, suggest these long-term [Ca2+]i increases 
involve distinct mechanisms from those producing ischemia-induced [Ca2+]i overload. 
Additionally, the lack of a DTG effect on Aβ-evoked [Ca2+]i overload suggests that not all 
σ-1 agonists may promote neuronal survival in this model. This hypothesis is further 
supported by our observation that DTG fails to decrease neuronal apoptosis following 24 
hr incubation Aβ25-35. The difference in responses between afobazole and DTG may be 
due to off-target effects of DTG counteracting the benefits of this pan-selective sigma 
agonist. Such a possibility needs to be explored further. 
It has been suggested that one of the downstream consequences of [Ca2+]i 
dysregulation in neurons caused by Aβ25-35 is the production of ROS (Ekinci et al., 2000, 
Abramov et al., 2004). Afobazole has been shown to reduce ROS accumulation in rat 
brains after focal ischemia (Silkina et al., 2006). However, data presented here show that 
afobazole does not block the ROS increases caused by the Aβ fragment. It has been 
suggested that Aβ, and in particular Aβ25-35, can increase oxidative stress via 
mechanisms independent of [Ca2+]i dysregulation (Varadarajan et al., 2001). Given that 
afobazole inhibits [Ca2+]i dysregulation produced by Aβ25-35 in neurons but not the 
increase in ROS, it is unlikely that afobazole is affecting this [Ca2+]i-independent ROS 
production. It is important to note that while afobazole may not decrease ROS 
production, it has been shown that σ-1 receptors decrease H2O2 evoked apoptosis 
(Meunier and Hayashi, 2010). Thus, afobazole may in part decrease Aβ25-35-induced cell 
death by acting downstream of the observed ROS increase. 
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Aβ25-35 has been shown to increase nitric oxide synthase (NOS) activity and 
produce neuronal injury via nitrosative stress (Parks et al., 2001, Cho et al., 2009). Aβ25-
35-evoked increases in NO were significantly decreased following afobazole application. 
Inhibition of inducible NOS (iNOS) has been proposed as a mechanism by which 
activation of σ-1 receptors is neuroprotective after stroke (Vagnerova et al., 2006). 
Similarly, functional downregulation of neuronal NOS (nNOS) has been shown to 
contribute to σ receptor neuroprotection following ischemia in striatal neurons (Yang et 
al., 2010). Since Aβ25-35 appears to increase both iNOS and nNOS in neurons (Limon et 
al., 2009), activation of σ receptors by afobazole is predicted to reduce NO production by 
both of these enzymes, and will ultimately contribute to protection from Aβ25-35 induced 
injury. 
One of the pro-apoptotic proteins upregulated in neurons both by the pathological 
sequela induced by Aβ25-35 application and in patients with Alzheimer’s disease is Bax 
(Paradis et al., 1996, Yao et al., 2005). Consistent with previous findings, the current 
study shows that the number of Bax positive neurons is significantly increased following 
24 hr incubation in Aβ25-35. However, when afobazole is applied in combination with Aβ25-
35, Bax upregulation is diminished significantly. It has also been shown that the σ-1 
agonist, PRE-084, can reduce apoptosis in cortical neurons caused by Aβ25-35 via 
reduction in Bax (Marrazzo et al., 2005). However, glutamatergic neurotransmission was 
blocked in those experiments (Marrazzo et al., 2005). Glutamatergic transmission is a 
factor in Aβ25-35-induced cell death, and elevated glutamate levels have been shown to 
induce Bax upregulation in neurons (Schelman et al., 2004, Revett et al., 2013). Thus, 
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our data suggest that σ receptor activation by afobazole can reduce Bax expression and 
concomitant cell death in the presence of Aβ25-35 even when glutamatergic transmission 
is not blocked.   
In addition to decreasing Bax levels, afobazole effectively reduced activated 
caspase-3 expression in response to Aβ25-35. The active form of caspase-3 has been 
implicated in the loss of hippocampal neurons in Alzheimer’s disease (Selznick et al., 
1999). In addition to serving as a late event involved in neuronal death during 
Alzheimer’s disease, caspase activation may be an early event that promotes the 
pathology of AD. Several caspases, including caspase-3, have been shown to cause 
pathological tau filament assembly in neurons, which underlies AD etiology (Gamblin et 
al., 2003). Selective inhibition of caspase-3 has been shown to protect neurons from 
Aβ25-35-induced apoptosis (Allen et al., 2001). Sigma receptor activation has been shown 
to decrease caspase-3 and to protect cortical neurons and RGC-5 cells against 
excitotoxicity (Tchedre and Yorio, 2008, Griesmaier et al., 2012). Such a mechanism is 
likely to contribute to afobazole neuroprotection from Aβ25-35 toxicity and may in part 
explain the reduced neuronal death observed here. 
The neuroprotective properties of afobazole following exposure to Aβ25-35 also 
involves long-term upregulation of Bcl-2. Our data indicate that there is a biphasic 
change in Bcl-2 levels in neurons following application of Aβ25-35 with an initial increase 
at 24 hr followed by a suppression of Bcl-2 expression at 48 hr. A similar transient 
expression pattern was previously reported in rat hippocampal neurons exposed to Aβ25-
35 (Kim et al., 1998). It was proposed that this initial increase in Bcl-2 expression is a 
non-sustainable cellular response to the apoptotic pathways induced by Aβ (Kim et al., 
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1998). Our observations indicate that when afobazole is applied along with Aβ25-35, Bcl-2 
levels do not drop below control at the 48 hr time point. Previous studies have shown 
that Bcl-2 is a target for σ receptor mediated neuroprotection. The HIV-1 protein gp120 
was shown to downregulate Bcl-2 in cortical neurons, but activation of σ receptors with 
the σ ligand, PPBP, increased Bcl-2 expression (Zhang et al., 2012). PPBP was shown 
to have a similar effect in a glutamate excitotoxicity model (Yang et al., 2007), 
suggesting that Bcl-2 upregulation may occur after σ receptor stimulation under various 
pathophysiological conditions. 
In conclusion, our experiments show that afobazole can decrease Aβ25-35-evoked 
neuronal apoptosis by activating σ-1 receptors. The activation of σ-1 receptors prevents 
Aβ25-35-induced [Ca2+]i overload and is associated with a decrease in NO levels. The 
molecular mechanisms mediating neuroprotection by afobazole include downregulation 
of both Bax and activated caspase-3, and long-term upregulation of Bcl-2. Given the 
importance of direct Aβ neurotoxicity in the etiology of Alzheimer’s disease, the findings 
reported here suggest that σ-1 receptors are a putative target for AD therapy and that 
the σ receptor agonist, afobazole, in particular, shows significant potential.  
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CHAPTER 4 
 
 
Stimulation of Sigma Receptors with Afobazole Blocks Activation of  
Microglia and Reduces Toxicity Caused by Amyloid-β25-35 
 
 
Introduction 
 
Aβ has been shown to initiate a sequence of events in microglia, including a pro-
inflammatory cascade and enhanced hemichannel formation, which ultimately produces 
neuronal death (Orellana et al., 2011). In contrast, data also suggest that microglia may 
be beneficial in AD by removing Aβ plaques (Wilcock et al., 2004, Herber et al., 2007). It 
has been proposed that microglial senescence, and not activation, is a contributing factor 
to late-onset Alzheimer's disease (Streit et al., 2009). Given the importance of microglial 
cells in AD pathology, there is great interest in identifying molecular targets for 
modulating the responses of these cells to Aβ, and for regulating their contribution to AD 
pathology in general. 
One possible target that has been explored for therapeutics in other pathological 
states of the central nervous system but is not well-characterized in AD is sigma 
receptors. Sigma (σ) receptors are found in numerous cell types distributed throughout 
the mammalian body and modulate multiple signaling and regulatory pathways. Two 
subtypes of σ receptors have been pharmacologically identified, σ-1 and σ-2. 
Reprinted with permission of the American Society for Pharmacology and Experimental Therapeutics.  
Copyright © 2013 by the American Society for Pharmacology and Experimental Therapeutics 
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To date only the σ-1 receptor has been cloned (Walker et al., 1990, Quirion et al., 
1992, Seth et al., 1998). Sigma-1 receptors are intracellular chaperones that form a 
complex within the endoplasmic reticulum (ER) and the mitochondrion-associated ER 
membrane (MAM) (Kourrich et al., 2012). Activation of σ-1 receptors promotes migration 
of these receptors away from the MAM to the sub-plasmalemmal ER, where the 
receptors interact with and regulate numerous membrane channels (Zhang and Cuevas, 
2002, 2005, Herrera et al., 2008, Zhang et al., 2009, Su et al., 2010, Cuevas et al., 
2011b). Less is known about σ-2 receptors, but these proteins seem to be involved in 
regulation of inflammation, cell survival and calcium homeostasis (Vilner and Bowen, 
2000, Crawford and Bowen, 2002, Zhang and Cuevas, 2002, Iniguez et al., 2013). Our 
laboratory has shown that activation of σ receptors in microglia decreases ATP-induced 
membrane ruffling and cell migration and lipopolysaccharide-induced cytokine production 
(Hall et al., 2009a). Activation of σ receptors also protects microglia from ischemia-
induced cell death (Cuevas et al., 2011b). These observations led our laboratory to 
propose that the neuroprotection provided by σ receptor activation following stroke 
involves both a decrease in the inflammatory response mediated by microglia and 
enhanced survival of quiescent microglia (Cuevas et al., 2011b).  
While the effects of σ receptor activation on microglial responses to ischemia 
have been studied, there is little information on how σ receptors may affect microglial 
responses to Aβ. In the absence of glutamatergic transmission, activation of σ-1 
receptors has been shown to decrease neuronal apoptosis caused by Aβ25-35 (Marrazzo 
et al., 2005), but it is unclear how σ-1 activation will affect survival of microglia exposed 
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to Aβ. It has been reported that there is a reduction in the number of sigma ligand 
binding sites and σ-1 receptors in the brains of AD patients (Jansen et al., 1993, Mishina 
et al., 2008). If these receptors prevent microglial activation and/or senescence, a loss of 
these receptors may contribute to AD progression. Thus, it is of significant interested to 
determine how σ receptor activation influences microglial responses to Aβ. 
Experiments were carried out to determine if afobazole, an agonist at both σ-1 
and σ-2 receptors (Cuevas et al., 2011b), can reduce activation and toxicity of microglia 
by Aβ25-35. Afobazole decreased membrane ruffling and migration evoked by Aβ25-35. The 
effects of afobazole were dependent on activation of both σ-1 and σ-2 receptor and were 
blocked by inhibition of these receptors with BD-1047 and rimcazole. Furthermore, 
afobazole inhibited increases in the levels of the pro-apoptotic protein Bax and the death 
protease caspase-3 induced by Aβ25-35, resulting in an increase in microglia survival. 
Finally, afobazole was shown to prevent disruption of ATP signaling in microglia 
incubated in Aβ25-35, indicating that afobazole preserves microglial function following Aβ 
exposure. 
 
Materials and Methods 
 
 
Primary Cultures of Microglia 
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat 
pups (post-natal day 2-3) as previously described by our laboratory (Hall et al., 2009a, 
Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C 
prior to experiments being carried out. Microglia were mechanically separated from the 
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cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS 
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine 
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum 
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific 
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells 
were used immediately for migration and cytotoxicity assays or plated on glass 
coverslips for one day for imaging experiments.  
 
Membrane Morphology and Migration Assay 
 
Morphological changes to microglia induced by ATP or Aβ25-35 were assessed by 
plating the cells on poly-L-lysine coated coverslips, serum starving the cells for 4 h in 
DMEM, and exposing the cells to100 µM ATP or 25 µM Aβ25-35 for 10 min at 37º C. 
When afobazole or DTG were used, microglia were incubated in the σ ligands (in 
DMEM) for 10 min prior to ATP or Aβ25-35 exposure. Membrane ruffling was visualized by 
labeling the cells with the filamentous actin probe, phalloidin (AlexaFluor 488 conjugated, 
Life Technologies, Grand Island, NY). Quantification of membrane ruffling was carried 
out as previously described (Hall et al., 2009a). Briefly, cell ruffling was scored as: “0” – 
no ruffling and multiple filopodia; “1” – ruffling and filopodia; “2” – fully ruffled with no 
filopodia.  
Migration assays were carried out using a 48-well chemotaxis chamber (neuro 
Probe, Inc., Gaithersburg, MD) as previously described (Cuevas et al., 2011b). The 
bottom wells of the chamber were filled with 25 µM Aβ25-35 in DMEM and the top wells 
contained 1x106 freshly isolated microglia. These chambers were separated by a 
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fibronectin coated polycarbonate membrane with 8 µm pores at a density of 1 x 103 
pores/mm2. Each well had an exposed filter area of 8 mm2. Test compounds (i.e. σ 
ligands) were added to both the top and bottom wells at identical concentrations. The 
microglia were permitted to migrate for 2 hr while incubated at 37oC. The membranes 
containing microglia were processed as previously described and mounted on slides 
using Vectashield Hardset containing 4'-6-diamidino-2-phenylindole (DAPI) (Vector Labs, 
Burlingame Ca) (Cuevas et al., 2011b). DAPI positive cells were counted in 4 random 
fields of view per well and averaged to determine migration for that well. For each 
experiment, a minimum of 2-3 wells were used, and at least three migration experiments 
were carried out for each condition. The n values given represent the total number of 
fields of view recorded. 
 
Calcium Imaging Measurements 
 
Intracellular Ca2+ concentrations ([Ca2+]i) as a function of time were measured 
using fluorescent imaging techniques and fura-2 as previously reported (Hall et al., 
2009a, Cuevas et al., 2011b). Microglia plated on coverslips were incubated for 1 hour at 
room temperature in DMEM-PLUS containing 25 µM Aβ and 3 µM acetoxymethyl ester 
fura-2 and 0.3 % dimethyl sulfoxide. Prior to the experiments, the coverslips were 
washed in Aβ and fura-2-free physiological saline solution (PSS) containing (in mM): 140 
NaCl, 5.4 KCl, 1.3 CaCl2, 1.0 MgCl2, 20 glucose, and 25 HEPES (pH to 7.4 with NaOH). 
For studies on ATP-evoked [Ca2+]i changes, ATP was applied in PSS using a rapid 
application system as described previously (Cuevas and Berg, 1998).   
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ROS and NO Imaging 
Intracellular ROS and NO concentrations were measured in isolated microglia 
using the fluorometric indicators di-hydroethidiumbromide (DHE) and diacetate (4-amino-
5-methylamino-2',7'-difluorofluorescein diacetate) (DAF-FM), respectively. Cells plated 
on poly-L-lysine coated coverslips were incubated at 37°C in DMEM-PLUS containing 10 
µM DHE with 0.25 % DMSO for 30 min or 5 µM DAF-FM with 0.1 % DMSO for 1 hr. Prior 
to beginning the experiments, the coverslips were rinsed with PSS. DHE and DAF-FM 
labeled microglia were measured by digital microscopy (CoolSnap HQ2; Photometrics, 
Surrey, BC, Canada), excited at 518 nm and 495 nm and emission captured at 605 nm 
and 515 nm, respectively. Excitation exposure times were auto-calibrated to the control 
(absence of drugs or Aβ) using this function on the acquisition software (Nikon Elements; 
Nikon, Melville, NY, USA) and used for all slides in that dish. Image analysis was 
performed using the Nikon Elements software. Images were acquired every second for 
ten seconds and the average of the acquisitions was used for the fluorescence 
intensities (A.U.). Statistical analysis was performed using SigmaPlot 11 (Systat 
Software, Inc., San Jose, CA). 
 
Cell Death Assay 
 
Microglia plated on coverslips were incubated at 37°C for 72 hr in DMEM-PLUS 
with 25 µM Aβ25-35 in the absence (Control) and presence of 30 µM afobazole. The 
coverslips were rinsed with phosphate buffered saline (PBS) and then incubated for 30 
min in 4 µM EthD-1 solution at room temperature. The coverslips were washed with PBS 
and deionized water, air dried and mounted on a microscope slide with Vectashield 
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Hardset mounting media (Vector Labs, Burlingame, CA). EthD-1 positive cells were 
visualized at 400x using a Zeiss Axioskop 2 and counted using Image-J software in four 
random fields per slide. For each experiment, a minimum of three slides were used, and 
the results of at least three experiments were averaged together. Coverslips were 
visualized in bright field to confirm homogeneous cell density. 
 
Immunocytochemistry 
 
Microglia plated on poly-L-lysine coverslips were incubated at 37°C for 24 hr in 
DMEM-PLUS with 25 µM Aβ25-35 in the absence (Control) and presence of 30 µM 
afobazole. The coverslips were rinsed three times, followed by a step-wise ethanol 
fixation, permeabilized with 0.1 % Triton X, rehydrated and blocked with 2 % BSA. 
Primary antibodies were diluted in PBS with 0.5 % BSA and incubated at 4°C for 24 hr. 
The following dilutions were used: anti-Bax 1:20, anti-activated Caspase-3 1:25 and anti-
Bcl-2 1:100. The secondary antibodies used were Alexa Fluor 488 conjugated anti-
mouse or anti-rabbit, as appropriate, and diluted at a ratio of 1:300 in PBS with 0.5% 
BSA. Coverslips were mounted onto slides using VectaShield with DAPI. Excitation and 
emission wavelengths used were 359 nm and 461 nm (DAPI) and 485 nm and 530 nm 
(Alexa Fluor 488), respectively. Cells were imaged at 400x and counted in four random 
fields per slide using Image-J software. The average for the fields was used as the value 
for each slide. For each experiment, a minimum of three slides were analyzed, and the 
results of at least three experiments were averaged together, with n values representing 
number of experiments.  
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Reagents and Antibodies 
All test compounds were applied in DMEM-PLUS for 10 min prior to Aβ25-35 
exposure, and throughout the Aβ25-35 incubation. The following drugs were used in this 
investigation: DTG and BD-1047 (Tocris Biosciences, Ellisville, MO); rimcazole (Sigma-
Aldrich, St. Louis, MO); fura-2 acetoxymethyl ester, DHE, DAF-FM, Live/Dead 
Viability/Cytotoxicity Kit, Alexa Fluor 488 Phalloidin (A-12379), Alexa Fluor 488 anti-
mouse (A-11001) and anti-rabbit (A-11008) (Invitrogen, Grand Island, NY); Bax 
(ab5714), activated caspase-3 (ab32351) and Bcl-2 (ab32370) (abcam, Cambridge, MA); 
Afobazole was generously provided by IBC Generium (Moscow, Russian Federation). 
Aβ25-35 was obtained from (American Peptides, Sunnyvale, CA).  
 
Data Analysis 
 
Fura-2 fluorescence intensities as a function of time were recorded from microglia 
in the same manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a, 
Cuevas et al., 2011b) and converted to [Ca2+]i using an in situ calibration kit (Invitrogen). 
Data were analyzed using SigmaPlot 11 (Systat Software, Inc., San Jose, CA). Data 
points represent peak means ± standard error of the mean (S.E.M.). One- or two-way 
analysis of variance were used for determining significant differences for multiple group 
comparisons, as appropriate, followed by post hoc analysis using the Holm-Sidak test. 
Results were considered statistically significant if p < 0.05. 
 
Results 
 
Previously, our laboratory has shown that the pan-selective σ agonist DTG 
prevents activation of microglia occurring in response to various stimuli, including  
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Figure 4.1 
 
Afobazole blocks membrane ruffling induced by ATP in microglial cells. A, 
Photomicrographs of microglial cells exposed for 10 min (37° C) to media alone 
(Control), media containing 30 µM afobazole (Afob), or media containing 30 µM DTG 
(DTG) in the absence (i, iii, v) and presence (ii, iv, vi) of 100 µM ATP, respectively. Insets 
show zoomed in images of the indicated regions. Scale bar = 3 µm. B, Bar graph of 
mean degree of membrane ruffling (±SEM) observed in cells exposed to the same 
conditions as (A). Asterisks denote significant difference between Control and ATP 
groups within Media, Afob and DTG (p < 0.001, 0.05, & 0.01, respectively); pound 
symbols denote significant difference within ATP between Media and Afob or Media and 
DTG (p < 0.001 for both). For all groups, n > 67. 
 
lipopolysaccharide, ATP and MCP-1 (Hall et al., 2009a, Cuevas et al., 2011b). While 
afobazole preserves the functional capacity of microglia and responsiveness to ATP 
(Figure 4.1), data from our laboratory suggest that afobazole can reduce activation of 
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these cells by ATP (Cuevas et al., 2011b). This previous work had shown that afobazole 
inhibits migration of microglia, but did not examine if afobazole prevents the 
morphological changes evoked by ATP in microglial. Incubation of the microglia in 100 
µM ATP for 10 min (37° C) resulted in retraction of filopodia and increased membrane 
ruffling (Figure 4.1A ii). Co-incubation of the cells in 30 µM afobazole or 30 µM DTG 
decrease membrane ruffling elicited by ATP (Figure 4.1A iv & vi). Quantification of the 
degree of membrane ruffling shows that ATP significantly increases membrane ruffling 
by 271 ± 14% and that this change is statistically reduced by both afobazole and DTG, 
49 ± 5 and 37 ± 5% respectively (Figure 4.1B).  
Experiments were carried out to see afobazole could also block microglial 
activation caused by application of amyloid-β25-35 (Aβ25-35). One of the events associated 
with microglial activation that has been shown to be regulated by σ receptors is 
membrane ruffling (Hall et al., 2009a). Thus, we examined how afobazole affects 
morphological changes induced by the amyloid peptide in these cells. In cultured, 
quiescent microglia, filopodia are readily observed, and these membrane processes are 
not directly affected by incubation of the cells in 30 µM afobazole or a second pan-
selective σ agonist, DTG (30 µM) (Figure 4.2A). Incubation of the microglia in 25 µM 
Aβ25-35 for 10 min (37° C) resulted in retraction of filopodia and increased membrane 
ruffling (Figure 4.2A ii). When afobazole (30 µM) was applied along with the Aβ fragment, 
there was a decrease in membrane ruffling compared to Aβ25-35 alone (Figure 4.2A iv). 
Pronounced membrane ruffling was still observed when DTG was added with Aβ25-35 
(Figure 4.2A vi). Quantification of the degree of membrane ruffling in microglia in  
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Figure 4.2 
 
Afobazole blocks membrane ruffling induced by Aβ25-35 in microglial cells. A, 
Representative photomicrographs of microglial cells exposed for 10 min (37° C) to 
media, media containing 30 µM afobazole, or media containing 30 µM DTG in the 
absence (i, iii, v) and presence (ii, iv, vi) of 25 µM Aβ25-35, respectively. Fields of view of 
each photomicrograph are representative regions within larger image used to calculate 
membrane ruffling. Insets show expanded images of the indicated regions. Scale bar = 3 
µm. B, Bar graph of mean degrees of membrane ruffling (±SEM) observed in cells 
incubated in media alone (Media), media with 30 µM Afobazole (Afob), and media with 
30 µM DTG (DTG), in the absence (Control) or presence of 25 µM Aβ25-35 (Aβ). Asterisks 
denote significant difference between Control and Aβ groups within Media and DTG, 
respectively (p < 0.001 for both). Pound symbols denote significant difference from 
Media within Aβ (Afob, p < 0.001; DTG p < 0.05), and dagger indicates significant 
difference between Afob and DTG, also within Aβ (p < 0.001). For all groups, n ≥ 35. 
 
experiments identical to those of Figure 4.2A shows that Aβ25-35 increases membrane 
ruffling by more than 5-fold (Figure 4.2B). Incubation of the cells in either afobazole or 
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DTG significantly reduced the degree of membrane ruffling caused by Aβ25-35 (Figure 
4.2B). However, the effect of afobazole on Aβ25-35-induced membrane ruffling was 
significantly greater than that produced by DTG, with the membrane ruffling being 
decreased by 70 ± 7% and 21 ± 9% by these drugs, respectively (Figure 4.2B). 
In addition to membrane ruffling, Aβ25-35 induces chemotaxis of microglia, and σ 
receptor activation has been shown to disrupt migration of microglia in response to other 
stimuli (Hall et al., 2009a, McLarnon, 2012). Experiments were therefore carried out to 
determine if application of afobazole can inhibit microglial migration caused by Aβ25-35. A 
concentration-response relationship for afobazole reduction in microglial migration when 
Aβ25-35 is used as the chemoattractant is shown in Figure 4.3A. Afobazole, at 
concentrations as low as 10 µM, reduced the number of microglia migrating in response 
to Aβ25-35. Half maximal inhibition of Aβ25-35-induced migration was observed at 122 µM 
afobazole and maximal recorded block was achieved at 1 mM afobazole (Figure 4.3A).  
To verify that σ receptors are involved in afobazole suppression of microglial 
activation by Aβ25-35, the σ receptor subtype-specific antagonists BD-1047 and rimcazole 
were used to block the effects of afobazole on migration. Afobazole was applied at 30 
µM in the absence and presence of the selective σ-1 and σ-2 receptor antagonist, BD-
1047 (10 µM) (Matsumoto et al., 1995) and rimcazole (300 nM) (Gilmore et al., 2004), 
and migration in response to Aβ25-35 was assessed. Afobazole alone decreased 
microglial migration caused by Aβ25-35 by 29 ± 1%.This inhibition was reduced to 10 ± 1% 
and 8 ±1% when afobazole was combined with BD-1047 and rimcazole, respectively 
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(Figure 4.3B). Therefore, inhibition of either σ-1 or σ-2 significantly reduced afobazole-
mediated suppression of microglial activation by Aβ25-35. 
 
 
Figure 4.3 
 
Afobazole blocks the migration of microglia elicited by Aβ25-35. A, Concentration-
response relationship for afobazole inhibition of microglial migration evoked by 25 µM 
Aβ25-35. Solid line represents best fit to the data using a one-component Langmuir-Hill 
equation, with the IC50 value and Hill coefficient being 122 µM and 0.6, respectively. Points 
represent mean (±SEM) normalized to control values (no afobazole), for all points n = 36. 
B, Bar graph of the mean (± S.E.M.) percent inhibition of Aβ25-35-induced migration of 
microglial cells by afobazole (30 µM) in the absence (Control) and presence of 10 µM 
BD-1047 (BD-1047) or 300 nM rimcazole (Rimcazole). Asterisks denote significant 
difference from Control (p < 0.001 and n = 24 for all). 
  
The microglia-mediated inflammatory response caused by Aβ is in part mediated via 
upregulation in the production of ROS and NO (Weldon et al., 1998, Bianca et al., 1999, 
Combs et al., 2001). Therefore, experiments were carried out to determine if afobazole 
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affects ROS or NO levels in microglia following incubation in Aβ25-35. Incubation in 
afobazole alone produced a decrease in basal levels of ROS in isolated microglia (Figure 
4.4A). As predicted, incubation of microglia for 24 hr in Aβ25-35 increased ROS in the 
cells. However, afobazole failed to block this increase in ROS. Unlike ROS, basal NO 
 
Figure 4.4 
Afobazole does not decrease microglial ROS or NO production induced by Aβ25-35. A, 
Bar graph of mean (±SEM) DHE fluorescence intensity (ROS levels) measured in 
microglial cells incubated for 24 hr in the absence (Control) or presence of 25 µM Aβ25-35 
(Aβ) without (Media) and with 30 µM Afobazole (Afob). Asterisks denote significant 
difference between Control and Aβ within Media and Afob groups, respectively (p < 
0.05). Pound symbol indicates significant difference between Media and Afob groups 
within Control (p < 0.05). For all groups, n ≥ 149. B, Bar graph of mean (±SEM) DAF-FM 
fluorescence intensity (NO levels) measured in microglia incubated for 24 hr in absence 
(Control) or presence of 25 µM Aβ25-35 (Aβ) without (Media) and with 30 µM Afobazole 
(Afob). Asterisks denote significant difference between Control and Aβ groups within 
Media and Afob groups (p < 0.05 for both). For all groups, n ≥ 200. 
86 
 
 
levels in microglia were not significantly affected by afobazole (Figure 4.4B). Aβ25-35 did 
produce a small but statistically significant increase in NO, and as with ROS, afobazole 
failed to block this effect of the amyloid peptide (Figure 4.4B).  
Given that microglial cell senescence has been suggested to contribute to AD 
pathology and that Aβ has been shown to produce microglial apoptosis (Korotzer et al., 
1993, Streit et al., 2009), experiments were carried out to determine how activation of σ 
receptors with afobazole affects microglial survival following application of Aβ25-35. Figure 
4.5A shows representative photomicrographs of microglia labeled with EthD-1 following 
72 hr (37º C) incubation in media alone or media containing Aβ25-35 in the absence and 
presence of 30 µM afobazole. Few apoptotic microglia were detected when the cells 
were incubated in media alone (Figure 4.5A i), but there was a significant increase in 
EthD-1-positive cells following Aβ25-35 application (Figure 4.5A ii). Afobazole alone did 
not visibly alter the number of EthD-1-positive cells (Figure 4.5A iii), but there was a 
decrease in the number of apoptotic cells in the afobazole- Aβ25-35 group (Figure 4.5A iv) 
relative to Aβ25-35 alone (Figure 4.5A ii). In identical experiments, Aβ25-35 was found to 
produce a nearly 3-fold increase in the number of apoptotic cells relative to control (no 
Aβ25-35) (Figure 4.5B). However, afobazole application significantly counteracted the pro-
apoptotic effects of Aβ25-35 such that no significant increase in EthD-1 labeling was 
observed in the Aβ25-35 + afobazole group (Figure 4.5B).  
Microglial cell death induced by Aβ25-35 has been linked to upregulation of the pro-
apoptotic gene, Bax (Jang et al., 2005). Immunocytochemical experiments were 
conducted to determine if levels of Bax expression increase in our rat microglia model 
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and if afobazole can affect expression of this protein. Representative photomicrographs 
of microglia double labeled with DAPI and anti-Bax antibody are shown in Figures 4.6A. 
Whereas Bax labeling was rarely observed in control (untreated) microglia, Bax 
immunolabeling was prominent in cultures treated for 24 hr (37º C) with Aβ25-35 (Figures 
4.6A i & ii). Incubation of microglia in afobazole alone had no effect on Bax expression 
 
Figure 4.5 
 
Afobazole decreases microglial cell death produced by application of Aβ25-35. A, 
Photomicrographs showing EthD-1 labeling (red) of microglial cells following 72 hr 
incubation in media alone (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 30 µM 
afobazole (Afob) (iii), or 30 µM afobazole + 25 µM Aβ25-35 (iv). Fields of view shown are 
representative regions within larger images used to calculate cell death.  B, Bar graph of 
the mean (±SEM) relative number of apoptotic cells identified by EthD-1 labeling in 
multiple experiments when the cultures were incubated under the same conditions as 
(A). Data for each experiment were normalized to the mean cell death observed with 
media alone (Media, Control). Asterisk denotes significant difference between Control 
and Aβ groups within Media (p < 0.05). Pound symbol indicates significant difference 
between Media and Afob groups within Aβ (p < 0.05) (n ≥ 12) Scale bar in (i) is 10 µm. 
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levels, but application of the σ agonist inhibited Aβ25-35 -induced elevated Bax expression 
(Figure 4.6A iii & iv). Compilation of data from several identical experiments indicates 
 
Figure 4.6 
 
Afobazole reduces Aβ25-35-evoked expression of the pro-apoptotic gene product Bax, in 
microglia. A, Photomicrographs of merged images of cultured microglia exposed for 24 
hr to media alone (i), or media containing 25 µM Aβ25-35 (Aβ) (ii), 30 µM afobazole (iii) or 
25 µM Aβ25-35 + 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) 
and anti-Bax antibody (green). Fields of view shown are representative regions within 
larger images used to calculate Bax expression. B, Bar graph of the mean (±SEM) 
number of Bax-positive microglia in experiments in which the cells were exposed to 
media (Control) or 25 µM Aβ25-35 (Aβ) in the absence (Media) or presence of 30 µM 
afobazole (Afob). Data are expressed as the percent of Bax positive microglia, using 
DAPI to identify the number of microglia per slide. Asterisks denote significant difference 
between Control and Aβ within Media and Afob (p < 0.001 for both). Pound symbol 
indicates significant difference between Media and Afob within Aβ (p < 0.001). For all, n 
= 9. Scale bar in (i) is 10 µm. 
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that approximately 20% of control microglia expressed Bax, but that this number 
increases to over 80% following Aβ25-35 incubation (Figure 4.6B). While an increase in 
Bax expression was noted when microglia were incubated in a combination of afobazole 
and Aβ25-35, there was a 54 ± 4% reduction in the number of cells showing Bax reactivity 
when compared to microglia incubated in Aβ25-35 alone (Figure 4.6B). 
Caspase-3 has also been implicated in Aβ25-35-induced microglial apoptosis, and 
σ-1 receptor activation has been shown to induce caspase-3 downregulation in these 
cells (Jang et al., 2005, Tchedre and Yorio, 2008). Thus, we examined the effects of 
afobazole on the levels of the death protease, caspase-3, after microglial cell were 
exposed to Aβ25-35 for 24 hr (37º C). Incubation of microglia in Aβ25-35 increased the 
number of cells expressing the active form of caspase-3 relative to control (Figure 4.7A i 
& ii). While afobazole alone had no significant effect on activated caspase-3 expression, 
afobazole inhibited the increases in active caspase-3 evoked by Aβ25-35 (Figure 4.7A iii & 
iv). In identical experiments, comparing the number of cells expressing activated 
caspase-3 in cultures treated with Aβ25-35 alone to those treated with Aβ25-35 + afobazole 
indicates that afobazole reduces caspase-3 expression by 47 ± 5% (Figure 4.7B).  
The anti-apoptotic gene product, Bcl-2, has been shown to be upregulated by 
interventions that decrease microglial cell death caused by Aβ25-35 (Jang et al., 2005). In 
neurons, the expression levels of this protein increase after 24 hr exposure to Aβ and 
then decreases after 48 hr (Kim et al., 1998). Thus, to explore how afobazole protects 
microglia from Aβ25-35-induced apoptosis, we used the 48 hr time point to assess how 
afobazole affects Bcl-2 expression. Bcl-2 was readily detected at 48 hr in microglia under 
all conditions tested (Figures 4.8A). Quantification of the data shows that afobazole 
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application produced a small, but significant, increase of 14 ± 1% in the number of 
microglia expressing Bcl-2 (Figure 4.8B). Similarly, Aβ25-35 alone increased the number 
of cells expressing Bcl-2 by 11 ± 1%. While afobazole co-application did not increase 
 
Figure 4.7 
 
Afobazole reduces expression of activated caspase-3 in response to application of Aβ25-
35 in microglia. A, Photomicrographs of merged images of cultured microglia exposed for 
24 hr to media alone (i) or media containing 25 µM Aβ25-35 (ii), 30 µM afobazole (iii) or 25 
µM Aβ25-35 + 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and 
anti-activated caspase-3 antibody (green). Fields of view shown are representative 
regions within larger images used to calculate activated caspase-3 expression. Scale bar 
in (i) is 10 µm. B, Bar graph of mean (±SEM) percent of caspase-3 positive microglia in 
experiments in which the cells were exposed to media (Control) or 25 µM Aβ25-35 (Aβ) in 
the absence (Media) or presence of 30 µM afobazole (Afob). Asterisks denote significant 
difference between Control and Aβ groups within Media and Afob (p < 0.001); pound 
symbol indicates significant difference between Media and Afob within Aβ (p < 0.001). 
For all condition, n =9.  
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Bcl-2 expression significantly above afobazole alone, the combination of afobazole and 
Aβ25-35 yielded a small but significant increase (4 ± 1%) in the number of microglia 
expressing Bcl-2 after 48 hr when compared to Aβ alone (Figure 4.8B).  
 
Figure 4.8 
 
Afobazole has minor effects on Bcl-2 levels in microglia following application of Aβ25-35. 
A, Photomicrographs of merged images of cultured microglia exposed for 24 hr to media 
alone (i) or media containing 25 µM Aβ25-35 (ii), 30 µM afobazole (iii) or 25 µM Aβ25-35 + 
30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and anti-Bcl-2 
antibody (green). Areas shown are representative regions within larger images used to 
calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean (±SEM) 
percent of Bcl-2 positive microglia in experiments in which the cells were exposed to 
media (Control) or 25 µM Aβ25-35 (Aβ) in the absence (Media) or presence of 30 µM 
afobazole (Afob). Asterisk denotes significant difference between Control and Aβ within 
Media (p < 0.01). Pound symbols indicate significant difference between Media and Afob 
within Control and Aβ, respectively (p < 0.01 for both, n = 9 for all).  
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While our observations indicate that activation of σ receptors with afobazole 
decreases microglial cell death, it is unclear if the surviving cells have been 
compromised such that they fail to exhibit responses to normal stimuli. Thus, functional 
studies were carried out to evaluate microglia using ATP to stimulate changes in [Ca2+]i 
following Aβ25-35 application in the absence and presence of afobazole. Figure 4.9A 
shows a series of traces of [Ca2+]i as a function of time recorded from four microglia 
incubated in Aβ25-35 for 24 hr and exposed to ATP in the absence and presence of 
afobazole. Focal application of 100 µM ATP produced transient elevations in [Ca2+]i in 
microglia under control conditions and when the cells were incubated in 25 µM Aβ25-35 
(Figure 4.9A, top traces). However, the ATP-induced elevations in [Ca2+]i were greatly 
reduced in the microglia incubated in Aβ25-35. In contrast, microglia incubated in 30 µM 
afobazole displayed similar ATP-induced increases in [Ca2+]i in absence and presence of 
the Aβ fragment (Figure 4.9A, bottom traces). In identical experiments, ATP evoked 
comparable increases in [Ca2+]i in microglia incubated in media alone (Control) and 30 
µM afobazole (Figure 4.9B). However, microglia incubated in Aβ25-35 showed a 
statistically significant 34 ± 4% reduction in ATP-evoked [Ca2+]i responses (Figure 4.9B). 
While afobazole pre-incubation did not have a long-term effect on ATP-evoked 
responses, co-application of 30 µM afobazole along with the 25 µM Aβ25-35 rescued the 
ATP-evoked responses such that the increases in [Ca2+]i observed in this group were 
statistically similar to both the Control group and the afobazole alone group. The [Ca2+]i 
responses in the afobazole + Aβ25-35 group were 44 ± 8% greater than the Aβ25-35 only 
group (Figure 4.9B).  
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Figure 4.9 
 
Afobazole preserves [Ca2+]i responses to ATP in microglial cells exposed to Aβ25-35. A, 
representative traces of [Ca2+]i as a function of time recorded from four microglia during 
10 second application of 100 µM ATP following 24 hr incubation in media alone 
(Control), or media containing 25 µM Aβ25-35 (Aβ), 30 µM Afobazole (Afob) or 25 µM 
Aβ25-35 + 30 µM Afobazole (Afob + Aβ). The afobazole and Aβ were washed out for 5 min 
prior to application of ATP. Line above [Ca2+]i responses indicates duration of ATP 
application. B, Bar graph of mean (± SEM) peak increases in [Ca2+]i (∆[Ca2+]i) evoked by 
application of 100 µM ATP onto isolated microglia. [Ca2+]i responses were recorded from 
microglia in experiments identical to those performed in (A). Asterisk symbolizes 
significant difference between Control and Aβ within Media (p < 0.001). Pound symbol 
denotes significant difference between Media and Afob within Aβ (p < 0.001). For all 
conditions, n ≥ 33. 
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Discussion 
The most salient finding reported here is that activation of both σ-1 and σ-2 
receptors by afobazole rescues microglia from the deleterious consequences of Aβ25-35 
exposure. Afobazole application reduced the activation of microglia caused by incubation 
of the cells in Aβ25-35 as evident by a decrease in membrane ruffling and cell migration 
induced by the Aβ fragment. The apoptosis of microglia induced by Aβ25-35 was also 
reduced by afobazole. This decrease in cell death is likely due to a reduction in the 
expression of the pro-apoptotic gene, Bax, and the death protease, caspase-3. 
Afobazole also preserved functional responses of the microglia to ATP after Aβ25-35 
incubation, which has significant implications for Alzheimer’s disease progression.  
Afobazole application reduced the activation of microglia caused by incubation of 
the cells in ATP, as evident by a decrease in membrane ruffling. Previous studies from 
our laboratory have shown that microglia quickly become activated and withdraw their 
filopodia when exposed to various stimuli, such as LPS and ATP (Hall et al., 2009a). 
This activated state, which allows the microglia to migrate to the site of injury, is 
preceded by the release of neurotoxic substances (Kierdorf and Prinz, 2013). Previously 
we have shown that microglia, in response to ATP, alter their morphology to a less 
ramified state and this reaction was inhibited by DTG (Hall et al., 2009a). Afobazole 
effectively blocked membrane ruffling by approximately 50% in response to ATP. For 
comparison we used a second pan-selective σ receptor agonist, DTG, which reduced 
ruffling comparable to afobazole and to the extent as previously reported.  
Previous studies have shown that microglia rapidly respond to Aβ by withdrawing 
their filopodia and assuming an amoeboid, ruffled morphology (Araujo and Cotman, 
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1992). This early event is indicative of microglial activation and precedes the 
inflammatory response that includes release of neurotoxic substances from the microglia 
(Combs et al., 2001, Garcao et al., 2006, Orellana et al., 2011). Afobazole (30 µM) 
effectively blocked membrane ruffling in response to Aβ25-35. While a second pan-
selective σ receptor agonist, DTG (30 µM), also decreased membrane ruffling caused by 
Aβ25-35, this drug was significantly less potent than afobazole. It has been shown that 
higher concentrations of DTG (100 µM) are also required to block ATP-induced 
microglial membrane ruffling (Hall et al., 2009a).  
Afobazole also effectively blocked microglial migration induced by Aβ25-35. It has 
been shown previously that various Aβ fragments, including Aβ25-35, are microglial 
chemotactic agents (Davis et al., 1992). The Aβ-induced chemotaxis is in part due to 
release of ATP from microglia following Aβ25-35 application and subsequent activation of 
P2Y2 receptors on these cells (Kim et al., 2012). We have previously shown that 
afobazole blocks microglial migration induced by activation P2Y receptors (Cuevas et al., 
2011b). Afobazole appears to inhibit microglial migration caused by UTP via σ receptor-
mediated disruption in P2Y signaling, since afobazole treatment also inhibited P2Y-
induced elevation in [Ca2+]i in microglia (Cuevas et al., 2011b). The IC50 for afobazole 
inhibition of microglial migration caused by Aβ25-35 is 120 µM, which is similar to the low-
affinity site reported for afobazole inhibition of UTP-induced microglial migration (102 
µM) (Cuevas et al., 2011b). Therefore, afobazole may in part prevent microglial 
chemotaxis caused by Aβ25-35 via σ receptor-mediated inhibition of P2Y receptors in 
these cells.  
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Data shown here indicate that both σ receptor subtypes are involved in afobazole 
inhibition of Aβ25-35-evoked microglial activation. Afobazole-mediated inhibition of 
microglial migration was reduced by ~50% by 10 µM BD 1047, which is indicative of a σ-
1 receptor mediated effect (Matsumoto et al., 1995). An identical concentration of BD 
1047 had a similar effect on afobazole inhibition of ATP-induced microglial cell migration 
(Cuevas et al., 2011b). Likewise, involvement of σ-2 receptors is confirmed by results 
obtained using the σ receptor antagonist, rimcazole, which binds to σ-2 receptors with 
nanomolar affinity (Ferris et al., 1986, Rybczynska et al., 2008). Nanomolar 
concentrations of rimcazole also blocked afobazole inhibition of microglial migration in 
response to ATP (Cuevas et al., 2011b). 
Given that one of the consequences of microglial activation is increased oxidative 
and nitrosative stress, which leads to Aβ25-35 toxicity (Weldon et al., 1998, Bianca et al., 
1999, Combs et al., 2001), we examined how afobazole affects Aβ25-35-induced 
increases in cellular ROS and NO levels. Consistent with previous reports, both ROS 
and NO levels were increased significantly following Aβ25-35 application. However, 
afobazole failed to attenuate the increases in ROS and NO evoked by the Aβ fragment. 
Activation of σ receptors has been shown to decrease oxidative injury and nitrosative 
stress in various models. It was recently shown, using σ receptor knockout mice, that σ-1 
has a dual function of both reducing oxidative stress and activating antioxidant response 
elements (Pal et al., 2012). In microglia, stimulation of σ receptors by DTG reduces NO 
production in response to lipopolysaccharide (Hall et al., 2009a). Taken together, 
however, our data suggest that the reduction in Aβ-evoked microglial cell toxicity 
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provided by afobazole application is not the result of σ receptor-mediated decrease in 
oxidative or nitrosative stress. 
While decreased activation of microglia will be beneficial in AD by reducing the 
neuroinflammatory response, recent data suggests that enhanced microglial survival is 
also important for improved outcomes given the ability of these cells to phagocytose Aβ 
plaques (Streit et al., 2009, Solito and Sastre, 2012). Application of 30 µM afobazole 
significantly reduced the number of microglia undergoing apoptosis following 72 hr 
incubation in Aβ25-35. The concentrations of afobazole shown to be effective here are 
identical to those previously shown to decrease microglial cell death caused by ischemia 
in a σ receptor dependent manner and consistent with the binding affinity of afobazole 
for σ-1 receptors (Seredenin et al., 2009, Cuevas et al., 2011a, Cuevas et al., 2011b). 
This observation suggests that afobazole is similarly acting through σ receptor activation 
to prevent microglial cell death. Both melatonin and N-acetylcysteine have been shown 
to decrease Aβ25-35-evoked apoptosis in microglia via a reduction in ROS (Jang et al., 
2005). Given that afobazole does not appear to affect Aβ25-35-elicited increases in ROS, 
it is unlikely that afobazole provides cytoprotection via a similar mechanism to these 
compounds.   
Our findings demonstrate that afobazole mitigates Aβ25-35-induced apoptosis of 
microglia by decreasing expression of the pro-apoptotic gene, Bax, and the death 
protease caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. An 
increase in Bax levels has been observed in both neurons and microglia of AD brains 
(Su et al., 1997). Moreover, interventions that decrease Aβ25-35-induced microglial 
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apoptosis have been shown to lower Bax expression (Jang et al., 2005, Shang et al., 
2012). Likewise, caspase activity has been detected in plaque-associated neurons and 
microglia in AD brains (Yang et al., 1998). Caspase-3 levels have been shown to be 
upregulated in microglia following Aβ administration, while reduced levels of this death 
protease have been associated with inhibition of Aβ toxicity (Shang et al., 2012). 
Conversely, expression of the anti-apoptotic gene, Bcl-2, is inversely correlated with 
disease severity in AD. Increases in Bcl-2 levels promote microglial survival following 
exposure to Aβ25-35 (Satou et al., 1995, Jang et al., 2005). Therefore, afobazole likely 
enhances microglial survival and resistance to Aβ25-35 toxicity via a complex response 
involving both anti-apoptotic and pro-apoptotic genes. This multifaceted effect is 
consistent with afobazole acting as a σ agonist, since σ receptor activation has been 
shown to modulate Bax, caspase-3 and Bcl-2 levels (Tchedre and Yorio, 2008, Meunier 
and Hayashi, 2010).  
Importantly, not only did afobazole protect microglia from Aβ25-35-evoked 
apoptosis, but application of the σ agonist preserved the functional capacity of these 
cells, as evident from the continued [Ca2+]i responses to ATP. Ultimately, one of the 
theoretical benefits to increased microglial survival would be continued clearance of Aβ, 
as this peptide has been shown to be phagocytosed by microglia (Wilcock et al., 2004, 
Herber et al., 2007). This hypothesis is further supported by the recent observation that 
microglial clearance of Aβ directly correlates with expression of the gene CD33, such 
that a CD33 deficiency reduces brain levels of both insoluble Aβ1-42 and amyloid plaque 
burden in a mouse AD model (Griciuc et al., 2013). Moreover, there is a decrease in both 
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CD33 expression and insoluble Aβ1-42 in the brains of individuals expressing the minor 
allele of the CD33 (SNP rs3865444) gene, which was identified previously as imparting 
protection against AD (Naj et al., 2011, Griciuc et al., 2013). The fact that responses to 
ATP itself are preserved is significant, since the clearance of Aβ has been shown to be 
dependent of the activation of P2Y2 receptors. Microglia respond to Aβ by releasing ATP 
and this nucleotide functions in a paracrine manner, acting on P2Y2 receptors expressed 
on the microglia to enhance Aβ uptake by these cells (Kim et al., 2012). We have 
previously shown that in our model these increases in [Ca2+]i are due to activation of P2Y 
receptors, since they can be elicited by UTP (Cuevas et al., 2011b). Therefore, by 
preserving ATP responses in microglia, afobazole will permit these cells to respond to Aβ 
in vivo and potentially decrease amyloid burden. 
In conclusion, our study demonstrates that afobazole can mitigate activation of 
microglial cells in response to Aβ25-35. Afobazole also reduced microglial toxicity caused 
by Aβ25-35, but this cytoprotection does not involve regulation of either ROS or NO 
production caused by the amyloid peptide. The observed decrease in apoptosis is due to 
afobazole-mediated regulation of multiple genes, with a noted decrease in Bax and 
caspase-3 and a concomitant increase in Bcl-2 expression. In addition to the decrease in 
cell death, afobazole preserved functional activity of the cells as evident by the 
conserved ATP-induced increases in [Ca2+]i following prolonged incubation in Aβ25-35. 
Taken together our data suggest that afobazole may prevent microglia from entering the 
activated state associated with neurotoxicity following exposure to Aβ, and increasing 
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their survival, which will facilitate clearance of the amyloid peptide. These properties 
make afobazole an attractive drug for potential Alzheimer’s therapeutics. 
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CHAPTER 5 
 
 
Activation of Sigma Receptors via Afobazole Modulates Microglial but not 
Neuronal Apoptotic Expression in Response to Long-Term Ischemia Exposure 
 
 
Introduction 
 
Our laboratory has previously shown that stroke is a multicellular disease and that 
any attempts to treat this disease must involve several different cell types (Hall et al., 
2009b, Leonardo et al., 2010, Cuevas et al., 2011a, Cuevas et al., 2011b). Neurons have 
previously been the sole target in the treatment of stroke, but we have shown that 
microglia cells play a dynamic roll the pathophysiology of stroke (Hall et al., 2009a, 
Cuevas et al., 2011b). In response to stroke or other types of CNS injury, microglia 
become activated and migrate to the site of injury (Kierdorf and Prinz, 2013), while the 
initial action is neuroprotective in nature, overtime microglial cells become over-activated 
and neurotoxic (Hellwig et al., 2013). It is possible that the injury occurring, following the 
days and weeks after a stroke, is due to microglia over-activation (Hellwig et al., 2013). 
However, completely inhibiting activation and migration of microglial cells would result in 
unintended, detrimental side effects as microglia play an important, neuroprotective role 
in the early stages following a stroke insult (Kitamura et al., 2004). Therefore, it is 
important to provide neuroprotection by regulating neuronal and microglial mechanisms. 
Previously studies have shown that sigma (σ) receptors play a vital role in 
neuroprotection and cell regulation as a whole (Ajmo et al., 2006, Katnik et al., 2006, Su 
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et al., 2010). Largely distributed throughout the mammalian body, these receptors 
perform a number of functions such as regulating membrane ion channels (Hayashi et 
al., 2000, Tchedre et al., 2008), altering expression of antiapoptotic and proapoptotic 
transcription factors (Yang et al., 2007, Tchedre and Yorio, 2008, Meunier and Hayashi, 
2010) and modulating activation and migration of microglial cells (Hall et al., 2009a). 
Once thought to be a type of opioid receptor, sigma receptors were later placed into their 
own class of opioid-like receptors (Walker et al., 1990, Seth et al., 1998). Consisting of 
two subtypes, σ-1 & σ-2, these receptors have been shown to provide protection to both 
neurons and glial cells following in vitro ischemia and in vivo middle cerebral artery 
occlusion (MCAO) stroke models (Ajmo et al., 2006, Katnik et al., 2006). The σ-1 
receptor is an inter-organelle chaperone localized to the mitochondrion-associated ER 
membrane (MAM) (Su et al., 2010). This σ-1 receptor-MAM complex plays an important 
role in cell signaling, mitochondrial function, maintaining intracellular calcium 
homeostasis and the expression of cellular proteins (Tsai et al., 2009). In contrast, σ-2 
receptors are not well understood, in part because the gene encoding this receptor has 
not been cloned. However, σ-2 receptors are known to play important roles in regulating 
intracellular calcium (Vilner and Bowen, 2000) and are involved in the activation and 
migration of microglial cells (Cuevas et al., 2011b, Iniguez et al., 2013). 
Our laboratory has previously shown the pan-selective sigma receptor agonist 
afobazole (5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole), an anxiolytic currently 
used clinically in Russia, to be protective in neurons (Cuevas et al., 2011a) and microglia 
(Cuevas et al., 2011b) in an in vitro chemical ischemia and acidosis model. Furthermore, 
afobazole prevented neuronal and glial cell death in an in vivo MCAO stroke model 
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(Katnik et al., 2013). Other studies have suggested that afobazole may provide 
neuroprotection in a variety of pathophysiological diseased states, which involve 
oxidative stress and glutamate toxicity (Zenina et al., 2005). Recently our laboratory 
showed that afobazole maintained neuronal and microglial cell viability when exposed to 
amyloid-β25-35 by the downregulation of the pro-apoptotic protein Bax and the death 
protease caspase-3, while preserving Bcl-2 expression (Behensky et al., 2013a, b). 
Experiments were carried out to determine how afobazole affects neuronal and 
microglial responses to chemical ischemia. Afobazole also reduced ischemia-induced 
cell death in both microglia and neurons. In addition, afobazole application prevented 
upregulation of the proapoptotic protein Bax and death protease caspase-3 in microglia 
but not in neurons. Conversely, Bcl-2 expression was preserved in microglia, but not 
neurons, by afobazole following exposure to ischemia. This study demonstrates that one 
way in which afobazole maintains cellular viability in microglia cells is through the 
regulation of apoptotic proteins. We also show that afobazole provides neuroprotection 
against chemical ischemia in neurons, but by mechanisms other than direct regulation of 
apoptosis. 
 
Materials and Methods 
 
 
Primary Cultures of Microglia 
Primary cultures of microglia were prepared from Sprague-Dawley mixed sex rat 
pups (post natal day 2-3) as previously described by our laboratory (Hall et al., 2009a, 
Cuevas et al., 2011b). The mixed glial cultures were incubated for 7-12 days at 37 o C 
prior to experiments being carried out. Microglia were mechanically separated from the 
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cultures by brief shaking. Isolated microglia were resuspended in DMEM PLUS 
containing: 500 mL Dulbecco’s Modified Eagle Medium with 4.5 g/L glucose, L-glutamine 
and sodium pyruvate (DMEM) (Corning Cellgro, Manassas, VA), 40 mL horse serum 
(Corning Cellgro), 12.5 mL heat-inactivated fetal bovine serum (Thermo Scientific 
Hyclone, Logan, UT ), and 5 mL 10x antibiotic/antimycotic (Corning Cellgro). These cells 
were used immediately for cytotoxicity assays or plated on glass coverslips for one day 
for imaging experiments.  
 
Preparation of Cortical Neurons 
 
All experiments were carried out on cultured cortical neurons from mixed sex 
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used 
here were identical to those previously reported for the isolation and culturing of these 
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated 
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium 
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for 
experiments after 10-21 days in culture, which permits synaptic contact formation and 
yields robust responses to other pathophysiological conditions such as in vitro ischemia 
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in 
accordance with the regulations and guidelines set forth by the University of South 
Florida’s College of Medicine Institution on Animal Care and Use Committee. 
 
Live/Dead Cell assay 
 
Neurons or microglia plated on poly-L-lysine coverslips were incubated at 37°C for 
72 hr in Neurobasal Complete or DMEM Plus, respectively, with 4 mM sodium azide in 
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the absence (Control) and presence of 100 µM afobazole for neurons and 30 µM 
afobazole or for microglia. The coverslips were rinsed with PBS followed by 30 min 
incubation at room temperature in PBS with 4 µL of a 2mM ethidium homodimer-1 (EthD-
1) dissolved in 1:4 DMSO:H2O solution. The coverslips were washed with PBS and 
deionized water, dried, and mounted on a microscope slide with Vectashield Hardset 
mounting media (Vector Labs, Burlingame, CA). EthD-1 loaded cells were illuminated 
with light at 530 nm and visualized at 645 nm using a Zeiss Axioskop 2 equipped with a 
20X objective. EthD-1-positive cells were identified and counted using Image-J in four 
random fields per slide, and the average for the fields used as the value for the slide. For 
each experiment, a minimum of three slides were used, and the results of at least three 
experiments were averaged together for each condition tested. 
 
Immunocytochemistry 
 
Neurons or microglia plated on poly-L-lysine coverslips were incubated at 37°C for 
24 hr in Neurobasal complete or DMEM Plus with 4 mM sodium azide in the absence 
and presence of 100 µM or 30 µM afobazole, respectively. The coverslips were rinsed 
with phosphate-buffered saline (PBS) followed by an ethanol step-wise fixation. The cells 
were permeabilized with 0.1% Triton X in PBS for 15 min, then rehydrated with PBS and 
washed with 0.5% bovine serum albumin (BSA) in PBS. Blocking was achieved with 45 
min incubation in 2% BSA, followed by multiple washes with 0.5% BSA. Primary 
antibodies were diluted in PBS with 0.5% BSA and applied onto cells at 4°C for 24 hr. 
Primary antibody dilutions were as follows: Bax 1/20, Caspase-3 1/25 and Bcl-2 1/100. 
The cells were then washed multiply times with 0.5% BSA in PBS and then incubated in 
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secondary antibodies for 60 min at room temperature. Secondary antibodies were either 
Alexa Fluor 488 conjugated anti-mouse or anti-rabbit diluted at a ratio of 1/300 in PBS 
with 0.5% BSA. Following incubation in secondary antibodies, cells were washed with 
0.5% BSA in PBS and then with PBS alone. Coverslips were rinsed with deionized water 
and inverted onto a slide VectaShield containing DAPI. DAPI and the Alexa Fluor 488 
conjugated secondary antibodies were illuminated at 359 and 485 nm and visualized at 
461 and 530 nm, respectively, using a Zeiss Axioskop 2 outfitted with a 40X objective. 
Images of DAPI and Alexa Fluor 488 positive cells were counted and merged to 
demonstrate co-localization using Image-J software. Four random fields per slide were 
used to determine an average value for the slide. For each experiment, a minimum of 
three slides were used, and the results of at least three experiments were averaged 
together. 
 
Calcium Imaging 
 
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using 
ratiometric fluorometry as previously described (Katnik et al., 2006). Neurons were 
loaded with fura-2 by adding 3 µg/ml of the acetoxymethylester form of fura-2 (fura-2 
AM) in 0.3% DMSO to the media and incubating the cells at room temperature for 1 hr. 
Prior to beginning the experiments, the coverslips were rinsed with physiological saline 
solution (PSS) consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3 
CaCl2, and 1.0 MgCl2 (pH to 7.4 with NaOH). For each cell, [Ca2+]i was measured once a 
second for a 100 second period and the values averaged to determine mean peak and 
net [Ca2+]i.  
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Compounds, Reagents and Antibodies 
The following compounds and reagents were used in this investigation: DTG 
(Tocris Biosciences, Ellisville, MO); Live/Dead Viability/Cytotoxicity Kit (Life 
Technologies); Sodium Azide (ACROS Organics, Fair Lawn, NJ). The following 
antibodies were also used: Alexa Fluor 488 anti-mouse (A-11001) and anti-rabbit (A-
11008) (Life Technologies); anti-Bax (ab5714), anti-activated caspase-3 (ab32351) and 
anti-Bcl-2 (ab32370) (abcam, Cambridge, MA). Afobazole was generously provided by 
IBC Generium (Moscow, Russian Federation). Vehicle for drugs and reagents used were 
either water (H2O), ethanol (EtOH) or dimethyl sulfoxide (DMSO), and appropriate 
vehicle controls were carried out for each study.  
 
Data Analysis 
 
Fluorescence intensities were recorded from cortical neurons and microglia in the 
same manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a, Cuevas 
et al., 2011b). Data were analyzed using Image J or SigmaPlot 11 software (Systat 
Software, Inc., San Jose, CA). Data points represent peak means ± standard error of the 
mean (S.E.M.). One-, two- and three-way analysis of variance were used for determining 
significant differences for multiple group comparisons, as appropriate, followed by post 
hoc analysis using the Holm-Sidak method. Results were considered statistically 
significant if p < 0.05. 
 
Results 
 
Previous studies suggested that activation of σ receptors decreased microglial cell death 
in response to ischemia. To further examine the effects of ischemia on survival of 
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microglia, the Live/Dead cytotoxicity assay was used. Ethidium Homodimer-1 (EthD-1) 
labeled cells were counted in microglia cultures in the absence (Control) and presence of 
ischemia (Isch). There was significant microglia death when exposed to 72 hr ischemia 
 
Figure 5.1 
 
Afobazole reduces microglia death produced by application of ischemia. A, 
Photomicrographs showing EthD-1 labeling (red) of microglial cells following 72 hr 
incubation in media alone (i), or media containing 4 mM Azide (in vitro ischemia, Isch) 
(ii), 30 µM afobazole (Afob) (iii), or 30 µM afobazole + 4 mM Azide (iv). Fields of view 
shown are representative regions within larger images used to calculate cell death. B, 
Bar graph of relative cell death observed following 72 hr incubation of microglia in control 
(Control) or ischemic condition (Isch), with (Afob) or without (Media) 30 µM afobazole (n 
> 12). Data were normalized to cell death observed with media alone (Control). Asterisks 
denote significant difference between Control and Isch within Media and Afob, 
respectively (p < 0.001 & = 0.001, respectively); pound symbol indicates difference 
between Afob and Media within Isch (p < 0.001). 
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(Figure 5.1). Afobazole significantly mitigated microglial cell death when co-incubated 
with ischemia. 72hr incubation in media alone or media with 30µM afobazole had no 
effect on microglia death, respectively. Counting the number EthD-1-positive cells 
showed that afobazole mitigates ischemia induced cell death by 75 ± 8%.  
The mechanism by which activation of σ receptors may decrease cell death 
remain unknown. Thus, experiments were carried out to determine if activation of σ 
receptors alters the expression of molecules involved in cell apoptosis. One pro-
apoptotic gene product that has been shown to be affected by ischemia and may 
regulated by σ receptors is the protein Bax (Schelman et al., 2004, Tchedre and Yorio, 
2008). Immunocytochemical experiments were conducted to measure Bax levels 
following 24 hr ischemia incubation to ascertain and whether afobazole application 
affects the levels of protein. Ischemia significantly increases the pro-apoptotic gene, Bax, 
in microglia (Figure 5.2). Co-labeling of microglia with DAPI and an anti-Bax antibody 
shows that Bax is rarely detected in control cells but is readily visible in microglia 
following ischemia. Afobazole alone had no effect on Bax levels, but this drug reduced 
Bax expression after ischemia incubation. Nearly all microglia show Bax expression after 
ischemia, but this is reduced by 41 ± 1% when afobazole is co-applied. This reduction in 
Bax expression was found to be statistically significant (Figure 5.2). 
Bax-dependent caspase-3 activation is a key component in cellular apoptosis 
(Cregan et al., 1999). Therefore, we examined how afobazole effects the levels of the 
death protease, caspase-3, in microglia after ischemia treatment. Following ischemic 
exposure, the activated form of caspase-3 was observed in a greater number of cells  
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Figure 5.2 
 
Afobazole prevents upregulation of the pro-apoptotic gene, Bax, observed in response to 
ischemia in microglia. Microglia were double labeled with DAPI (blue) and anti-Bax 
antibody followed by Alexa Fluor 488 conjugated secondary antibody (green). A, 
Photomicrographs of merged images of cultured microglia exposed for 24 hr to media 
alone (i) or media containing 4 mM Azide (Isch) (ii), 30 µM afobazole (iii) or 4 mM Azide 
+ 30 µM afobazole (iv). Microglia were double labeled with DAPI (blue) and anti-Bax 
antibody (green). Fields of view shown are representative regions within larger images 
used to calculate Bax expression. Scale bar in (i) is 10 µm. B, Bar graph of mean 
number of Bax-positive microglia in experiments in which the cells were exposed to 
normal conditions (Control) or ischemia (Isch) in the absence (Media) or presence of 30 
µM afobazole (Afob). Data are expressed as percent (± SEM) of total number of 
microglia per slide (n = 9). Asterisk denotes significant difference between Control and 
Isch within Media and Afob, respectively (p < 0.001 for both). Pound symbol indicates 
significant difference between Media and Afob within Isch (p < 0.001). 
 
relative to control (Figure 5.3). Afobazole alone significantly decreased caspase-3 levels 
relative to the control, and diminished the increases in caspase-3 evoked by ischemia. 
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Examining the number of cells showing caspase-3 signal demonstrates that afobazole 
reduced the number of caspase-3 positive cells by 53 ± 6% in the absence of ischemia. 
 
Figure 5.3 
 
Afobazole reduces expression of caspase-3 in response to ischemia in microglia. 
Microglia were double labeled with DAPI (blue) and anti-caspase-3 antibody followed by 
Alexa Fluor 488 conjugated secondary antibody (green). A, Photomicrographs of merged 
images of cultured microglia exposed for 24 hr to media alone (i) or media containing 4 
mM Azide (Isch) (ii), 30 µM afobazole (iii) or 4 mM Azide + 30 µM afobazole (iv). Fields 
of view shown are representative regions within larger images used to calculate 
activated caspase-3 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number 
of caspase-3-positive microglia in experiments in which the cells were exposed to normal 
conditions (Control) or ischemia (Isch) using media alone (Media) of media with 30 µM 
afobazole  (Afob). Data are expressed as percent (± SEM) of total number of microglia 
per slide (n = 9). Asterisks denote significant difference between Control and Isch within 
Media and Afob (p < 0.001 for both). Pound symbols indicate significant difference 
between Media and Afob within Control and Isch, respectively (p < 0.001 for both). 
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Following ischemia, afobazole reduced caspase-3 levels by 59 ± 5%, such that the levels 
of caspase-3 were similar to those observed under control conditions (no ischemia or 
afobazole) both of which were statistically significant.  
The effects of Bax can be counteracted by upregulation of the anti-apoptotic 
protein Bcl-2 (Hockenbery et al., 1993, Korsmeyer et al., 1993, Oltvai et al., 1993), which 
may be a second mechanism by which σ receptors reduce cell death following ischemia. 
The relationship between afobazole and expression of the anti-apoptotic gene, Bcl-2, 
during ischemia in microglia was examined via immunocytochemistry. Following 
ischemia, the levels of Bcl-2 expressed by microglia decreased by ~20% compared to 
that of control (Figure 5.4). Afobazole alone produced a ~10% increase in the number of 
cells expressing Bcl-2. Moreover, afobazole rescued Bcl-2 expression following 
ischemia. Both afobazole and afobazole with ischemia treated microglia showed nearly 
100% expression in all cells. 
Previous studies showed that σ receptor activation can decrease neuronal death 
following a 24 hr ischemic event in vitro. However, it has not been determined if 
neuroprotection occurs following longer ischemic events such as those used for 
microglia here. Thus, experiments were carried out to see if afobazole can decrease 
neuronal death under these conditions. Neurons labeled with EthD-1 were counted in the 
absence (Control) and presence of ischemia (Isch). There was significant neuronal death 
when exposed to 72 hr Isch (Figure 5.5). Afobazole significantly mitigated neuronal cell 
death when co-incubated with ischemia. Incubation in media alone (Control) set the 
limits of normal neuronal death, whereas media with 100µM afobazole had reduced 
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neuron death beyond control levels. Counting the number EthD-1 positive cells showed 
that afobazole mitigates ischemia-induced cell death by 49 ± 9%.   
 
Figure 5.4 
 
Afobazole enhances Bcl-2 expression under control conditions and following ischemia in 
microglia. Microglia were double labeled with DAPI (blue) and anti-Bcl-2 antibody 
followed by Alexa Fluor 488 conjugated secondary antibody (green). A, 
Photomicrographs of merged images of cultured microglia exposed for 24 hr to media 
alone (i) or media containing 4 mM Azide (ii), 30 µM afobazole (iii) or 4 mM Azide + 30 
µM afobazole (iv). Areas shown are representative regions within larger images used to 
calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number of 
Bcl-2-positive microglia in experiments in which the cells were exposed to normal 
conditions (Control) or ischemia (Isch), in the absence (Media) and presence of 30 µM 
afobazole (Afob). Data are expressed as percent (± SEM) of total number of microglia 
per slide (n = 9). Asterisk denotes significant difference between Control and Isch within 
Media (p < 0.001); pound symbols indicate significant difference between Media and 
Afob within Control and Isch, respectively (p < 0.01 for Control & < 0.001 for Isch). 
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Experiments were next carried out to determine if the enhanced neuronal survival 
observed following σ receptor stimulation in neurons involves a pathway similar to that 
observed in microglial cells. As in microglia, ischemia significantly increased the pro-
apoptotic gene, Bax, in neurons (Figure 5.6). Co-labeling neurons with DAPI and an anti-
Bax antibody showed that Bax is detected in control cells but increased in neurons 
 
Figure 5.5 
 
Afobazole reduces neuronal death induced under ischemic conditions. Bar graph of 
relative cell death observed following 72 hr incubation of neurons in media (Media) or 
media containing ischemia (Isch), 100 µM afobazole (Afob) or ischemia + 100 µM 
afobazole (Isch + Afob) (n > 12). Data were normalized to cell death observed with 
media alone (Control). Asterisks denote significant difference between Control and Isch 
within Media and Afob, respectively (p < 0.001 for both); pound symbol indicates 
significant difference between Media and Afob within Control and Ischemia, respectively 
(p < 0.05 for Control & < 0.001 for Isch). 
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following ischemia. Afobazole alone showed a slight reduction in Bax levels but this was 
not significant. When afobazole is co-applied with ischemia, Bax expression was 
reduced by ~ 10%, however this was not significant. Thus, unlike the case in microglia, σ 
receptor activation fails to significantly block ischemia-induced upregulation of the pro-
apoptotic gene, Bax, in neurons. 
 
Figure 5.6 
 
Afobazole fails to prevent upregulation of the pro-apoptotic gene, Bax, observed in 
response to extended ischemia in neurons A, Photomicrographs of merged images of 
cultured neurons exposed for 24 hr to media alone (Control) (i), or media containing 4 
mM Azide (ii), 100 µM afobazole (Afob) (iii) or 4 mM Azide + 100 µM afobazole (Isch + 
Afob) (iv). Neurons were double labeled with DAPI (blue) and anti-Bax antibody (green). 
Fields of view shown are representative regions within larger images used to calculate 
Bax expression. Scale bar in (i) is 10 µm. B, Bar graph of mean number of Bax-positive 
neurons in experiments in which the cells were exposed to the same conditions as A. 
Data are expressed as percent (± SEM) of total number of neurons. Asterisks denote 
difference between Control and Isch within Media and Afob, respectively (p < 0.001) (n = 
9).  
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We further examined how afobazole effects the levels of the death protease, 
caspase-3, in neurons after an ischemic insult. Following ischemia, caspase-3 
expression was observed in a greater number of cells relative to control (Figure 5.7). 
 
Figure 5.7 
Afobazole fails to reduce expression of caspase-3 in response to prolonged ischemia in 
neurons. A, Photomicrographs of merged images of cultured neurons exposed for 24 hr 
to media alone (Control) (i), or media containing 4 mM Azide (Isch) (ii), 100 µM 
afobazole (Afob) (iii) or 4 mM Azide + 100 µM afobazole (Isch + Afob) (iv). Neurons were 
double labeled with DAPI (blue) and anti-active caspase-3 antibody (green). Fields of 
view of each photomicrograph are representative regions within larger image used to 
calculate caspase-3 expression. Scale bar in (i) is 10 µm. B, Bar graph of mean percent 
of caspase-3-positive neurons in experiments in which the cells were exposed to 
conditions identical to A. Data are expressed as percent (± SEM) of total number of 
neurons. Asterisks denote significant difference between Control and Isch within Media 
and Afob groups (p < 0.001 for both); pound symbol indicates significant difference 
between Media and Afob within Isch (p < 0.05) (n = 9). 
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Afobazole alone decreased caspase-3 levels relative to control, but failed to diminished 
the increase in caspase-3 levels evoked by ischemia. Examining the number of cells 
showing caspase-3 signal demonstrates that afobazole reduces the number of caspase-
3 positive cells by 38 ± 16% in the absence of ischemia. Following ischemia, afobazole  
 
Figure 5.8 
 
Afobazole alone upregulates the anti-apoptotic gene, Bcl-2, but does not enhance Bcl-2 
levels following 24 hr ischemic incubation in neurons. Neurons were double labeled with 
DAPI (blue) and anti-Bcl-2 antibody followed by Alexa Fluor 488 conjugated secondary 
antibody (green). A, Photomicrographs of merged images of cultured neurons exposed 
for 24 hr to media alone (i) or media containing 4 mM Azide (ii, Isch), 100 µM afobazole 
(iii) or 4 mM Azide + 100 µM afobazole (iv). Areas shown are representative regions 
within larger images used to calculate Bcl-2 expression. Scale bar in (i) is 10 µm. B, Bar 
graph of mean percent of Bcl-2-positive neurons in experiments in which the cells were 
exposed to conditions identical to A. Data are expressed as percent (± SEM) of total 
number of neurons. Asterisk denote significant difference between Control and Isch 
within Media and Afob, respectively (p < 0.05 & < 0.01) (n = 9).  
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reduced caspase-3 levels by ~14%, unlike microglia levels of caspase-3, which were 
significantly different than the control, neuronal levels where similar to those observed 
under ischemic conditions.  
We wanted to see if the relationship between afobazole and the expression of the 
anti-apoptotic gene, Bcl-2, was similar to what we saw in microglia after ischemia 
incubation. Following ischemia, the levels of Bcl-2 expressed by the neurons decreased 
by ~20% compared to that of control levels (Figure 5.8). Afobazole alone produced a 
 
Figure 5.9 
 
Afobazole prolongs neuronal survival but fails to preserve function after prolonged 
ischemia. A, bar graph of mean change in depolarization-induced increase in peak 
[Ca2+]i, evoked by application of high K+ (30 mM KCl) (±S.E.M.) in isolated cortical 
neurons incubated for 72 hr in media alone (Media) or media containing 4mM azide + 
100µM afobazole (Isch + Afob). B, in experiments are identical to (A) shows the total net 
calcium influx. For each condition, n ≥ 79. Asterisk denotes significant difference 
between Media and Isch + Afob (p < 0.001). 
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~10% increase in the number of cells expressing Bcl-2. However, afobazole failed to 
rescue Bcl-2 expression following ischemia. Both ischemia and afobazole with ischemia 
treated neurons showed a statistically significant decrease in the expression of Bcl-2 by 
21 ± 3 and 36 ± 8%, respectively. 
The failure of σ receptors to affect Bax, caspase 3 and Bcl-2 in neurons following 
ischemia suggests that a distinct pathway may be involved in σ receptor protection of 
neurons and microglia. However, a second possibility is that these neurons are 
significantly injured and will eventually undergo programmed cell death. Thus, 
experiments were carried out to determine if the surviving neurons were functionally 
compromised, and thus likely to proceed towards apoptosis. Fluorometric calcium 
imaging experiment were carried out to determine if surviving cortical neurons showed 
functional responses consistent with membrane depolarizations. Neurons incubated 
under ischemic conditions in the absence and presence of 100 µM afobazole for 72 hrs 
followed by focal application of 30mM KCl failed to have any response compared to 
control neurons. These data suggest that the surviving neurons are not depolarizing and 
are thus functionally compromised (Figure 5.9). 
 
Discussion 
 
The novel findings reported in this study are that the σ receptor agonist, 
afobazole, rescues microglia from ischemia-induced cell death through mechanisms 
involving the regulated expression of apoptosis-regulating proteins. Subsequently, 
afobazole provides neuroprotection against ischemia-induced toxicity in cortical neurons 
but not through changes in the expression of these proteins. This decrease in microglial 
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cell death is likely due to a reduction in the expression of the pro-apoptotic gene, Bax 
and the death protease, caspase-3.  Further reduction in microglial cell death likely 
results from the preserved Bcl-2 expression caused by afobazole. In contrast, afobazole 
failed to inhibit the pro-apoptotic signaling induced by ischemia as the pro-apoptotic gene 
product, Bax and the death protease, caspase-3, were not depressed following 
afobazole application nor was the ischemia-induced downregulation of the anti-apoptotic 
protein, Bcl-2 prevented. These findings suggest that activation of σ receptors 
differentially affects survival mechanisms in neurons and microglia.  Furthermore, 
treatment with the sigma receptor agonist, afobazole did not preserve neuronal function 
after prolonged ischemia.  
It has been suggested that over-activation of microglia result in neuronal death 
(Hellwig et al., 2013). However, the need to maintain viable microglia that respond to 
sites of injury are equally necessary. Neurons exposed to ischemic conditions release 
cytotoxic and neurotropic factors that both activate and attract microglia to the area of 
injury (Hellwig et al., 2013, Kierdorf and Prinz, 2013). Unfortunately, in disease states 
like stroke, over-activation of microglia is a common occurrence and often times result in 
neuronal and microglial cell death. Thus it is of great importance to identify factors that 
contribute to the demise of microglia and find treatments to combat these mechanisms. 
Exposure of microglia cells to ischemia resulted in approximately 150-fold increase in 
cell death from control alone. Afobazole reduced the number of dyeing microglia by 75 ± 
8% when co-incubated with ischemia.  
Our laboratory has previously shown that afobazole can mitigate intracellular 
calcium dyshomeostasis in neurons and microglia following ischemia, acidosis and ATP 
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exposure (Katnik et al., 2006, Herrera et al., 2008, Cuevas et al., 2011a, Cuevas et al., 
2011b). A rise in intracellular concentration, if unresolved, can promote the initiation of 
apoptosis (Mattson and Chan, 2003a). In addition to regulating intracellular calcium 
homeostasis, our findings show that afobazole mitigates ischemia-evoked apoptosis of 
microglia by decreasing expression of the pro-apoptotic gene, Bax, and death protease 
caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. Experiments 
were conducted to ascertain the mechanism by which afobazole mitigates microglia cell 
death following ischemia. Following a stroke, cells in the core undergo necrosis and in 
the days and weeks following the insult if the penumbra is not rescued from undergoing 
apoptosis, it too will die and become part of the core (Butler et al., 2002). Previous 
studies have shown that activation of σ-1 receptors protect RGC-5 cells from apoptosis 
by regulating the expression of the proapoptotic protein, Bax and death protease, 
caspase-3 (Tchedre and Yorio, 2008). We carried out immunocytochemical experiments 
to determine if afobazole affects expression of the pro-apoptotic protein Bax or the death 
caspase-3 following 24 hr ischemic exposure. Both Bax and caspase-3 expression 
increased > 270 and 150% from the control, respectively. We found that afobazole alone 
decreased caspase-3 expression and when co-incubated with ischemia both Bax and 
caspase-3 expression were mitigated approximately 42 and 59%, respectively. Further 
experiments were conducted to determine if levels of Bcl-2 were affected by ischemia 
and to what if affect afobazole had on its expression. Microglia cells were incubated for 
24 hr in the absence (Control) and presents of ischemia, with and with afobazole. 
Following ischemia incubation, microglial Bcl-2 expression was decreased by ~ 21% 
from that of the control. Incubation with afobazole alone increased Bcl-2 expression by a 
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modest but significant 10%. However, when co-incubated with ischemia, afobazole 
preserved Bcl-2 expression by approximately 24%, making it comparable to afobazole 
alone.  
Following suit, we wanted to know if afobazole conveyed neuroprotection in a 
similar mechanism as shown previously with microglia. Immunocytochemical 
experiments were carried out to determine if one mechanism by which afobazole is 
neuroprotective is through sigma receptor regulation of apoptotic expression. Both Bax 
and caspase-3 expression were observed under all conditions. Following ischemic 
exposure, both Bax and caspase-3 levels increased by ~ 47 and 135%, respectively. 
However, unlike the results we observed in microglia cells, afobazole did not mitigate 
increases in Bax or caspase-3 expression in neurons. The ratio of Bcl-2:Bax has been 
shown to positively correlate to cell survival in neurons exposed to Aβ (Patel and Brewer, 
2008). Likewise, the ratio of Bcl-2:Bax is important in regulating cell survival following 
glutamate excitotoxicity (Schelman et al., 2004) and previous studies have shown that 
Bcl-2 is a target for σ receptor mediated neuroprotection (Yang et al., 2007, Meunier and 
Hayashi, 2010). Additionally, experiments were performed to determine if afobazole 
could preserve expression of Bcl-2 levels following ischemia. As we observed with 
microglia, Bcl-2 expression decreased in neurons under ischemic conditions. We found 
that afobazole alone increased Bcl-2 expression; however, when co-incubated with 
ischemia, afobazole failed to preserve Bcl-2 expression levels and were comparable to 
ischemia alone. Exposing cells to ischemic conditions has been shown to decrease cell 
viability. Our laboratory has shown that afobazole mitigates death following 2 hr ischemia 
exposure (Cuevas et al., 2011a, Cuevas et al., 2011b). This model resembles injury 
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caused by reperfusion of the tissues with oxygen, more of a transient ischemic model. 
We wanted to see to what extent afobazole could be neuroprotective following 72 hr 
exposure to ischemic conditions, more a permanent occlusion model. There was an 
approximant 3-fold increase in the number of expired neurons from that of the control. 
This increase in the demise of neurons was mitigated by approximately 55% when 
neurons were co-incubated with afobazole and ischemia. Incidentally, afobazole alone 
reduced neuronal cell death from control levels by ~ 49%. This data indicates that even 
under prolonged ischemic conditions afobazole was to some extent neuroprotective. 
However, when functional integrity of these surviving neurons was examined by 
attempting to depolarize them with a focal application of 30mM KCl, we found them 
unresponsive.  
In conclusion, our study demonstrates that afobazole reduce microglial toxicity 
and cell death following ischemic exposure. This cytoprotection most likely involves 
regulation of multiple genes, with a noted decrease in Bax and caspase-3 and a 
concomitant increase in Bcl-2 expression. Furthermore, our experiments show that 
afobazole can decrease ischemia-evoked neuronal cell death. However, the molecular 
mechanisms mediating neuroprotection by afobazole following an ischemic insult appear 
to be different than with microglia and do not involve the downregulation of both Bax and 
activated caspase-3, nor preserving upregulation of Bcl-2 expression. Taken together our 
data suggest that afobazole may prevent microglia from entering the activated state 
associated with neurotoxicity following exposure to ischemia, and increasing the survival 
of both microglia and neurons following an ischemic insult. These properties make 
afobazole an attractive drug for treatment of ischemia.  
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CHAPTER 6 
 
 
Afobazole Abolishes Amyloid-β25-35 Potentiation of Ischemia-Acidosis  
Evoked Increases in Neuronal Intracellular Calcium Levels 
 
 
Introduction 
In addition to large vessel ischemic strokes there are a subset known as lacunar 
infarcts, which account for approximately 25% of all ischemic insults (Samuelsson et al., 
1996). These strokes result from the blockage of small penetrating arteries to the 
subcortical regions of the brain (Kang et al., 2012). While the injury from these strokes 
were once thought to be negligible, lacunar infarcts can and do result in death and long-
term disability. This type infarct is a leading cause of cognitive impairment and vascular 
dementia (Charidimou and Werring, 2012). While the risk factors resulting in lacunar 
verse large artery infarcts differ, the resulting cellular cascade promoting cerebral cell 
death may have overlapping mechanisms. One of these mechanisms may be the 
increased production and toxicity of the amyloid-β peptide, which has been shown to be 
upregulated following an ischemic event (Popa-Wagner et al., 1998, Guglielmotto et al., 
2009, Pluta et al., 2013). The presence of Aβ has been shown to increase [Ca2+]i levels, 
increase ROS production and promote apoptosis (Behensky et al., 2013a, b). In addition, 
the accumulation of Aβ can contribute to vascular dementia, which has been shown to 
significantly increase the chances of having a recurrent stroke (Pendlebury and Rothwell, 
2009). Furthermore, this Aβ-induced arterial weakening may potentiate the chances of 
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having a hemorrhagic stroke significantly increasing the patient’s chance of developing 
serious long-term disability or even death (Sudduth et al., 2013, Sudduth et al., 2014).  
The mechanisms that contribute to the injury of both lacunar and large vessel 
ischemia are still unclear. However, the activation of NMDA receptors is known to 
contribute, in part, to both of these types of strokes (Shih et al., 2013). This brings into 
question the prospect that even though lacunar and large-vessel strokes occur via 
different vascular pathologies the mechanisms promoting their injury may overlap. Data 
from our laboratory has shown that activation of sigma receptors mitigates ischemia, 
acidosis and Aβ-induced calcium overload (Katnik et al., 2006, Herrera et al., 2008, 
Behensky et al., 2013a, b). This calcium overload if left unchecked will promote 
apoptosis through pathways including NMDA receptor activation. Our laboratory has also 
shown that acid-sensing ion channel 1a (ASIC1a) contributes to the downstream activity 
of NMDA receptors (Mari et al., 2014). Aβ levels increase following ischemia, which may 
lead to potentiated responses that increase the risk for various vascular dementias and 
ultimately result increased cell death. Currently, the mechanisms contributing to this 
interaction remain unknown. 
Experiments were carried out to determine the effects of Aβ on ischemia + 
acidosis evoked elevations in intracellular Ca2+ overload in cortical neurons. Aβ 
incubation was found to significantly potentiate the ischemia + acidosis induced 
increases in [Ca2+]i but required 24 hr incubation before affects were seen, indicating that 
non-acute mechanisms are involved. Furthermore, afobazole co-incubation was found to 
abolish the Aβ-induce intracellular Ca2+ increase. The kinetics of the [Ca2+]i overload 
produced by ischemia + acidosis following pre-incubation in Aβ were indicative of acid-
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sensing ion channels 1a (ASIC1a) involvement. In conclusion, our data show a 
mechanism by which Aβ may enhance neuronal injury during ischemia, increased [Ca2+]i 
overload, and identify ASIC1a as the channel mediating this phenomenon. Finally, our 
data suggest that activation of σ receptors may represent a therapeutic strategy for 
mitigating injury produced by Aβ and stroke. 
 
Materials and Methods 
 
 
Preparation of Rat Cortical Neurons 
All experiments were carried out on cultured cortical neurons from mixed sex 
embryonic day 18 (E18) Sprague-Dawley rats (Harlan, Indianapolis, IN). Methods used 
here were identical to those previously reported for the isolation and culturing of these 
cells (Katnik et al., 2006). Cortical neurons were plated on poly-L-lysine coated 
coverslips and cultured in B27 and L-glutamine supplemented Neurobasal medium 
(Neurobasal Complete) (Life Technologies, Grand Island, NY). Cells were used for 
experiments after 10-21 days in culture, which permits synaptic contact formation and 
yields robust responses to other pathophysiological conditions such as in vitro ischemia 
and acidosis (Katnik et al., 2006, Herrera et al., 2008). Animals were cared for in 
accordance with the regulations and guidelines set forth by the University of South 
Florida’s College of Medicine Institution on Animal Care and Use Committee. 
 
Calcium Imaging 
 
Intracellular Ca2+ concentrations were measured in isolated cortical neurons using 
ratiometric fluorometry as previously described (Katnik et al., 2006, Cuevas et al., 2011a, 
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Cuevas et al., 2011b). For most experiments, cultured neurons were incubated in 25 µM 
Aβ25-35 for 24 hr prior to [Ca2+]i being measured. Neurons were loaded with fura-2 by 
adding 3-5 µg/ml of the acetoxymethylester form of fura-2 (fura-2 AM) in 0.3% DMSO to 
the media and incubating the cells at room temperature for 1 hr. Prior to beginning the 
experiments, the coverslips were rinsed with physiological saline solution (PSS) 
consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 20 glucose, 1.3 CaCl2, and 1.0 
MgCl2 (pH to 7.4 with NaOH). For neurons, [Ca2+]i was measured once every second for 
approximately a 4 min period and the ischemia-acidosis induced values for baseline, 
peak, area and slope (± SEM) [Ca2+]i was calculated.  
 
Electrical Recordings  
 
Proton-activated membrane currents were recorded using the protocol previously 
described by our laboratory (Herrera et al., 2008). Briefly, neurons plated on glass 
coverslips were transferred to a recording chamber and membrane currents were 
amplified, filtered at 1 kHz, digitized at 5 kHz, and acquired using Clampex 9 (Axon), a 
MultiClamp 700A amplifier and a Digidata 1322A. Electrical access was achieved using 
the amphotericin B perforated patch method to preserve intracellular integrity of neurons 
(Rae et al., 1991). An amphotericin B stock solution (60 mg/ml in DMSO) was made 
fresh daily and diluted to 240 μg/ml (0.4% DMSO) in control pipette solution immediately 
prior to seal formation. The control pipette solution consisted of (in mM): 75 K2SO4, 55 
KCl, 5 MgSO4, and 10 HEPES (titrated to pH 7.2 with N-methyl-d-glutamine). Patch 
electrodes were pulled from thin-walled borosilicate glass (World Precision Instruments 
Inc., Sarasota, FL) using a Sutter Instruments P-87 pipette puller (Novato, CA) and had 
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resistances of 1.0–1.5 MΩ. Access resistance (Rs) was monitored throughout 
experiments for stable values ≤ 30 MΩ and were compensated at 40% (lag, 10 μs). In all 
electrical recordings, cells were voltage-clamped at −70 mV. 
 
Compounds, Reagents and Peptides  
 
The following compounds and reagents were used in this investigation: Amyloid-β 
fragments 25-35 (62-0-72), 35-25 (62-0-33) 1-40 (62-0-78) and 1-42 (62-0-30)  
(American Peptides, Sunnyvale, CA); Tetrodotoxin and YM244769 (Tocris Biosciences, 
Ellisville, MO); fura-2 acetoxymethyl ester (Life Technologies); Psalmotoxin-1 
(ab120483) (abcam, Cambridge, MA. Vehicle for drugs and reagents will be either water 
(H2O) or dimethyl sulfoxide (DMSO), and appropriate vehicle controls will be carried out 
for each study. For the Aβ oligomerization experiment, Aβ25-35 was made to stock 
concentration (1mM) and allowed to oligomerize for 24 hr at 37º C prior to cell 
incubation. Afobazole was generously provided by IBC Generium (Moscow, Russian 
Federation). 
 
Data Analysis 
 
Fura-2 fluorescence intensities as a function of time were recorded in the same 
manner as previously described (Katnik et al., 2006, Cuevas et al., 2011a, Cuevas et al., 
2011b) and converted to [Ca2+]i using control values obtained with an in situ calibration 
kit (Invitrogen). Electrophysiology data was converted to text files and imported into 
Clampfit 9 for analysis. Data was analyzed using SigmaPlot 11 (Systat Software, Inc., 
San Jose, CA). Data points represent peak means ± standard error of the mean 
(S.E.M.). Statistical analysis involved the use of paired or unpaired t-tests, as 
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appropriate, and one- or two-way analysis of variance for determining significant 
differences for multiple group comparisons, followed by post hoc analysis using the 
Holm-Sidak test. Results were considered statistically significant if p < 0.05. 
 
Results 
 
Experiments were carried out to determine if incubation of 25 µM amyloid-β25-35 
affects the elevations in [Ca2+]i in response to ischemia, acidosis and ischemia + acidosis 
application in rat cortical neurons. Figure 6.1A-C shows representative traces of [Ca2+]i 
as a function of time recorded from two cells during focal application of ischemia, 
acidosis or ischemia + acidosis that produced robust elevations in [Ca2+]i in the neurons, 
consistent with previous reports (Katnik et al., 2006, Herrera et al., 2008, Mari et al., 
2014). Following 12 hour incubation in media with 25 µM amyloid-β25-35, neurons were 
exposed to a focal application of ischemia, acidosis or ischemia + acidosis, which 
produced increases in [Ca2+]i levels similar to the control. Quantification of these calcium 
increases showed that 12 hr of Aβ incubation did not increase the peak calcium levels. 
However, there was a small but significant increase in the total net calcium influx evoked 
from all three conditions (Figure 6.1D).  
Given that Aβ modulation of these responses may require a longer incubation time, 
neurons were exposed to applications of ischemia, acidosis or ischemia + acidosis 
following 24 hr incubation in media alone, or media containing 25 µM of Aβ25-35. Figure 
6.2A-C shows representative traces of [Ca2+]i as a function of time recorded from two 
cells during focal application of ischemia, acidosis or ischemia + acidosis that produced 
robust elevations in [Ca2+]i in the neurons. Calcium increases in the Aβ-treated group  
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Figure 6.1 
 
Incubation for 12 hr with amyloid-β25-35 does not potentiate intracellular calcium 
responses to focal ischemia, acidosis or ischemia + acidosis application. A-C, show 
representative traces of [Ca2+]i as a function of time recorded from two neurons during 
application of ischemia, acidosis and ischemia + acidosis following 12 hr incubation in 
media alone (Control), or media containing 25 µM Aβ25-35 (Aβ), respectively. Aβ was 
washed out for 1hr prior to focal application. Line above [Ca2+]i responses indicates 
duration of ischemia, acidosis or ischemia + acidosis application. D, Bar graph of mean 
(± SEM) peak and total net increases in [Ca2+]i evoked by focal applications following 12 
hr Aβ in isolated cortical neurons. [Ca2+]i responses were recorded from neurons in 
experiments identical to those performed in (A-C). Asterisk symbolizes significant 
difference between Control and Aβ (p < 0.05). For all conditions, n ≥ 74. 
 
were significantly higher than the respective controls. When quantified, Aβ evoked a 
significant increase in both the peak and the total net calcium influx following ischemia by 
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Figure 6.2 
 
24 hr incubation with amyloid-β25-35 significantly potentiates the intracellular calcium 
responses to ischemia, acidosis and ischemia + acidosis application. A-C, show 
representative traces of [Ca2+]i as a function of time recorded from two neurons during 
application of ischemia, acidosis and ischemia + acidosis following 24 hr incubation in 
media alone (Control), or media containing 25 µM Aβ25-35 (Aβ), respectively. Aβ was 
washed out for 1hr prior to focal application. Line above [Ca2+]i responses indicates 
duration of ischemia, acidosis or ischemia + acidosis application. D, Bar graph of mean 
(± SEM) peak and total net increases in [Ca2+]i evoked by focal applications following 24 
hr Aβ in isolated cortical neurons. [Ca2+]i responses were recorded from neurons in 
experiments identical to those performed in (A-C). Asterisk symbolizes significant 
difference between Control and Aβ (p < 0.001). For all conditions, n ≥ 81. 
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72 ± 6 and 82 ± 6%, acidosis 42 ± 7 and 33 ± 10% and ischemia + acidosis 43 ± 4 and 
85 ± 2% applications, respectively (Figure 6.2D). 
Amyloid-β peptide has been shown to induce toxicity in several disease states 
including AD and cerebral amyloid angiopathy through a number of mechanisms 
including calcium toxicity, reactive species and hemichannel formation to name a few 
(Mantha et al., 2006, Rezende et al., 2007, Orellana et al., 2011, Lazzari et al., 2015). To 
ensure that the fragment Aβ25-35 shows similar toxicity to other more researched 
 
Figure 6.3 
 
Amyloid-β fragments 25-35 and 1-42 potentiate ischemia + acidosis induce [Ca2+]i 
increases. A, shows a bar graph of mean peak (± SEM) of neurons incubated for 24 hr in 
25µM Amyloid-β, either fragment 25-35, 1-40 or 1-42. Asterisk indicates a significant 
difference from the Control, whereas the pound symbol shows significance from 
fragment 1-40. B, is a bar graph of the mean total net Ca2+ influx (± SEM) in experiments 
identical to A. Asterisk indicates a significant difference from the Control, whereas the 
pound symbol shows significance from fragment 1-42 and 25-35 or 1-40 (p < 0.001 for 
all) (n ≥ 158). 
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fragments, experiments were conducted to assess various Aβ fragments effects on 
potentiating increases in [Ca2+]i evoked by ischemia + acidosis application. Figure 6.3 
shows a bar graph of the peak and total net calcium influx-induced by ischemia + 
acidosis application following 24 hr incubation in media with Aβ fragments 25-35, 1-40 or 
1-42. While fragment 1-40 showed no significance from the control, both fragment 25-35 
and 1-42 showed a potentiation in the peak [Ca2+]i induced by ischemia + acidosis by 65 
± 1 and 51 ± 9%, respectively. This potentiation in peak [Ca2+]i level by the Aβ fragments 
25-35 and 1-42 were not significantly different from each other. Moreover, pre-incubation 
with these fragments resulted in an increase in the total net calcium influx by 19 ± 2 and 
37 ± 3% following focal application of ischemia + acidosis. 
 
Figure 6.4 
 
Oligomerized amyloid-β25-35 fails to potentiate ischemia + acidosis evoked increases in 
[Ca2+]i following a 1 hr incubation. Bar graph of the mean peak and total net Ca2+ influx 
(±SEM) in neurons incubated for 1 hr in media alone or media (Control) with 25 µM 
oligomerized Aβ25-35 (Aβ) (n ≥ 43). 
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Even though Aβ has been shown to bind directly to various ion channels including 
NMDA and nAChRs (Nagele et al., 2002, Texido et al., 2011) it has been suggested that 
the effects seen on Aβ-potentiated increases in [Ca2+]i be due to the oligomerized and 
not the free Aβ. Therefore, experiments were conducted to determine if 1 hr incubation 
with the oligomerized Aβ25-35 produced significant increases in [Ca2+]i following ischemia 
+ acidosis application. Figure 6.4 shows a bar graph of the peak and total net calcium 
influx in neurons incubated in media alone or media with the oligomerized Aβ. Following 
application of ischemia + acidosis there was no significant difference between the media 
or Aβ incubated increases in [Ca2+]i levels. 
Given that afobazole has been shown to reduced ischemia and acidosis evoked 
elevations in [Ca2+]i (Cuevas et al., 2011a) and that σ-1 receptor activation has been 
shown to reduce Aβ-induced toxicity (Marrazzo et al., 2005), experiments were 
conducted to determine if afobazole could mitigate the Aβ potentiated increase in [Ca2+]i 
following ischemia + acidosis application. Figure 6.5A shows representative traces of 
[Ca2+]i as a function of time recorded from 3 cells during ischemia + acidosis. Increases 
in [Ca2+]i were observed in all groups with a potentiated increase in the Aβ incubated 
cells with responses similar to those observed in experiments from Figure 6.2C. In cells 
were afobazole was co-incubated with Aβ, [Ca2+]i elevations were not statistically 
different from the control (Figure 6.5B&C), indicating that afobazole blocked the Aβ-
induced potentiation of [Ca2+]i overload.  
The kinetics of the [Ca2+]i overload produced by ischemia + acidosis following pre-
incubation with Aβ suggest that the acid-sensing ion channels 1a (ASIC1a) is involved in 
the potentiation. To determine if Aβ is potentiating ASIC or only downstream effector 
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targets of these channels, patch-clamp electrophysiological recordings were carried out.  
Figure 6.6A shows proton-evoked membrane currents recorded from two neurons 
 
Figure 6.5 
 
Afobazole inhibits increases in [Ca2+]i evoked by ischemia + acidosis application 
following 24hr Aβ25-35 incubation. A, Representative traces of [Ca2+]i as a function of time 
recorded from three neurons during focal application of ischemia + acidosis in the 
absence (Control) and presence of 25µM amyloid-β25-35 (Aβ) or 25µM amyloid-β25-35 and 
100 µM afobazole (Afob + Aβ). Afobazole was co-incubated with Aβ for 24 hr and 
washed out 1 hr prior to Ischemia + acidosis application. In experiments identical to A, 
bar graphs of mean peak and total net Ca2+ influx (±SEM) measured in neurons. 
Asterisks denote significant difference between Aβ and Control or Aβ + Afob (p < 0.001) 
(B & C) (n ≥ 137).  
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following 24 hr incubation in media alone or media with 25 µM Aβ25-35 held at a 
membrane potential of -70 mV. Application of protons evoked a rapid inward current 
which was potentiated by 68 ± 17% in Aβ incubated neurons. Varying pH showed that 
Aβ potentiated responses at both pH 6.5 and pH 6.0, but not pH 7.0 (Figure 6.6B). 
These data suggest that Aβ is potentiating the responses rather than shifting the half 
maximal activation of ASIC to a higher pH. 
The elevations of [Ca2+]i evoked by protons in cortical neurons are due to 
activation of ASIC, but these channels themselves account for only a small portion of the 
increase in [Ca2+]i observed during acidosis (Herrera et al., 2008). One possible 
contributor to Aβ increases in [Ca2+]i that are downstream of ASIC are the ion 
 
Figure 6.6 
 
Amyloid-β25-35 incubation potentiates proton-evoked currents in cortical neurons. A, 
Representative current traces recorded from two neurons held at -70 mV during acidosis 
in neurons incubated in media alone (Control) or media with 25µM Amyloid-β25-35 (Aβ). B, 
Bar graph of mean peak (±SEM) of the proton-evoked inward current in experiments 
identical to A (n ≥ 8). Asterisk denotes significant difference between Aβ and respective 
controls (p < 0.05). 
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exchangers. Thus, calcium imaging experiments were conducted to determine if reversal 
of the sodium/calcium exchanger (NCX) contributed to the calcium overload evoked by 
Aβ incubation. Figure 6.7 is a bar graph of the mean peak and area of [Ca2+]i elevations 
evoked by focal application of ischemia + acidosis following 24 hr incubation in media 
alone or media with 25 µM Aβ. Similar to previous experiments, incubation with Aβ 
produced a potentiated increase in the [Ca2+]i levels. Following the initial recording, 
neurons were incubated with the NCX reversal mode inhibitor YM244769 (YM,1µM) for 
 
Figure 6.7 
 
Aβ potentiated calcium influx involves reversal of the sodium/calcium exchanger. A, Bar 
graphs of mean (±SEM) increases in peak [Ca2+]i or net [Ca2+]i (Area, area under the 
trace) elicited by focal ischemia + acidosis application in neurons incubated for 24 hr in 
media alone (Media) or media with 25 µM amyloid-β25-35 (Aβ), before (Control) and after 
20 min pre-incubation with YM224769 (YM, 1µM). Asterisks denote significant difference 
between Control and YM within Media and Aβ groups (p < 0.001). Pound symbol 
indicates significant difference between Controls within Media and Aβ groups  (p < 
0.001). B, Bar graph of relative YM inhibition of [Ca2+]i. Asterisks denote significant 
difference (p <0.01). For all groups, n ≥ 171. 
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20 minutes. YM incubation produced a significantly reduced increase in the ischemia + 
acidosis evoked [Ca2+]i peak and net elevations by 38 ± 2 and 36 ± 2%, respectively. 
This YM-induced reduction in calcium influx through the reversal NCX was also observed 
in Aβ incubated neurons, which lead to a 40 ± 2 and 44 ± 1% reduction in the peak and 
net Aβ-potentiated increase in [Ca2+]i, respectively. This resulted in relative inhibition of 
YM blocking a small but significant 3.2 ± 0.7 and 10 ± 1.8% influx in the peak and total 
net calcium potentiated by Aβ incubation, respectively. While blocking the reversal NCX 
in neurons that were incubated in Aβ reduced the total calcium influx, we cannot yet be 
sure that Aβ is having a direct effect on NCX or if it is an upstream mechanism(s), which 
is increasing the sodium loading and thus increasing the ion concentration gradient. 
Continuing to assess the role of ion exchangers in the Aβ potentiated increase in 
[Ca2+]i elevations following focal application of ischemia + acidosis, we decided to look at 
the sodium/calcium potassium-dependent exchanger (NCKX). Experiments were 
conducted following a 24 hr incubation in media or media with 25 µM Aβ25-35, using a 
physiological saline solution (PSS) with varying concentrations of K+ in attempts to 
assess the role of NCKX. Figure 6.8A shows representative traces of [Ca2+]i as a 
function of time recorded from 2 cells during ischemia + acidosis. Responses under 
control conditions (K+=5.4mM), were identical to previous experiments for both media 
and Aβ incubated neurons with Aβ having statistically higher peak and total net calcium 
influx then media. However, when we changed the PSS to low or high K+ (2.7 & 10.8 
mM, respectively) the ischemia + acidosis induced elevations in [Ca2+]i levels were not 
as pronounced. Furthermore, there was no longer a significant difference between the 
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media and Aβ incubated neurons. Indicating to us that the NCKX may not be contributing 
to the potentiation we observe in Aβ treated neurons (Figure 6.8B&C). 
 
Figure 6.8 
 
Amyloid-β25-35 potentiation of [Ca2+]i increases evoked by ischemia + acidosis is not 
dependent of the sodium/calcium potassium-dependent exchanger (NCKX). A, 
representative traces of focal application of ischemia + acidosis recorded from two 
neurons following 24 hr incubation in media (Media) or media with 25 µM Aβ25-35 (Aβ). 
Neuron were pre-incubated for 10 min in PSS with varying concentrations of K+ (in mM, 
normal = 5.4, low = 2.7, high = 10.8). B, bar graph of mean change in peak [Ca2+]i from 
experiments identical to A. Asterisk identifies significance Control and Aβ within 5.4 (p < 
0.001). Pound represents significance between Control or Aβ within groups 5.4, 2.7 and 
10.8 (Control p < 0.01, Aβ p < 0.001). Dagger denotes significance between Aβ within 
2.7 and 10.8. C, bar graph of mean net [Ca2+]i from experiments identical to A. Asterisk 
identifies significance between Control and Aβ within 5.4 (p < 0.001). Pound represents 
significance between Control or Aβ within groups 5.4, 2.7 and 10.8 (both p < 0.001). 
Dagger denotes significance between Control within 2.7 and 10.8 (n ≥ 80). 
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Figure 6.9 
 
Amyloid-β25-35 potentiation of the net [Ca2+]i increases evoked by ischemia + acidosis 
may involve intracellular protons. A, representative traces of focal application of ischemia 
+ acidosis recorded from two neurons following 24 hr incubation in media (Media) or 
media with 25 µM Aβ25-35 (Aβ). Neuron were pre-incubated for 10 min in PSS without 
(Control) and with 26 mM HCO3- (HCO3-). B, bar graph of mean change in peak [Ca2+]i 
from experiments identical to A. Asterisk identifies significance Control and HCO3- within 
Media and Aβ groups (p < 0.001). Pound represents significance between Control or 
HCO3- within groups Media and Aβ (Peak p < 0.05, Net p < 0.001). C, bar graph of 
relative HCO3- inhibition of [Ca2+]i from experiments identical to A. Asterisk identifies 
significance between Media and Aβ within Area (p < 0.001) (n ≥ 66). 
 
Since following an ischemic event cells undergo acidosis we were interested in 
looking at the roles of proton exchangers, specifically the sodium/hydrogen exchanger 
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(NHE) and the mitochondrial calcium/hydrogen exchanger (LETM1). To achieve this we 
used PSS with 26 mM HCO3- to sequester the intracellular protons. Prior to recording 
neurons were incubated for 24 hr in media alone or media with 25 µM Aβ25-35. Figure 
6.8A shows representative traces of [Ca2+]i as a function of time recorded from 2 cells 
during ischemia + acidosis before and after 10 min incubation in HCO3- PSS. As we have 
previously seen in identical experiments Aβ incubation potentiates both the peak and 
total net calcium influx following ischemia + acidosis application. Pre-incubation with 
HCO3- reduced the media and Aβ incubated peak by 36 ± 4 and 31 ± 3%, as well as the 
total net calcium influx by 49 ± 1 and 34 ± 1%, respectively (Figure 6.8B). When 
comparing the relative inhibitions that HCO3- had between the media and Aβ treated 
cells we found no significance in the peak levels, however there was a 30 ± 2% reduction 
in the total net calcium influx of media incubated neurons (Figure 6.8C). While still 
unclear, intracellular protons may be contributing to the calcium overload, possibly 
through the aforementioned exchangers.  
 
Discussion 
 
The major findings reported in the present study are that amyloid-β potentiates 
ischemia + acidosis evoked increases in [Ca2+]i in a time-dependent manner and through 
an acid-sensing ion channel 1a-dependent mechanism. The responses were also 
dependent on the use of amyloid-β fragments 25-35 or 1-42, whereas the fragment 1-40 
did not potentiate the increase in intracellular calcium. Moreover, co-incubation with the 
pan-selective σ receptor agonist, afobazole, completely abolished this potentiation. 
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Neuronal cultures were used to determine if incubation with 25 µM amyloid-β25-35 
produced an increase in the [Ca2+]i levels evoked by ischemia + acidosis application. 
Incubation for 12 hr failed to potentiate Ca2+ elevations. It has been shown that longer 
periods are needed (i.e. 24 hr) to up-regulate gene expression (Behensky et al., 2013a, 
b). Therefore, neurons were incubated for 24 hr with Aβ and found to have potentiated 
ischemia, acidosis and ischemia + acidosis induced increases in [Ca2+]i levels. We found 
that acidosis application alone produced an increase in mean peak [Ca2+]i by ~42%. 
Furthermore, application of ischemia alone or ischemia + acidosis also produced 
potentiated elevations in both the peak and total net calcium influx by ~72 and 82% for 
ischemia and ~43 and 85% for ischemia + acidosis, respectively. This dual potentiation 
in [Ca2+]i may indicated that the mechanism in these response involve multiple pathways 
including ASIC1a, VGCCs, NMDA and AMPA/kainate receptors. Previous studies from 
our laboratory have shown that ischemia-induced elevations in [Ca2+]i involved the 
activation of NMDA receptors (Katnik et al., 2006), whereas acidosis application 
activates ASIC1a receptors (Herrera et al., 2008). Moreover, the ischemia + acidosis 
activation of NMDA and ACIS1a receptors results in a synergistic increase in [Ca2+]i 
levels. This is a complicated interaction with NMDA receptors functionally up-regulating 
ASIC1a, while at the same time ASIC1a potentiates NMDA receptor activity (Mari et al., 
2014).  
Since activation of ASIC1a has been shown to potentiate ischemia-induced [Ca2+]i 
levels through NMDA receptors, we were interested in determining where Aβ potentiation 
occurred. Previous studies have shown that only a small part of the ischemia + acidosis 
evoked Ca2+ influx is directly due to ACIS1a with VGCCs, NMDA and AMPA/kainate 
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receptors contributing to the bulk influx (Gonzalez-Alvear and Werling, 1995, Alonso et 
al., 2000).  However, fluorometric calcium imaging showed that Aβ-induced a potentiated 
proton activated Ca2+ influx. Therefore, whole-cell patch-clamp experiments were 
performed to determine whether this potentiation was due to directly to ASIC1a activity 
or via ASIC1a enhanced downstream channels. Neurons incubated with Aβ for 24 hr 
were voltage-clamped at -70 mV, which prevents NMDA receptor and VGCC activation, 
demonstrated a ~68% increase in the proton evoked inward current. Taken together, our 
results indicate that Aβ incubation is directly up-regulating ASIC1a activity as well as the 
ASIC1a potentiated down-stream channels. 
These channels contribute directly and indirectly to the [Ca2+]i overload. Following 
ischemia there is a loss of ATP production and consequently Na+ loading due to failure in 
the Na+/K+ ATPase. This shift in the Na+ concentration gradient results in the reversal of 
the Na+/Ca2+ exchanger, which can contribute to the Ca2+ overload. Imaging experiments 
found that following Aβ incubation there was an increase NCX function, which was 
blocked by the NCX (reversal) inhibitor YM244769 (1µM). However, we are not able to 
say whether this increase in reversal NCX activity is the result of Aβ on NCX or due to 
increased Na+ loading, which increases the driving force of the exchanger. An additional 
consequence of the Na+/K+ ATPase failure is the accumulation of extracellular K+, which 
can result in the depolarization of neighboring neurons. However, it can also increase the 
activity of the Na+/Ca2+ K+-dependent exchanger (NCKX), which can further contribute to 
the [Ca2+]i overload. To assess the role of NCKX on Aβ potentiated increase in [Ca2+]i 
evaluations following focal application of ischemia + acidosis experiments were 
conducted using a physiological saline solution (PSS) with varying concentrations of K+. 
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Responses under control conditions (K+ = 5.4mM), were identical to previous 
experiments for both media and Aβ incubated neurons with Aβ having statistically higher 
peak and total net calcium influx then media. However, when we changed the PSS to 
low or high K+ (2.7 & 10.8 mM, respectively) the ischemia + acidosis induced elevations 
in [Ca2+]i levels were not as pronounced. Furthermore, there was no longer a significant 
difference between the media and Aβ incubated neurons. Indicating to us that the NCKX 
may not be contributing to the potentiation we observe in Aβ treated neurons. 
Reducing the Ca2+ overload produced by an ischemic insult is crucial to mitigating 
stroke injury. Previous studies from our laboratory have shown that σ-1 receptor 
activation in neurons can elevate the Ca2+ overload induced by ischemia, acidosis and 
Aβ (Cuevas et al., 2011a, Behensky et al., 2013a). However, not all sigma receptor 
agonists were shown to be as effective under these conditions (Behensky et al., 2013a). 
The pan-selective agonist afobazole was one such drug that did mitigate Ca2+ overload 
induced under all three conditions. Therefore, 100 µM afobazole was co-incubated with 
Aβ for 24 hr to assess what function activation of sigma receptors would have on the Aβ 
up-regulated function. Co-incubation with afobazole completely abolished the potentiated 
increases in [Ca2+]i levels-induced via focal application of ischemia + acidosis. Reducing 
the Aβ up-regulated Ca2+ increases will likely translate to an increase in neuronal 
survival.  
In conclusion, our data show one mechanism by which Aβ may potentiate 
neuronal injury during ischemia-acidosis is through increased [Ca2+]i overload, and 
identify ASIC1a as the channel mediating this phenomenon. Finally, our data suggest 
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that activation of σ receptors by afobazole may represent a therapeutic strategy for 
mitigating injury produced by Aβ and stroke. 
 
  
146 
 
 
 
 
 
 
 
CHAPTER 7 
 
 
Discussion 
 
 
Conclusions 
Stroke is the fifth leading cause of death and continues to be a major cause of 
serious long-term disability in the United States (Mozaffarian et al., 2015). An ischemic 
stroke accounts for about 87% of all strokes and occurs when blood flow to the brain is 
occluded by a thrombus or embolus. The only treatment currently approved by the FDA 
for ischemic stroke is recombinant tissue plasminogen activator (rtPA), a thrombolytic 
agent used to restore blood-flow interrupted by a blood clot (Weintraub, 2006). However, 
rtPA therapy is time sensitive, and the drug must be administered < 4.5 hours post-
infarct. In addition, aging patients presenting various comorbidities leads to an increase 
in rtPA’s risk to benefit ratio, resulting in less than 4% of patients being able to use it 
(Armstead et al., 2010). The goal of future therapies would be to treat these patients at 
24 to 48 hrs follow the insult.  
Our laboratory has shown that DTG can mitigate neuronal and glial cell injury 
following in vitro stroke models through activation of σ receptors (Katnik et al., 2006, Hall 
et al., 2009a). In attempts to improve upon the efficacy of DTG we conducted 
experiments, which involved shifting and removal of the methyl moiety of DTG. Our 
findings with the DTG analogues show that rearrangement of the methyl moiety did not 
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produce a compound which behaves differently from the parent compound in terms of 
modulating [Ca2+]i increases induced via ischemia and acidosis. Removal of the group 
entirely (DPhG) produces a significant 18.3 ± 0.05% increase over o-DTG in inhibiting 
elevations in [Ca2+]i during acidosis. Similarly, DPhG show a 12.2 ± 0.04% greater 
inhibition than o-DTG in the ischemia assay, but this difference was not statistically 
significant. Previous studies have reported that the σ receptor binding affinities for o-, m-, 
and p-DTG are approximately 30, 50, and 530 nM, respectively; whereas the affinity of 
DPhG for σ receptors is ~400 nM (Scherz et al., 1990, Reddy et al., 1994). Results from 
our functional studies, therefore, do not reflect the decrease in affinity observed for the p-
DTG or DPhG. Calcium elevations evoked by ischemia and acidosis are in part due to 
activation of NMDA receptors (Katnik et al., 2006, Herrera et al., 2008). However, neither 
p-DTG nor DPhG shows increased affinity for NMDA receptors compared to o-DTG 
(Scherz et al., 1990, Reddy et al., 1994), and thus actions on that receptor cannot 
account for the discrepancy between σ receptor binding and functional effects. Since the 
earlier studies did not examine specifically σ receptor subtype binding affinity, the 
difference may be due to changes in affinity for one receptor subtype versus the other 
(i.e. σ-2 receptor affinity decreases significantly but σ-1 receptor affinity remains 
unchanged). 
While migration and removal of the methyl moiety failed to alter functional 
properties of the molecule significantly, pronounced enhancement in potency were found 
with halide substitutions. Data presented in this study show that substituting a chloro for 
a methyl moiety in the meta and para positions of DTG produced compounds that had 
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~15% higher potency relative to the parent compound (o-DTG) at 100 µM concentration 
in the ischemia-induced increases in [Ca2+]i assay. The enhancement in potency was 
even more pronounced in the acidosis-evoked [Ca2+]i dysregulation assay. In this assay, 
m- and p-ClDPhG (100 µM) produced blocks of >100% greater than o-DTG. In contrast, 
substitution of a chloro moiety in the ortho position did not alter the functional effects of 
the parent compound in either the ischemia or acidosis assay. Similar observations were 
made using compounds with bromo substitutions (BrDPhG) of DTG in the meta and para 
positions with an ~22% increase of inhibition during ischemia and an ~160% increase 
during acidosis applications over o-DTG, respectively. The most potent compound tested 
was p-BrDPhG, which had an IC50 indicating 8-fold and 34-fold greater potency over that 
of o-DTG in the acidosis [Ca2+]i and ischemia [Ca2+]i assays, respectively.  
Functional assays indicated that p-BrDPhG was significantly more potent than o-
DTG, but a radioligand binding assay showed decreased affinity for both σ receptor 
subtypes. Our experiments showed that o-DTG binds σ-1 and σ-2 receptors with an 
affinity in the range of 60-90 nM, which is similar to what was previously reported in the 
literature (Torrence-Campbell and Bowen, 1996). In contrast, p-BrDPhG was found to 
bind σ-1 and σ-2 receptors with 296 ± 46 nM and 800 ± 57 nM affinities, respectively, 
with the σ-2 receptor affinity being significantly lower. These values are similar to a 
previous report which indicates that p-BrDPhG binds guinea pig brain membrane 
extracts with an affinity of 540 ± 25 nM (Scherz et al., 1990). That study also 
demonstrated that p-BrDPhG has lower binding affinity for the NMDA receptor than the 
parent compound (o-DTG), and therefore, the increased functional potency cannot be 
explained by increased action at the NMDA receptor. 
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Confirmation that p-BrDPhG mitigates [Ca2+]i dysregulation via activation of σ-1 
receptors was achieved via the use of the σ-1 receptor antagonist BD-1063. Using the 
acidosis [Ca2+]i functional assay, BD-1063 was shown to inhibit the effects of p-BrDPhG 
by >50% at a concentration of 10 nM, which is consistent with p-BrDPhG acting via σ-1 
receptors (Matsumoto et al., 1995, Herrera et al., 2008). To date, only activation of the σ-
1 receptor has been shown to affect ischemia- and acidosis-evoked [Ca2+]i dysregulation 
(Katnik et al., 2006, Herrera et al., 2008), and thus effects by the σ-2 receptor were not 
tested in these assays. 
The current study shows that p-BrDPhG also inhibits microglial activation and this 
DTG analogue is 4-fold more potent than the parent compound and a second pan-
selective σ agonist, afobazole (Hall et al., 2009a, Cuevas et al., 2011b). Unlike ischemia- 
and acidosis-evoked [Ca2+]i dysregulation, which appears to be exclusively affected by σ-
1 receptor activation, both σ-1 and σ-2 receptors can modulate microglial migration 
(Cuevas et al., 2011b). This observation may explain why p-BrDPhG, which has even 
lower affinity for σ-2 than σ-1, is only 4-fold more potent than o-DTG in the microglial 
migration assay but 8- to 34-fold more potent than the parent compound in the [Ca2+]i 
dysregulation experiments. The observation that p-BrDPhG is more potent than o-DTG 
in inhibiting microglial activation may have important therapeutic implications. Previous 
studies have demonstrated that activation of microglia following an ischemic insult 
results in the release of pro-inflammatory cytokines by these cells, which promotes 
neuronal death (Lee et al., 2001).  
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One mechanism which may explain the discrepancy between decreased binding 
affinity but increased functional potency of p-BrDPhG may be increased membrane 
permeability of the compound. It has been shown that chloro and bromo substitution in 
the para position on phenylalanine increases hydrophobicity and blood-brain barrier 
permeability of a drug (Gentry et al., 1999). Likewise, halogenation of small molecules 
has been demonstrated to increase membrane permeation (Gerebtzoff et al., 2004). It 
has been shown that increasing membrane permeability of a σ ligand by deprotonation 
increases potency of the compound, which was interpreted to suggest that the binding 
site for ligands such as BD-1063 are intracellular (Vilner and Bowen, 2000). Immuno-
labeling studies have confirmed this hypothesis, showing that σ-1 receptors localize to 
the endoplasmic reticulum (Dussossoy et al., 1999, Seminerio et al., 2012). Moreover, 
the proposed binding site for drugs such as o-DTG are, in part, located in the 
transmembrane domain of the receptor (Pal et al., 2007). Thus, by increasing membrane 
permeability, chloro and bromo substitution more than compensate for the decreased 
binding affinity. 
Our data, however, also suggest that factors other than membrane permeability 
are likely involved in the effects of the halogenation and methylation. Electronegativity 
and conformation of the molecule are also important. For example, fluoro substitution of 
a distal phenyl group of a piperidine greatly increased the lipophilicity of the compound 
(de Candia et al., 2009). Despite the likely increased lipid permeability, our findings show 
that fluoro substitution does not result in increased inhibition of [Ca2+]i dysregulation 
evoked via ischemia or acidosis relative to o-DTG. One possibility is that while the fluoro 
substitution may increase the drugs lipophilicity, the added increase in electronegativity 
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caused by addition of a fluoro moiety may have disrupted binding of the compound to the 
σ receptors. While fluorine has an electronegativity of 4.0, that of chlorine and bromine 
are ~ 3.0. Moreover, our data suggest that location of chloro and bromo substitutions on 
the phenyl ring for enhanced potency were limited to either the meta or para positions. A 
previous report on structure-activity relationship of DTG analogues suggested that the 
ortho position was the most tolerant to structural modifications, including addition of 
electronegative moiety (Scherz et al., 1990). However, that report did not distinguish 
between σ-1 and σ-2 receptor binding, and thus the effects of those modifications on the 
respective receptors remains to be determined.  
 It has been shown that following a stroke there is an increase in the production 
of the amyloid-β peptide (Stephenson et al., 1992, Jablonski et al., 2011, Pluta et al., 
2013). There are currently no studies that have looked at potential therapeutic targets to 
mitigate post-stroke amyloid-β induce toxicity. Aβ25-35 was found to produce increases in 
[Ca2+]i after cells were incubated in the Aβ fragment for ≥ 1 hr, with short applications ≤ 
15 min failing to alter [Ca2+]i. Maximal increases in [Ca2+]i were observed after 12 hr 
incubation of the neurons in Aβ25-35 and [Ca2+]i remained significantly elevated even after 
24 hr incubation in the Aβ fragment. The observed 2-fold increase in [Ca2+]i caused by 
Aβ25-35 is similar to that previously reported for rat cortical neurons incubated for 24 hr in 
Aβ25-35 (Ferreiro et al., 2004). Despite the DTG analogue p-BrDPhG showing a greater 
potency for mitigating ischemia- and acidosis-induced increases in [Ca2+]i elevations, we 
decided to use another pan-selective sigma receptor agonist. The decision to use 
afobazole was predominately two-fold. First, the guanidine compounds are known to be 
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“dirty” (i.e. bind to many receptors), whereas afobazole has minimal non-target effects. 
Second, afobazole has been better characterized and is currently being used clinically. 
Therefore, neurons were incubated in 100 µM afobazole and found to reduce Aβ25-35-
evoked increases in [Ca2+]i by ~60%. This decrease in [Ca2+]i is similar to that observed 
when afobazole was used to inhibit [Ca2+]i increases produced in cortical neurons by 
acidosis (IC50 = 164 µM) (Cuevas et al., 2011a). Reducing Aβ25-35 perturbation of [Ca2+]i 
is likely to promote neuronal survival, since [Ca2+]i destabilization has been linked to cell 
death in AD (Mattson and Chan, 2003b). Moreover, the Aβ25-35-induced changes in 
[Ca2+]i  precede pro-apoptotic signals in the model used here (e.g. decrease in Bcl-2 
levels occurring 48 hrs after Aβ25-35 application).  
The inhibition of Aβ25-35-elicited increases in [Ca2+]i by afobazole is due to 
activation of σ-1, but not σ-2 receptors. Incubation in the σ-1 receptor antagonist, BD-
1047 (Matsumoto et al., 2004), reduced the effects of afobazole by ~40%. The 
concentration and degree of block reported here is consistent with previous studies 
showing BD-1047 inhibition of σ-1 receptor-mediated effects in cortical neurons and 
retinal ganglion cells (Katnik et al., 2006, Cuevas et al., 2011a, Mueller et al., 2013). The 
lack of involvement of σ-2 receptors is confirmed by results obtained using the σ-2 
receptor antagonist, rimcazole (Gilmore et al., 2004). Rimcazole binds to σ-2 receptors 
with nanomolar affinity, but to σ-1 receptor with low micro molar affinity (Ferris et al., 
1986, Husbands et al., 1999, Rybczynska et al., 2008). Given that 300 nM rimcazole 
failed to inhibit the actions of afobazole on Aβ25-35-evoked increases in [Ca2+]i, but that 
the higher concentration of the drug reduced these effects, it is unlikely that afobazole 
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activates σ-2 receptors to suppress Aβ25-35-evoked increases in [Ca2+]i. Surprisingly, a 
second pan-selective σ receptor agonist, DTG, failed to mimic the effects of afobazole on 
Aβ25-35-evoked [Ca2+]i perturbation. DTG and afobazole both block acidosis- and 
ischemia-induced Ca2+ overload in neurons to a similar extent (Cuevas et al., 2011a). It 
was shown that ischemia-induced [Ca2+]i increases were due primarily to Ca2+ influxes 
through voltage-gated Ca2+ channels and NMDA receptors which were regulated by σ 
receptor activation (Katnik et al., 2006). However, the difference between afobazole and 
DTG effects on Aβ modulation of [Ca2+]i, suggest these long-term [Ca2+]i increases 
involve distinct mechanisms from those producing ischemia-induced [Ca2+]i overload. 
Additionally, the lack of a DTG effect on Aβ-evoked [Ca2+]i overload suggests that not all 
σ-1 agonists may promote neuronal survival in this model. This hypothesis is further 
supported by our observation that DTG fails to decrease neuronal apoptosis following 24 
hr incubation Aβ25-35. The difference in responses between afobazole and DTG may be 
due to off-target effects of DTG counteracting the benefits of this pan-selective sigma 
agonist. 
 It has been suggested that one of the downstream consequences of [Ca2+]i 
dysregulation in neurons caused by Aβ25-35 is the production of ROS (Ekinci et al., 2000, 
Abramov et al., 2004). Afobazole has been shown to reduce ROS accumulation in rat 
brains after focal ischemia (Silkina et al., 2006). However, data presented here show that 
afobazole does not block the ROS increases caused by the Aβ fragment. It has been 
suggested that Aβ, and in particular Aβ25-35, can increase oxidative stress via 
mechanisms independent of [Ca2+]i dysregulation (Varadarajan et al., 2001). Given that 
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afobazole inhibits [Ca2+]i dysregulation produced by Aβ25-35 in neurons but not the 
increase in ROS, it is unlikely that afobazole is affecting this [Ca2+]i-independent ROS 
production. It is important to note that while afobazole may not decrease ROS 
production, it has been shown that σ-1 receptors decrease H2O2 evoked apoptosis 
(Meunier and Hayashi, 2010). Thus, afobazole may in part decrease Aβ25-35-induced cell 
death by acting downstream of the observed ROS increase. 
Aβ25-35 has been shown to increase nitric oxide synthase (NOS) activity and 
produce neuronal injury via nitrosative stress (Parks et al., 2001, Cho et al., 2009). Aβ25-
35-evoked increases in NO were significantly decreased following afobazole application. 
Inhibition of inducible NOS (iNOS) has been proposed as a mechanism by which 
activation of σ-1 receptors is neuroprotective after stroke (Vagnerova et al., 2006). 
Similarly, functional downregulation of neuronal NOS (nNOS) has been shown to 
contribute to σ receptor neuroprotection following ischemia in striatal neurons (Yang et 
al., 2010). Since Aβ25-35 appears to increase both iNOS and nNOS in neurons (Limon et 
al., 2009), activation of σ receptors by afobazole is predicted to reduce NO production by 
both of these enzymes, and will ultimately contribute to protection from Aβ25-35 induced 
injury. 
 One of the pro-apoptotic proteins upregulated in neurons both by the 
pathological sequela induced by Aβ25-35 application and in patients with Alzheimer’s 
disease is Bax (Paradis et al., 1996, Yao et al., 2005). Consistent with previous findings, 
the current study shows that the number of Bax positive neurons is significantly 
increased following 24 hr incubation in Aβ25-35. However, when afobazole is applied in 
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combination with Aβ25-35, Bax upregulation is diminished significantly. It has also been 
shown that the σ-1 agonist, PRE-084, can reduce apoptosis in cortical neurons caused 
by Aβ25-35 via reduction in Bax (Marrazzo et al., 2005). However, glutamatergic 
neurotransmission was blocked in those experiments (Marrazzo et al., 2005). 
Glutamatergic transmission is a factor in Aβ25-35-induced cell death, and elevated 
glutamate levels have been shown to induce Bax upregulation in neurons (Schelman et 
al., 2004, Revett et al., 2013). Thus, our data suggest that σ receptor activation by 
afobazole can reduce Bax expression and concomitant cell death in the presence of 
Aβ25-35 even when glutamatergic transmission is not blocked.   
 In addition to decreasing Bax levels, afobazole effectively reduced activated 
caspase-3 expression in response to Aβ25-35. The active form of caspase-3 has been 
implicated in the loss of hippocampal neurons in Alzheimer’s disease (Selznick et al., 
1999). In addition to serving as a late event involved in neuronal death during 
Alzheimer’s disease, caspase activation may be an early event that promotes the 
pathology of AD. Several caspases, including caspase-3, have been shown to cause 
pathological tau filament assembly in neurons, which underlies AD etiology (Gamblin et 
al., 2003). Selective inhibition of caspase-3 has been shown to protect neurons from 
Aβ25-35-induced apoptosis (Allen et al., 2001). Sigma receptor activation has been shown 
to decrease caspase-3 and to protect cortical neurons and RGC-5 cells against 
excitotoxicity (Tchedre and Yorio, 2008, Griesmaier et al., 2012). Such a mechanism is 
likely to contribute to afobazole neuroprotection from Aβ25-35 toxicity and may in part 
explain the reduced neuronal death observed here. 
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 The neuroprotective properties of afobazole following exposure to Aβ25-35 also 
involves long-term upregulation of Bcl-2. Our data indicate that there is a biphasic 
change in Bcl-2 levels in neurons following application of Aβ25-35 with an initial increase 
at 24 hr followed by a suppression of Bcl-2 expression at 48 hr. A similar transient 
expression pattern was previously reported in rat hippocampal neurons exposed to Aβ25-
35 (Kim et al., 1998). It was proposed that this initial increase in Bcl-2 expression is a 
non-sustainable cellular response to the apoptotic pathways induced by Aβ (Kim et al., 
1998). Our observations indicate that when afobazole is applied along with Aβ25-35, Bcl-2 
levels do not drop below control at the 48 hr time point. Previous studies have shown 
that Bcl-2 is a target for σ receptor mediated neuroprotection. The HIV-1 protein gp120 
was shown to downregulate Bcl-2 in cortical neurons, but activation of σ receptors with 
the σ ligand, PPBP, increased Bcl-2 expression (Zhang et al., 2012). PPBP was shown 
to have a similar effect in a glutamate excitotoxicity model (Yang et al., 2007), 
suggesting that Bcl-2 upregulation may occur after σ receptor stimulation under various 
pathophysiological conditions. 
Previous studies from our laboratory have shown that microglia quickly become 
activated and withdraw their filopodia when exposed to various stimuli, such as LPS and 
ATP (Hall et al., 2009a). This activated state, which allows the microglia to migrate to the 
site of injury, is preceded by the release of neurotoxic substances (Kierdorf and Prinz, 
2013). Previously we have shown that microglia, in response to ATP, alter their 
morphology to a less ramified state and this reaction was inhibited by DTG (Hall et al., 
2009a). Afobazole effectively blocked membrane ruffling by approximately 50% in 
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response to ATP. For comparison we used a second pan-selective σ receptor agonist, 
DTG, which reduced ruffling comparable to afobazole and to the extent as previously 
reported. In addition, afobazole was recently shown to mitigate microglial migration in a 
concentration dependent manor in response to ATP and UTP. Other studies have shown 
that microglia rapidly respond to Aβ by withdrawing their filopodia and assuming an 
amoeboid, ruffled morphology (Araujo and Cotman, 1992). This early event is indicative 
of microglial activation and precedes the inflammatory response that includes release of 
neurotoxic substances from the microglia (Combs et al., 2001, Garcao et al., 2006, 
Orellana et al., 2011). Afobazole (30 µM) effectively blocked membrane ruffling in 
response to Aβ25-35. While a second pan-selective σ receptor agonist, DTG (30 µM), also 
decreased membrane ruffling caused by Aβ25-35, this drug was significantly less potent 
than afobazole. It has been shown that higher concentrations of DTG (100 µM) are also 
required to block ATP-induced microglial membrane ruffling (Hall et al., 2009a).  
Afobazole also effectively blocked microglial migration induced by Aβ25-35. It has 
been shown previously that various Aβ fragments, including Aβ25-35, are microglial 
chemotactic agents (Davis et al., 1992). The Aβ-induced chemotaxis is in part due to 
release of ATP from microglia following Aβ25-35 application and subsequent activation of 
P2Y2 receptors on these cells (Kim et al., 2012). We have previously shown that 
afobazole blocks microglial migration induced by activation P2Y receptors (Cuevas et al., 
2011b). Afobazole appears to inhibit microglial migration caused by UTP via σ receptor-
mediated disruption in P2Y signaling, since afobazole treatment also inhibited P2Y-
induced elevation in [Ca2+]i in microglia (Cuevas et al., 2011b). The IC50 for afobazole 
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inhibition of microglial migration caused by Aβ25-35 is 120 µM, which is similar to the low-
affinity site reported for afobazole inhibition of UTP-induced microglial migration (102 
µM) (Cuevas et al., 2011b). Therefore, afobazole may in part prevent microglial 
chemotaxis caused by Aβ25-35 via σ receptor-mediated inhibition of P2Y receptors in 
these cells.  
Data shown here indicate that both σ receptor subtypes are involved in afobazole 
inhibition of Aβ25-35-evoked microglial activation. Afobazole-mediated inhibition of 
microglial migration was reduced by ~50% by 10 µM BD 1047, which is indicative of a σ-
1 receptor mediated effect (Matsumoto et al., 1995). An identical concentration of BD 
1047 had a similar effect on afobazole inhibition of ATP-induced microglial cell migration 
(Cuevas et al., 2011b). Likewise, involvement of σ-2 receptors is confirmed by results 
obtained using the σ receptor antagonist, rimcazole, which binds to σ-2 receptors with 
nanomolar affinity (Ferris et al., 1986, Rybczynska et al., 2008). Nanomolar 
concentrations of rimcazole also blocked afobazole inhibition of microglial migration in 
response to ATP (Cuevas et al., 2011b). 
Given that one of the consequences of microglial activation is increased oxidative 
and nitrosative stress, which leads to Aβ25-35 toxicity (Weldon et al., 1998, Bianca et al., 
1999, Combs et al., 2001), we examined how afobazole affects Aβ25-35-induced 
increases in cellular ROS and NO levels. Consistent with previous reports, both ROS 
and NO levels were increased significantly following Aβ25-35 application. However, 
afobazole failed to attenuate the increases in ROS and NO evoked by the Aβ fragment. 
Activation of σ receptors has been shown to decrease oxidative injury and nitrosative 
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stress in various models. It was recently shown, using σ receptor knockout mice, that σ-1 
has a dual function of both reducing oxidative stress and activating antioxidant response 
elements (Pal et al., 2012). In microglia, stimulation of σ receptors by DTG reduces NO 
production in response to lipopolysaccharide (Hall et al., 2009a). Taken together, 
however, our data suggest that the reduction in Aβ-evoked microglial cell toxicity 
provided by afobazole application is not the result of σ receptor-mediated decrease in 
oxidative or nitrosative stress. 
While decreased activation of microglia will be beneficial following a stroke by 
reducing the neuroinflammatory response, recent data suggests that enhanced 
microglial survival is also important for improved outcomes given the ability of these cells 
to phagocytose Aβ plaques (Streit et al., 2009, Solito and Sastre, 2012). Application of 
30 µM afobazole significantly reduced the number of microglia undergoing apoptosis 
following 72 hr incubation in Aβ25-35. The concentrations of afobazole shown to be 
effective here are identical to those previously shown to decrease microglial cell death 
caused by ischemia in a σ receptor dependent manner and consistent with the binding 
affinity of afobazole for σ-1 receptors (Seredenin et al., 2009, Cuevas et al., 2011a, 
Cuevas et al., 2011b). This observation suggests that afobazole is similarly acting 
through σ receptor activation to prevent microglial cell death. Both melatonin and N-
acetylcysteine have been shown to decrease Aβ25-35-evoked apoptosis in microglia via a 
reduction in ROS (Jang et al., 2005). Given that afobazole does not appear to affect 
Aβ25-35-elicited increases in ROS, it is unlikely that afobazole provides cytoprotection via 
a similar mechanism to these compounds.   
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Our findings demonstrate that afobazole mitigates Aβ25-35-induced apoptosis of 
microglia by decreasing expression of the pro-apoptotic gene, Bax, and the death 
protease caspase-3 while preserving the levels of the anti-apoptotic gene, Bcl-2. An 
increase in Bax levels has been observed in both neurons and microglia of AD brains 
(Su et al., 1997). Moreover, interventions that decrease Aβ25-35-induced microglial 
apoptosis have been shown to lower Bax expression (Jang et al., 2005, Shang et al., 
2012). Likewise, caspase activity has been detected in plaque-associated neurons and 
microglia in AD brains (Yang et al., 1998). Caspase-3 levels have been shown to be 
upregulated in microglia following Aβ administration, while reduced levels of this death 
protease have been associated with inhibition of Aβ toxicity (Shang et al., 2012). 
Conversely, expression of the anti-apoptotic gene, Bcl-2, is inversely correlated with 
disease severity in AD. Increases in Bcl-2 levels promote microglial survival following 
exposure to Aβ25-35 (Satou et al., 1995, Jang et al., 2005). Therefore, afobazole likely 
enhances microglial survival and resistance to Aβ25-35 toxicity via a complex response 
involving both anti-apoptotic and pro-apoptotic genes. This multifaceted effect is 
consistent with afobazole acting as a σ agonist, since σ receptor activation has been 
shown to modulate Bax, caspase-3 and Bcl-2 levels (Tchedre and Yorio, 2008, Meunier 
and Hayashi, 2010).  
Importantly, not only did afobazole protect microglia from Aβ25-35-evoked 
apoptosis, but application of the σ agonist preserved the functional capacity of these 
cells, as evident from the continued [Ca2+]i responses to ATP. Ultimately, one of the 
theoretical benefits to increased microglial survival would be continued clearance of Aβ, 
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as this peptide has been shown to be phagocytosed by microglia (Wilcock et al., 2004, 
Herber et al., 2007). This hypothesis is further supported by the recent observation that 
microglial clearance of Aβ directly correlates with expression of the gene CD33, such 
that a CD33 deficiency reduces brain levels of both insoluble Aβ1-42 and amyloid plaque 
burden in a mouse AD model (Griciuc et al., 2013). Moreover, there is a decrease in both 
CD33 expression and insoluble Aβ1-42 in the brains of individuals expressing the minor 
allele of the CD33 (SNP rs3865444) gene, which was identified previously as imparting 
protection against AD (Naj et al., 2011, Griciuc et al., 2013). The fact that responses to 
ATP itself are preserved is significant, since the clearance of Aβ has been shown to be 
dependent of the activation of P2Y2 receptors. Microglia respond to Aβ by releasing ATP 
and this nucleotide functions in a paracrine manner, acting on P2Y2 receptors expressed 
on the microglia to enhance Aβ uptake by these cells (Kim et al., 2012). We have 
previously shown that in our model these increases in [Ca2+]i are due to activation of P2Y 
receptors, since they can be elicited by UTP (Cuevas et al., 2011b). Therefore, by 
preserving ATP responses in microglia, afobazole will permit these cells to respond to Aβ 
in vivo and potentially decrease amyloid burden. 
It has been suggested that over-activation of microglia result in neuronal death 
(Hellwig et al., 2013). However, the need to maintain viable microglia that respond to 
sites of injury are equally necessary. Neurons exposed to ischemic conditions release 
cytotoxic and neurotropic factors that both activate and attract microglia to the area of 
injury (Hellwig et al., 2013, Kierdorf and Prinz, 2013). Unfortunately, in disease states 
like stroke, over-activation of microglia is a common occurrence and often times result in 
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neuronal and microglial cell death. Thus it is of great importance to identify factors that 
contribute to the demise of microglia and find treatments to combat these mechanisms. 
Exposure of microglia cells to ischemia resulted in approximately 150-fold increase in 
cell death from control alone. Afobazole reduced the number of dyeing microglia by 75 ± 
8% when co-incubated with ischemia.  
Our laboratory has previously shown that afobazole can mitigate intracellular 
calcium dyshomeostasis in neurons and microglia following ischemia, acidosis and ATP 
exposure (Katnik et al., 2006, Herrera et al., 2008, Cuevas et al., 2011a, Cuevas et al., 
2011b). A rise in intracellular concentration, if unresolved, can promote the initiation of 
apoptosis (Mattson and Chan, 2003a). Immunocytochemical experiments were 
conducted to determine if afobazole affects microglial expression of the pro-apoptotic 
protein Bax or the death protease, caspase-3, following 24 hr ischemic exposure. Both 
Bax and caspase-3 expression increased > 270 and 150% from the control, respectively. 
We found that afobazole alone decreased caspase-3 expression and when co-incubated 
with ischemia both Bax and caspase-3 expression were mitigated approximately 42 and 
59%, respectively. Further experiments were conducted to determine if levels of Bcl-2 
were affected by ischemia and to what if affect afobazole had on its expression. 
Following ischemic incubation, microglial Bcl-2 expression was decreased by ~ 21% 
from that of the control. However, when co-incubated with ischemia, afobazole preserved 
Bcl-2 expression by approximately 24%, making it comparable to afobazole alone.  
Exposing cells to ischemic conditions has been shown to decrease cell viability. 
Our laboratory has shown that afobazole mitigates death following 2 hr ischemia 
exposure (Cuevas et al., 2011a, Cuevas et al., 2011b). This model resembles injury 
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caused by reperfusion of the tissues with oxygen, more of a transient ischemic model. 
Experiments were conducted to determine to what extent afobazole could be 
neuroprotective following prolonged ischemic exposure (72 hr). There was an 
approximant 3-fold increase in the number of expired neurons from that of the control. 
This increase in the demise of neurons was mitigated by approximately 55% when co-
incubated with afobazole. This data indicates that even under prolonged ischemic 
conditions afobazole was to some extent neuroprotective. Immunocytochemical 
experiments were carried out to determine if one mechanism by which afobazole is 
neuroprotective is through sigma receptor regulation of apoptotic expression. Both Bax 
and caspase-3 expression were observed under all conditions. Following ischemic 
exposure, both Bax and caspase-3 levels increased by ~ 47 and 35%, respectively. 
However, unlike the results we observed in microglia cells, afobazole did not mitigate 
increases in Bax or caspase-3 expression in neurons. The ratio of Bcl-2:Bax has been 
shown to positively correlate to cell survival in neurons exposed to Aβ (Patel and Brewer, 
2008). Likewise, the ratio of Bcl-2:Bax is important in regulating cell survival following 
glutamate excitotoxicity (Schelman et al., 2004) and previous studies have shown that 
Bcl-2 is a target for σ receptor mediated neuroprotection (Yang et al., 2007, Meunier and 
Hayashi, 2010). Additionally, experiments were performed to determine if afobazole 
could preserve expression of Bcl-2 levels following ischemia. As we observed with 
microglia, Bcl-2 expression decreased in neurons under ischemic conditions. We found 
that afobazole alone increased Bcl-2 expression; however, when co-incubated with 
ischemia, afobazole failed to preserve Bcl-2 expression levels and were comparable to 
ischemia alone.  
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However, when functional integrity of these surviving neurons was examined by 
attempting to depolarize them with a focal application of 30mM KCl, we found them 
unresponsive. It appeared that afobazole might not be as neuroprotective as we first 
thought against prolonged ischemic exposure. However we realized that the conditions 
in which these neurons were exposed resembled a near core environment and not the 
penumbra. Neuronal necrosis contributes to the expansion of the core into the 
penumbra. The fact that afobazole prevents the dumping of neuronal cellular contents 
into surrounding tissue and allows for these damaged cells to undergo controlled cell 
death.  
Lastly, In addition to large vessel ischemic strokes there are small vessel ischemic 
stroke known as lacunar infarcts, which account for approximately 25% of all ischemic 
insults (Samuelsson et al., 1996). These strokes result from the blockage of small 
penetrating arteries to the subcortical regions of the brain (Kang et al., 2012). This type 
infarct is a leading cause of cognitive impairment and vascular dementia (Charidimou 
and Werring, 2012). While the risk factors resulting in lacunar verse large artery infarcts 
differ, the resulting cellular cascade promoting cerebral cell death may have overlapping 
mechanisms. One of these mechanisms may be the increased production and toxicity of 
the amyloid-β peptide, which has been shown to be upregulated following an ischemic 
event (Popa-Wagner et al., 1998, Guglielmotto et al., 2009, Pluta et al., 2013). Neuronal 
cultures were used to determine if incubation with 25 µM amyloid-β25-35 produced an 
increase in the [Ca2+]i levels evoked by ischemia + acidosis application. Incubation for 12 
hr failed to potentiate Ca2+ elevations. Given that Aβ modulation of these responses may 
require longer incubation period for gene up-regulation. Therefore, neurons were 
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incubated for 24 hr with Aβ and found to have potentiated ischemia, acidosis and 
ischemia + acidosis induced increases in [Ca2+]i levels. We found that acidosis 
application alone produced an increase in mean peak [Ca2+]i by ~42%. Furthermore, 
application of ischemia alone or ischemia + acidosis also produced potentiated 
elevations in both the peak and total net calcium influx by ~72 and 82% for ischemia and 
~43 and 85% for ischemia + acidosis, respectively. This dual potentiation in [Ca2+]i may 
indicated that the mechanism in these response involve multiple pathways including 
ASIC1a, VGCCs, NMDA and AMPA/kainate receptors. Previous studies from our 
laboratory have shown that ischemia-induced elevations in [Ca2+]i involved the activation 
of NMDA receptors (Katnik et al., 2006), whereas acidosis application activates ASIC1a 
receptors (Herrera et al., 2008). Moreover, the ischemia + acidosis activation of NMDA 
and ACIS1a receptors results in a synergist increase in [Ca2+]i levels. This is a 
complicated interaction with NMDA receptors functionally up-regulating ASIC1a, while at 
the same time ASIC1a potentiates NMDA receptor activity (Mari et al., 2014).  
 Since activation of ASIC1a has been shown to potentiate ischemia-induced 
[Ca2+]i levels through NMDA receptors, we were interested in determining were Aβ 
potentiation occurred. Previous studies have shown that only a small part of the ischemia 
+ acidosis evoked Ca2+ influx is directly due to ACIS1a with VGCCs, NMDA and 
AMPA/kainate receptors contributing to the bulk influx (Gonzalez-Alvear and Werling, 
1995, Alonso et al., 2000).  However, fluorometric calcium imaging showed that Aβ-
induced a potentiated proton activated Ca2+ influx. Therefore, whole-cell patch-clamp 
experiments were performed to determine whether this potentiation was due to directly to 
ASIC1a activity or via ASIC1a enhanced downstream channels. Neurons Aβ-incubated 
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for 24 hr were voltage-clamped at -70 mV, which prevents NMDA receptor and VGCC 
activation, demonstrated a ~68% increase in the proton evoked inward current. Taken 
together, our results indicate that Aβ incubation is directly up-regulating ASIC1a activity 
as well as the ASIC1a potentiated down-stream channels. 
Reducing the Ca2+ overload produced by an ischemic insult is crucial to mitigating 
stroke injury. Previous studies from our laboratory have shown that σ-1 receptor 
activation in neurons can elevate the Ca2+ overload induced by ischemia, acidosis and 
Aβ (Cuevas et al., 2011a, Behensky et al., 2013a). However, not all sigma receptor 
agonists were shown to be as effective under these conditions (Behensky et al., 2013a). 
The pan-selective agonist afobazole was one such drug that did mitigate Ca2+ overload 
induced under all three conditions. Therefore, 100 µM afobazole was co-incubated with 
Aβ for 24 hr to assess what function activation of sigma receptors would have on the Aβ 
up-regulated function. Co-incubation with afobazole completely abolished the potentiated 
increases in [Ca2+]i levels-induced via focal application of ischemia + acidosis. Reducing 
the Aβ up-regulated Ca2+ increases will likely translate to an increase in neuronal 
survival.  
The overall significance of this study shows that sigma receptor activation via 
afobazole can decrease both ischemic- and Aβ-induced injury following a stroke. The 
activation of σ-1 receptors prevented Aβ25-35-induced [Ca2+]i overload and mediated 
neuroprotection by downregulation of both Bax and activated caspase-3, and long-term 
upregulation of Bcl-2. This translated to a decrease in Aβ25-35-evoked neuronal 
apoptosis. In addition, afobazole through σ-1 and σ-2 receptors mitigated the activation 
and migration of microglial cells in response to Aβ25-35. The observed decrease in 
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apoptosis is due to afobazole-mediated regulation of multiple genes, with a noted 
decrease in Bax and caspase-3 and a concomitant increase in Bcl-2 expression. In 
addition to the decrease in cell death, afobazole preserved functional activity of the cells 
as evident by the conserved ATP-induced increases in [Ca2+]i following prolonged 
incubation in Aβ25-35. Taken together our data suggest that afobazole may prevent 
microglia from entering the activated state associated with neurotoxicity following 
exposure to Aβ, and increasing their survival, which will facilitate clearance of the 
amyloid peptide. Our data show one mechanism by which Aβ may potentiate neuronal 
injury during ischemia-acidosis is through increased [Ca2+]i overload, and identify 
ASIC1a as the channel mediating this phenomenon. Finally, our data suggest that 
activation of σ receptors by afobazole may represent a therapeutic strategy for mitigating 
concurrent injury produced by Aβ and stroke. 
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